{"PMC6998146": [["IntroductionThe past few years have seen increasing attention devoted to the topic of procedural sedation analgesia (PSA) in pediatric patients [1].", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["procedural sedation analgesia", "TREATMENT", 86, 115]]], ["Even premature babies and newborns are today eligible for a wide range of diagnostic and/or interventional procedures such as computed tomography, magnetic resonance imaging, a wide range of endoscopic interventions, organ biopsies, or catheter examinations.", [["organ", "ANATOMY", 217, 222], ["babies", "ORGANISM", 15, 21], ["newborns", "ORGANISM", 26, 34], ["organ biopsies", "MULTI-TISSUE_STRUCTURE", 217, 231], ["interventional procedures", "TREATMENT", 92, 117], ["computed tomography", "TEST", 126, 145], ["magnetic resonance imaging", "TEST", 147, 173], ["endoscopic interventions", "TREATMENT", 191, 215], ["organ biopsies", "TEST", 217, 231], ["catheter examinations", "TEST", 236, 257], ["catheter", "OBSERVATION", 236, 244]]], ["As more and more of these procedures are being performed on children and adolescents in clinical practice, the administration of sedation and analgesia in this patient group has grown accordingly [1\u20134].IntroductionWhile this growing requirement has engendered many publications, the guidelines and recommendations developed on their basis do exhibit discrepancies in specific areas [5, 6].", [["children", "ORGANISM", 60, 68], ["patient", "ORGANISM", 160, 167], ["children", "SPECIES", 60, 68], ["patient", "SPECIES", 160, 167], ["these procedures", "TREATMENT", 20, 36], ["sedation", "TREATMENT", 129, 137], ["analgesia", "TREATMENT", 142, 151], ["discrepancies in specific areas", "PROBLEM", 350, 381]]], ["Both the experience at our own center and discussions with colleagues from other parts of Germany have suggested to us that there is an increasing need for pediatricians to carry out techniques of PSA by themselves, given an inability of anesthesiologists to keep up with this growing demand.IntroductionTherefore we designed the first countrywide survey on the status quo of PSA administered to children and adolescents.", [["PSA", "GENE_OR_GENE_PRODUCT", 197, 200], ["PSA", "GENE_OR_GENE_PRODUCT", 376, 379], ["children", "ORGANISM", 396, 404], ["PSA", "PROTEIN", 197, 200], ["PSA", "PROTEIN", 376, 379], ["children", "SPECIES", 396, 404], ["adolescents", "SPECIES", 409, 420], ["PSA", "TEST", 197, 200], ["PSA", "TREATMENT", 376, 379]]], ["This was to be accomplished by developing a questionnaire and sending it to all pediatric hospital settings, with the goal of evaluating the degree to which the relevant current national and international recommendations have been implemented throughout Germany.Questionnaire and handling of the survey ::: MethodsThe questionnaire was developed on the basis of existing national and international guidelines and publications, also taking into consideration our own in-house standard [6].", [["Methods", "TREATMENT", 307, 314]]], ["Its purpose was to illustrate management practices before, during and after PSA.", [["PSA", "GENE_OR_GENE_PRODUCT", 76, 79], ["PSA", "PROTEIN", 76, 79], ["PSA", "TEST", 76, 79]]], ["Whenever a center had distinct units, we contacted each unit separately and later consolidated, for analysis, any multiple unit-level responses to center-level responses.", [["analysis", "TEST", 100, 108]]], ["Every center was assigned one specific random code number to prevent double responses.Major topics covered by the questionnaire ::: MethodsPart 1 of the questionnaire dealt with organizational structures.", [["Methods", "TREATMENT", 132, 139]]], ["Major items concerned the formal level of care provided by each pediatric center, the settings used for PSA, the number of sedations conducted per year, the existence of sedation teams, of regular training courses for sedation, of workflows defined in writing, as well as the degree of equipment available in the sedation environments.", [["PSA", "PROTEIN", 104, 107], ["PSA", "TEST", 104, 107], ["sedations", "TREATMENT", 123, 132], ["sedation teams", "TREATMENT", 170, 184], ["regular training courses", "TREATMENT", 189, 213], ["sedation", "TREATMENT", 218, 226], ["the sedation environments", "TREATMENT", 309, 334]]], ["Part 2 dealt with the medication and staffing standards implemented in the centers, focusing on the practical delivery of PSA in general, on specific examination scenarios in particular, as well as on training and safety requirements.", [["PSA", "PROTEIN", 122, 125], ["the medication", "TREATMENT", 18, 32], ["the practical delivery of PSA", "TREATMENT", 96, 125], ["specific examination scenarios", "TEST", 141, 171]]], ["The survey did neither contain any questions about the local standard for fasting nor the implementation of national or international fasting guidelines.Diagnostic and interventional procedures for sedation ::: MethodsEighteen scenarios of PSA (also see Figs.", [["PSA", "GENE_OR_GENE_PRODUCT", 240, 243], ["PSA", "PROTEIN", 240, 243], ["international fasting guidelines", "TREATMENT", 120, 152], ["sedation", "TREATMENT", 198, 206], ["PSA", "TEST", 240, 243]]], ["1 and 2) were considered: esophagogastro(duodeno)scopy, colonoscopy, percutaneous endoscopic gastrostomy, bronchoscopy, bone marrow aspiration and/or trephine biopsy, lumbar puncture, liver biopsy, kidney biopsy, pleural puncture/pleural drain insertion, pericardial puncture/pericardial drain insertion, arthrocentesis, placement of a central venous catheter, ultrasound examinations other than cardiac, echocardiography, transesophageal echocardiography, diagnostic cardiac catheterization, interventional cardiac catheterization, and imaging techniques other than ultrasound (computed tomography, magnetic resonance, fluoroscopy, scintigraphy).", [["percutaneous", "ANATOMY", 69, 81], ["bone marrow", "ANATOMY", 120, 131], ["lumbar", "ANATOMY", 167, 173], ["liver", "ANATOMY", 184, 189], ["kidney", "ANATOMY", 198, 204], ["pleural", "ANATOMY", 213, 220], ["pleural", "ANATOMY", 230, 237], ["pericardial", "ANATOMY", 255, 266], ["pericardial", "ANATOMY", 276, 287], ["venous", "ANATOMY", 344, 350], ["cardiac", "ANATOMY", 396, 403], ["cardiac", "ANATOMY", 468, 475], ["cardiac", "ANATOMY", 508, 515], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 120, 131], ["lumbar puncture", "MULTI-TISSUE_STRUCTURE", 167, 182], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 184, 196], ["kidney biopsy", "MULTI-TISSUE_STRUCTURE", 198, 211], ["pleural", "MULTI-TISSUE_STRUCTURE", 213, 220], ["venous", "MULTI-TISSUE_STRUCTURE", 344, 350], ["cardiac", "MULTI-TISSUE_STRUCTURE", 508, 515], ["esophagogastro(duodeno)scopy", "TREATMENT", 26, 54], ["colonoscopy", "TEST", 56, 67], ["percutaneous endoscopic gastrostomy", "TREATMENT", 69, 104], ["bronchoscopy", "TREATMENT", 106, 118], ["bone marrow aspiration", "TEST", 120, 142], ["trephine biopsy", "TEST", 150, 165], ["lumbar puncture", "TEST", 167, 182], ["liver biopsy", "TEST", 184, 196], ["kidney biopsy", "TEST", 198, 211], ["pleural puncture", "TREATMENT", 213, 229], ["pleural drain insertion", "TREATMENT", 230, 253], ["pericardial puncture", "TREATMENT", 255, 275], ["pericardial drain insertion", "TREATMENT", 276, 303], ["arthrocentesis", "TREATMENT", 305, 319], ["a central venous catheter", "TREATMENT", 334, 359], ["ultrasound examinations", "TEST", 361, 384], ["cardiac, echocardiography", "TEST", 396, 421], ["transesophageal echocardiography", "TEST", 423, 455], ["diagnostic cardiac catheterization", "TEST", 457, 491], ["interventional cardiac catheterization", "TEST", 493, 531], ["imaging techniques", "TEST", 537, 555], ["ultrasound (computed tomography", "TEST", 567, 598], ["magnetic resonance", "TEST", 600, 618], ["fluoroscopy", "TEST", 620, 631], ["scintigraphy", "TEST", 633, 645], ["gastrostomy", "OBSERVATION", 93, 104], ["bone", "ANATOMY", 120, 124], ["marrow", "ANATOMY", 125, 131], ["aspiration", "OBSERVATION", 132, 142], ["lumbar", "ANATOMY", 167, 173], ["liver", "ANATOMY", 184, 189], ["biopsy", "OBSERVATION", 190, 196], ["kidney", "ANATOMY", 198, 204], ["biopsy", "OBSERVATION", 205, 211], ["pleural", "ANATOMY", 213, 220], ["puncture", "OBSERVATION", 221, 229], ["pleural", "ANATOMY", 230, 237], ["drain", "OBSERVATION", 238, 243], ["pericardial", "ANATOMY", 255, 266], ["puncture", "OBSERVATION", 267, 275], ["pericardial", "ANATOMY", 276, 287], ["drain", "OBSERVATION", 288, 293], ["arthrocentesis", "OBSERVATION", 305, 319], ["central", "ANATOMY_MODIFIER", 336, 343], ["venous", "ANATOMY", 344, 350], ["catheter", "OBSERVATION", 351, 359]]]], "2bc42d72f7e8f70aee929da9d80d88eb17051362": [["IntroductionRespiratory tract infection is a major cause of hospitalization in children.", [["IntroductionRespiratory tract infection", "DISEASE", 0, 39], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["IntroductionRespiratory tract infection", "PROBLEM", 0, 39], ["tract", "OBSERVATION_MODIFIER", 24, 29], ["infection", "OBSERVATION", 30, 39]]], ["Most such infections are of viral origin, but viral infection is often hard to distinguish from bacterial infection [1] .", [["infections", "DISEASE", 10, 20], ["viral infection", "DISEASE", 46, 61], ["bacterial infection", "DISEASE", 96, 115], ["Most such infections", "PROBLEM", 0, 20], ["viral origin", "PROBLEM", 28, 40], ["viral infection", "PROBLEM", 46, 61], ["bacterial infection", "PROBLEM", 96, 115], ["infections", "OBSERVATION", 10, 20], ["viral origin", "OBSERVATION_MODIFIER", 28, 40], ["viral", "OBSERVATION_MODIFIER", 46, 51], ["infection", "OBSERVATION", 52, 61], ["bacterial", "OBSERVATION_MODIFIER", 96, 105], ["infection", "OBSERVATION", 106, 115]]], ["Pathogen-specific clinical symptoms are often lacking [1] .", [["Pathogen", "PROBLEM", 0, 8], ["specific clinical symptoms", "PROBLEM", 9, 35]]], ["Specific diagnosis, therefore, relies almost entirely on laboratory investigation [2] .IntroductionTreatment with antibiotics induces the development of antibiotic resistance in bacteria [3] and has a negligible effect on most acute respiratory infections (ARIs), which are generally of viral origin [4] .", [["respiratory", "ANATOMY", 233, 244], ["acute respiratory infections", "DISEASE", 227, 255], ["ARIs", "DISEASE", 257, 261], ["laboratory investigation", "TEST", 57, 81], ["antibiotics", "TREATMENT", 114, 125], ["antibiotic resistance in bacteria", "PROBLEM", 153, 186], ["most acute respiratory infections (ARIs)", "PROBLEM", 222, 262], ["antibiotic resistance", "OBSERVATION", 153, 174], ["negligible effect", "OBSERVATION_MODIFIER", 201, 218], ["most", "OBSERVATION_MODIFIER", 222, 226], ["acute", "OBSERVATION_MODIFIER", 227, 232], ["respiratory", "ANATOMY", 233, 244], ["infections", "OBSERVATION", 245, 255], ["viral origin", "OBSERVATION", 287, 299]]], ["Nevertheless, antibiotics are frequently prescribed due to a lack of clinically valid diagnostic tests verifying a viral etiology [5] .IntroductionSensitive methods, such as quantitative real-time polymerase chain reaction (qPCR) analyses on nasopharyngeal samples, for a number of viruses have been introduced in hospitals as a sensitive diagnostic tool among children with respiratory tract infection [6] .IntroductionInvestigations using specific PCR for individual viruses (Bmonoplex PCR^) are too time consuming and elaborate for the laboratory, and are usually used to detect influenza and respiratory syncytial virus (RSV).", [["nasopharyngeal samples", "ANATOMY", 242, 264], ["respiratory tract", "ANATOMY", 375, 392], ["respiratory tract infection", "DISEASE", 375, 402], ["influenza", "DISEASE", 582, 591], ["respiratory syncytial virus", "DISEASE", 596, 623], ["nasopharyngeal samples", "CANCER", 242, 264], ["children", "ORGANISM", 361, 369], ["tract", "ORGANISM_SUBDIVISION", 387, 392], ["respiratory syncytial virus", "ORGANISM", 596, 623], ["RSV", "ORGANISM", 625, 628], ["children", "SPECIES", 361, 369], ["respiratory syncytial virus", "SPECIES", 596, 623], ["respiratory syncytial virus", "SPECIES", 596, 623], ["RSV", "SPECIES", 625, 628], ["antibiotics", "TREATMENT", 14, 25], ["diagnostic tests", "TEST", 86, 102], ["nasopharyngeal samples", "TEST", 242, 264], ["respiratory tract infection", "PROBLEM", 375, 402], ["IntroductionInvestigations", "TEST", 408, 434], ["specific PCR", "TEST", 441, 453], ["individual viruses", "PROBLEM", 458, 476], ["Bmonoplex PCR", "TEST", 478, 491], ["influenza", "PROBLEM", 582, 591], ["respiratory syncytial virus", "PROBLEM", 596, 623], ["nasopharyngeal", "ANATOMY", 242, 256], ["respiratory tract", "ANATOMY", 375, 392]]], ["When the viruses targeted by monoplex PCR are negative, no specific etiology is identified to help clinical management of the patient and epidemiological monitoring of infections.", [["infections", "DISEASE", 168, 178], ["patient", "ORGANISM", 126, 133], ["monoplex PCR", "DNA", 29, 41], ["patient", "SPECIES", 126, 133], ["the viruses", "PROBLEM", 5, 16], ["monoplex PCR", "TEST", 29, 41], ["epidemiological monitoring", "TEST", 138, 164], ["infections", "PROBLEM", 168, 178], ["infections", "OBSERVATION", 168, 178]]], ["Multiplex PCR methods, on the other hand, enable testing for many pathogens in parallel in a single analysis and are, therefore, increasingly gaining importance [1] .MethodologyThis prospective case-control study was conducted during the period from October 2013 to February 2014 (winter season) at Cairo University Pediatric Hospitals (800 beds) and included all children who were hospitalized in intensive care units (ICUs) and hospital wards with severe acute respiratory infections (SARI) according to the World Health Organization (WHO) case definition for SARI [7] .", [["respiratory", "ANATOMY", 463, 474], ["acute respiratory infections", "DISEASE", 457, 485], ["SARI", "DISEASE", 487, 491], ["SARI", "DISEASE", 562, 566], ["children", "ORGANISM", 364, 372], ["children", "SPECIES", 364, 372], ["Multiplex PCR methods", "TEST", 0, 21], ["enable testing", "TEST", 42, 56], ["many pathogens", "PROBLEM", 61, 75], ["a single analysis", "TEST", 91, 108], ["control study", "TEST", 199, 212], ["severe acute respiratory infections", "PROBLEM", 450, 485], ["severe", "OBSERVATION_MODIFIER", 450, 456], ["acute", "OBSERVATION_MODIFIER", 457, 462], ["respiratory", "ANATOMY", 463, 474], ["infections", "OBSERVATION", 475, 485]]], ["A standardized study protocol was developed to record the demographic characteristics and medical history of the patients, clinical features including symptoms and signs, outcome of the illness, hospital course, and laboratory and radiological findings.MethodologyForty healthy age-matched asymptomatic children with no history of a recent respiratory tract infection during the previous 2 weeks, who were not admitted to the hospital, and who do not have any chronic underlying illness were included as a control group.MethodologyInformed verbal consent was obtained from the parents of all the patients and the controls.", [["respiratory tract", "ANATOMY", 340, 357], ["illness", "DISEASE", 186, 193], ["respiratory tract infection", "DISEASE", 340, 367], ["patients", "ORGANISM", 113, 121], ["children", "ORGANISM", 303, 311], ["tract", "ORGANISM_SUBDIVISION", 352, 357], ["patients", "ORGANISM", 596, 604], ["patients", "SPECIES", 113, 121], ["children", "SPECIES", 303, 311], ["patients", "SPECIES", 596, 604], ["A standardized study protocol", "TEST", 0, 29], ["symptoms", "PROBLEM", 151, 159], ["laboratory and radiological findings", "TEST", 216, 252], ["a recent respiratory tract infection", "PROBLEM", 331, 367], ["any chronic underlying illness", "PROBLEM", 456, 486], ["respiratory tract", "ANATOMY", 340, 357], ["infection", "OBSERVATION", 358, 367], ["chronic", "OBSERVATION_MODIFIER", 460, 467], ["illness", "OBSERVATION", 479, 486]]], ["The study design conformed to the Revised Helsinki Declaration of Bioethics and was approved by the Scientific Ethics Committee of the Department of Pediatrics, Faculty of Medicine of Cairo University.MethodologySampling and sample processing: nasopharyngeal (NP) and oropharyngeal (throat) swabs were obtained, transported, and preserved on viral transport media.", [["sample", "ANATOMY", 225, 231], ["nasopharyngeal", "ANATOMY", 244, 258], ["oropharyngeal", "ANATOMY", 268, 281], ["throat", "ANATOMY", 283, 289], ["swabs", "ANATOMY", 291, 296], ["nasopharyngeal", "CANCER", 244, 258], ["oropharyngeal", "ORGANISM_SUBDIVISION", 268, 281], ["throat", "ORGANISM_SUBDIVISION", 283, 289], ["The study", "TEST", 0, 9], ["MethodologySampling", "TREATMENT", 201, 220], ["sample processing", "TEST", 225, 242], ["nasopharyngeal (NP)", "TREATMENT", 244, 263], ["oropharyngeal (throat) swabs", "TEST", 268, 296], ["viral transport media", "TREATMENT", 342, 363], ["nasopharyngeal", "ANATOMY", 244, 258], ["oropharyngeal", "ANATOMY", 268, 281], ["throat", "ANATOMY", 283, 289]]], ["The swabs inside the 15-mL tube were agitated vigorously for 10 s using a vortex mixer to free cells from the swab tip.Real-time PCRViral testing was done by real-time multiplex PCR using Anyplex\u2122 II RV16 Detection (v1.1) (cat. no. RV7G01Y) supplied by Seegene, operated on a CFX96\u2122 Real-Time PCR Detection System (Bio-Rad), which simultaneously detects 16 respiratory viruses [adenovirus (AdV), influenza A virus (Flu A), influenza B virus (Flu B), parainfluenza viruses 1-4 (PIV-1, -2, -3, -4), rhinovirus (HRV), respiratory syncytial virus (RSV), bocavirus (HBoV), metapneumovirus (MPV), coronavirus 229E (CoV 229E), coronavirus NL63 (CoV NL63), coronavirus OC43 (CoV OC43), and enterovirus (HEV)].", [["swabs", "ANATOMY", 4, 9], ["cells", "ANATOMY", 95, 100], ["swab tip", "ANATOMY", 110, 118], ["RV7G01Y", "CHEMICAL", 232, 239], ["respiratory viruses", "DISEASE", 357, 376], ["influenza A", "DISEASE", 396, 407], ["influenza B", "DISEASE", 423, 434], ["parainfluenza viruses", "DISEASE", 450, 471], ["respiratory syncytial virus (RSV), bocavirus (HBoV), metapneumovirus (MPV)", "DISEASE", 515, 589], ["enterovirus (HEV)]", "DISEASE", 682, 700], ["tube", "TISSUE", 27, 31], ["cells", "CELL", 95, 100], ["swab tip", "MULTI-TISSUE_STRUCTURE", 110, 118], ["cat", "ORGANISM", 223, 226], ["adenovirus", "ORGANISM", 378, 388], ["AdV", "ORGANISM", 390, 393], ["influenza A virus", "ORGANISM", 396, 413], ["Flu A", "ORGANISM", 415, 420], ["influenza B virus", "ORGANISM", 423, 440], ["Flu B", "ORGANISM", 442, 447], ["parainfluenza viruses 1-4", "ORGANISM", 450, 475], ["PIV-1", "ORGANISM", 477, 482], ["-2", "GENE_OR_GENE_PRODUCT", 484, 486], ["3", "GENE_OR_GENE_PRODUCT", 489, 490], ["-4", "GENE_OR_GENE_PRODUCT", 492, 494], ["rhinovirus (HRV", "ORGANISM", 497, 512], ["respiratory syncytial virus", "ORGANISM", 515, 542], ["RSV", "ORGANISM", 544, 547], ["bocavirus", "ORGANISM", 550, 559], ["HBoV", "ORGANISM", 561, 565], ["metapneumovirus", "ORGANISM", 568, 583], ["MPV", "ORGANISM", 585, 588], ["coronavirus 229E", "ORGANISM", 591, 607], ["CoV 229E", "ORGANISM", 609, 617], ["coronavirus NL63", "ORGANISM", 620, 636], ["CoV NL63", "ORGANISM", 638, 646], ["coronavirus OC43", "ORGANISM", 649, 665], ["CoV OC43", "ORGANISM", 667, 675], ["enterovirus", "ORGANISM", 682, 693], ["HEV", "ORGANISM", 695, 698], ["RV7G01Y", "PROTEIN", 232, 239], ["influenza A virus", "SPECIES", 396, 413], ["influenza B virus", "SPECIES", 423, 440], ["parainfluenza viruses 1", "SPECIES", 450, 473], ["PIV-1", "SPECIES", 477, 482], ["respiratory syncytial virus", "SPECIES", 515, 542], ["RSV", "SPECIES", 544, 547], ["metapneumovirus", "SPECIES", 568, 583], ["coronavirus", "SPECIES", 591, 602], ["coronavirus", "SPECIES", 620, 631], ["coronavirus", "SPECIES", 649, 660], ["adenovirus", "SPECIES", 378, 388], ["AdV", "SPECIES", 390, 393], ["influenza A virus", "SPECIES", 396, 413], ["Flu A", "SPECIES", 415, 420], ["influenza B virus", "SPECIES", 423, 440], ["HRV", "SPECIES", 509, 512], ["respiratory syncytial virus", "SPECIES", 515, 542], ["RSV", "SPECIES", 544, 547], ["HBoV", "SPECIES", 561, 565], ["MPV", "SPECIES", 585, 588], ["coronavirus 229E (CoV 229E)", "SPECIES", 591, 618], ["coronavirus OC43 (CoV OC43", "SPECIES", 649, 675], ["HEV", "SPECIES", 695, 698], ["The swabs", "TREATMENT", 0, 9], ["the 15-mL tube", "TREATMENT", 17, 31], ["agitated", "PROBLEM", 37, 45], ["a vortex mixer to free cells", "TREATMENT", 72, 100], ["the swab tip", "TREATMENT", 106, 118], ["time PCRViral testing", "TEST", 124, 145], ["multiplex PCR", "TEST", 168, 181], ["Anyplex", "TEST", 188, 195], ["Bio-Rad)", "TEST", 315, 323], ["16 respiratory viruses", "PROBLEM", 354, 376], ["adenovirus", "PROBLEM", 378, 388], ["influenza A virus (Flu A", "TEST", 396, 420], ["influenza B virus (Flu B", "TEST", 423, 447], ["parainfluenza viruses", "TEST", 450, 471], ["PIV", "TEST", 477, 480], ["rhinovirus", "PROBLEM", 497, 507], ["HRV", "TEST", 509, 512], ["respiratory syncytial virus (RSV)", "PROBLEM", 515, 548], ["bocavirus (HBoV)", "TEST", 550, 566], ["metapneumovirus", "PROBLEM", 568, 583], ["MPV", "TEST", 585, 588], ["coronavirus", "PROBLEM", 591, 602], ["CoV", "TEST", 609, 612], ["coronavirus", "PROBLEM", 620, 631], ["CoV NL63", "TEST", 638, 646], ["coronavirus OC43 (CoV OC43", "PROBLEM", 649, 675], ["enterovirus", "PROBLEM", 682, 693], ["free cells", "OBSERVATION", 90, 100], ["respiratory viruses", "OBSERVATION", 357, 376], ["respiratory syncytial", "ANATOMY", 515, 536]]], ["Nucleic acid extraction was done automatically using SeePrep12\u2122 Viral (#SPN1004) supplied by NorDiag, using the extraction SeePrep machine (Seegene), as indicated as a nucleic acid extraction option by the manufacturer.", [["nucleic acid", "CHEMICAL", 168, 180], ["Nucleic acid", "SIMPLE_CHEMICAL", 0, 12], ["SeePrep12", "PROTEIN", 53, 62], ["Nucleic acid extraction", "TREATMENT", 0, 23], ["Viral (#SPN1004", "TREATMENT", 64, 79], ["the extraction SeePrep machine", "TREATMENT", 108, 138], ["a nucleic acid extraction option", "TREATMENT", 166, 198]]], ["Protocol viral NA was operated using 530 \u03bcL from the sample to result in an eluted volume of 60 \u03bcL.", [["sample", "ANATOMY", 53, 59], ["an eluted volume", "TEST", 73, 89]]], ["Reverse transcription was done using the cDNA synthesis kit for manual set up cDNA Synthesis Premix (SGRT801) from Seegene.", [["Premix", "GENE_OR_GENE_PRODUCT", 93, 99], ["the cDNA synthesis kit", "TREATMENT", 37, 59], ["manual set up cDNA Synthesis Premix", "TREATMENT", 64, 99]]], ["Interpretation of the results was done according to the manufacturer's instructions, in addition to automatic analysis using the Seegene viewer software after exporting the run data to it [8] .Statistical analysisData were coded and entered using the statistical package SPSS version 15 (IBM Corp., Armonk, NY, USA).", [["automatic analysis", "TEST", 100, 118]]], ["Data were summarized using mean [standard deviation (SD)] or median (range) for quantitative variables, and number and percentage for qualitative variables.", [["mean", "TEST", 27, 31], ["quantitative variables", "TEST", 80, 102]]], ["Comparison between groups was done using the Chi-square test for qualitative variables, and the Mann-Whitney U-test was used for quantitative variables that were not normally distributed.", [["the Chi-square test", "TEST", 41, 60], ["qualitative variables", "TEST", 65, 86], ["the Mann-Whitney U-test", "TEST", 92, 115]]], ["A p-value < 0.05 was considered significant.ResultsThe turnaround time for multiplex PCR was 6 h, but the test was done in batches three times per week.", [["A p-value", "TEST", 0, 9], ["multiplex PCR", "TEST", 75, 88], ["the test", "TEST", 102, 110]]], ["Nucleic acids of respiratory viruses causing SARI were detected in 159/177 (89.9 %) patients enrolled in the study.ResultsThe demographic and clinical characteristics of the patients are shown in Table 1 , and the frequency and monthly distribution of pathogens among the patients are shown in Table 2 and Fig. 1 .", [["Nucleic acids", "CHEMICAL", 0, 13], ["respiratory viruses", "DISEASE", 17, 36], ["SARI", "DISEASE", 45, 49], ["Nucleic acids", "AMINO_ACID", 0, 13], ["SARI", "CANCER", 45, 49], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 174, 182], ["patients", "ORGANISM", 272, 280], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 272, 280], ["Nucleic acids", "TEST", 0, 13], ["respiratory viruses", "PROBLEM", 17, 36], ["SARI", "PROBLEM", 45, 49], ["the study", "TEST", 105, 114], ["pathogens", "PROBLEM", 252, 261], ["respiratory viruses", "OBSERVATION", 17, 36], ["pathogens", "OBSERVATION", 252, 261]]], ["The median interval between the onset of symptoms and testing in our study was 3 days.Detection of multiple viruses among the patientsThe nucleic acids of more than one virus were detected in 83 patients (46.9 %).", [["nucleic acids", "CHEMICAL", 138, 151], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 195, 203], ["symptoms", "PROBLEM", 41, 49], ["testing", "TEST", 54, 61], ["our study", "TEST", 65, 74], ["multiple viruses", "PROBLEM", 99, 115], ["The nucleic acids", "TEST", 134, 151], ["multiple", "OBSERVATION_MODIFIER", 99, 107], ["viruses", "OBSERVATION", 108, 115]]], ["Dual detections were observed in 64 (36.2 %), triple detections in 17 (9.6 %), and quadruple detections in 2 (1.1 %) of 177 samples.", [["samples", "ANATOMY", 124, 131], ["Dual detections", "TEST", 0, 15], ["triple detections", "TEST", 46, 63], ["quadruple detections", "TEST", 83, 103]]], ["The frequency of co-detection with each of the studied viruses among the patients is shown in Table 2 .", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["co-detection", "PROBLEM", 17, 29]]], ["Important combinations included RSV with other viruses in 45 patients.", [["RSV", "ORGANISM", 32, 35], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["RSV", "SPECIES", 32, 35], ["RSV", "PROBLEM", 32, 35], ["other viruses", "TREATMENT", 41, 54]]], ["Rhinovirus was mostly detected in association with other viruses (64 out of 78 patients positive for HRV).", [["Rhinovirus", "GENE_OR_GENE_PRODUCT", 0, 10], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Rhinovirus", "SPECIES", 0, 10], ["Rhinovirus", "PROBLEM", 0, 10], ["other viruses", "PROBLEM", 51, 64]]], ["Bocavirus was detected in 16 patients.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["Bocavirus", "PROBLEM", 0, 9]]], ["It was the only virus detected in three of them, while it was detected in association with another virus in 13 patients.Detection of multiple viruses among the patientsA large proportion of the patients had received antibiotic therapy prior to hospital admission (121 patients, 68.4 %), and almost all the patients received antibiotic therapy during hospital admission (169 patients, 95.5 %).Detection of multiple viruses among the patientsSeventy-eight patients required ICU admission, of whom 28 (35.8 %) had co-infection with multiple viruses as follows; 24 had co-infection with two viruses, three had co-infection with three viruses, and one patient had co-infection with four viruses.", [["co-infection", "DISEASE", 511, 523], ["co-infection", "DISEASE", 565, 577], ["co-infection", "DISEASE", 606, 618], ["co-infection", "DISEASE", 659, 671], ["patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 160, 168], ["patients", "ORGANISM", 194, 202], ["patients", "ORGANISM", 268, 276], ["patients", "ORGANISM", 306, 314], ["patients", "ORGANISM", 374, 382], ["patients", "ORGANISM", 432, 440], ["patients", "ORGANISM", 454, 462], ["patient", "ORGANISM", 647, 654], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 194, 202], ["patients", "SPECIES", 268, 276], ["patients", "SPECIES", 306, 314], ["patients", "SPECIES", 374, 382], ["patients", "SPECIES", 432, 440], ["patients", "SPECIES", 454, 462], ["patient", "SPECIES", 647, 654], ["virus", "PROBLEM", 16, 21], ["another virus", "PROBLEM", 91, 104], ["multiple viruses", "PROBLEM", 133, 149], ["antibiotic therapy", "TREATMENT", 216, 234], ["antibiotic therapy", "TREATMENT", 324, 342], ["multiple viruses", "PROBLEM", 405, 421], ["co-infection", "PROBLEM", 511, 523], ["multiple viruses", "PROBLEM", 529, 545], ["co-infection", "PROBLEM", 565, 577], ["two viruses", "PROBLEM", 583, 594], ["co-infection", "PROBLEM", 606, 618], ["three viruses", "PROBLEM", 624, 637], ["co-infection", "PROBLEM", 659, 671], ["four viruses", "PROBLEM", 677, 689], ["virus", "OBSERVATION", 16, 21], ["multiple", "OBSERVATION_MODIFIER", 133, 141], ["viruses", "OBSERVATION", 142, 149], ["large", "OBSERVATION_MODIFIER", 170, 175], ["proportion", "OBSERVATION_MODIFIER", 176, 186], ["multiple", "OBSERVATION_MODIFIER", 405, 413], ["viruses", "OBSERVATION", 414, 421], ["multiple", "OBSERVATION_MODIFIER", 529, 537], ["viruses", "OBSERVATION", 538, 545], ["co-infection", "OBSERVATION", 659, 671]]], ["Twenty-one of the patients who were admitted to the ICU had RSV in association with other viruses, 14 of whom had co-infection of RSV and rhinovirus.Detection of viral pathogens in asymptomatic childrenAmong the 40 healthy asymptomatic children who were included as a control group, no virus was detected in 12 of them, while a viral pathogen was detected in 28 controls.", [["RSV", "DISEASE", 60, 63], ["RSV", "DISEASE", 130, 133], ["viral pathogens", "DISEASE", 162, 177], ["patients", "ORGANISM", 18, 26], ["RSV", "ORGANISM", 60, 63], ["RSV", "ORGANISM", 130, 133], ["rhinovirus", "ORGANISM", 138, 148], ["children", "ORGANISM", 236, 244], ["patients", "SPECIES", 18, 26], ["children", "SPECIES", 236, 244], ["RSV", "SPECIES", 60, 63], ["RSV", "SPECIES", 130, 133], ["RSV", "PROBLEM", 60, 63], ["other viruses", "PROBLEM", 84, 97], ["co-infection", "PROBLEM", 114, 126], ["RSV", "PROBLEM", 130, 133], ["rhinovirus", "PROBLEM", 138, 148], ["viral pathogens", "PROBLEM", 162, 177], ["virus", "PROBLEM", 286, 291], ["a viral pathogen", "PROBLEM", 326, 342], ["RSV", "OBSERVATION", 60, 63], ["viruses", "OBSERVATION", 90, 97], ["RSV", "OBSERVATION", 130, 133], ["rhinovirus", "OBSERVATION", 138, 148], ["viral pathogens", "OBSERVATION", 162, 177]]], ["The only viruses that were detected among the control group were AdV, HBoV, HEV, HCoV-OC43, and HRV, either as a single detection or as a co-detection (Table 3) .", [["AdV", "ORGANISM", 65, 68], ["HBoV", "ORGANISM", 70, 74], ["HEV", "ORGANISM", 76, 79], ["HCoV-OC43", "CELL", 81, 90], ["AdV", "SPECIES", 65, 68], ["HBoV", "SPECIES", 70, 74], ["HEV", "SPECIES", 76, 79], ["HCoV", "SPECIES", 81, 85], ["The only viruses", "PROBLEM", 0, 16], ["HBoV", "PROBLEM", 70, 74], ["HEV", "TEST", 76, 79], ["HCoV", "TEST", 81, 85], ["HRV", "PROBLEM", 96, 99], ["a single detection", "TEST", 111, 129], ["viruses", "OBSERVATION", 9, 16]]], ["A dual detection of these viruses was present in six controls, while triple detections of these viruses were present in four controls.", [["these viruses", "PROBLEM", 20, 33], ["these viruses", "PROBLEM", 90, 103], ["viruses", "OBSERVATION", 26, 33], ["viruses", "OBSERVATION", 96, 103]]], ["The frequency of detection of these viruses among the patients and the controls is shown in Fig. 2 .Detection of viral pathogens in asymptomatic childrenThe following viruses were not detected at all among the control group, either alone or as a co-detection with other viruses: RSV, hMPV, Flu A, Flu B, hPIV-1-2-3-4, HCoV-NL63, HCoV-229E.DiscussionWe used multiplex PCR for the detection of respiratory viruses among patients admitted with SARI.", [["viral pathogens", "DISEASE", 113, 128], ["HCoV-229E", "CHEMICAL", 329, 338], ["respiratory viruses", "DISEASE", 392, 411], ["SARI", "DISEASE", 441, 445], ["patients", "ORGANISM", 54, 62], ["children", "ORGANISM", 145, 153], ["RSV", "ORGANISM", 279, 282], ["hMPV", "ORGANISM", 284, 288], ["Flu A", "ORGANISM", 290, 295], ["Flu B", "ORGANISM", 297, 302], ["hPIV-1-2-3-4", "ORGANISM", 304, 316], ["HCoV-NL63", "ORGANISM", 318, 327], ["HCoV-229E", "ORGANISM", 329, 338], ["patients", "ORGANISM", 418, 426], ["HCoV", "PROTEIN", 318, 322], ["patients", "SPECIES", 54, 62], ["children", "SPECIES", 145, 153], ["patients", "SPECIES", 418, 426], ["RSV", "SPECIES", 279, 282], ["hMPV", "SPECIES", 284, 288], ["HCoV-229E", "SPECIES", 329, 338], ["these viruses", "PROBLEM", 30, 43], ["viral pathogens", "PROBLEM", 113, 128], ["RSV", "PROBLEM", 279, 282], ["hMPV", "PROBLEM", 284, 288], ["hPIV", "TEST", 304, 308], ["HCoV", "TEST", 318, 322], ["HCoV", "TEST", 329, 333], ["multiplex PCR", "TEST", 357, 370], ["respiratory viruses", "PROBLEM", 392, 411], ["SARI", "PROBLEM", 441, 445], ["viruses", "OBSERVATION", 36, 43], ["viral pathogens", "OBSERVATION", 113, 128], ["hMPV", "OBSERVATION", 284, 288], ["respiratory", "ANATOMY", 392, 403], ["viruses", "OBSERVATION", 404, 411]]], ["We also assessed the presence of viral nucleic acids by PCR in healthy asymptomatic children in order to better understand the etiologic role of the tested viruses in respiratory disease.", [["respiratory", "ANATOMY", 167, 178], ["nucleic acids", "CHEMICAL", 39, 52], ["respiratory disease", "DISEASE", 167, 186], ["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["viral nucleic acids", "PROBLEM", 33, 52], ["respiratory disease", "PROBLEM", 167, 186], ["viral nucleic acids", "OBSERVATION", 33, 52], ["respiratory disease", "OBSERVATION", 167, 186]]], ["Viral nucleic acids were detected in 89.9 % of patients admitted with severe lower respiratory tract infections.", [["lower respiratory tract", "ANATOMY", 77, 100], ["nucleic acids", "CHEMICAL", 6, 19], ["lower respiratory tract infections", "DISEASE", 77, 111], ["patients", "ORGANISM", 47, 55], ["lower", "ORGANISM_SUBDIVISION", 77, 82], ["respiratory tract", "ORGANISM_SUBDIVISION", 83, 100], ["patients", "SPECIES", 47, 55], ["Viral nucleic acids", "TEST", 0, 19], ["severe lower respiratory tract infections", "PROBLEM", 70, 111], ["nucleic acids", "OBSERVATION", 6, 19], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["lower", "ANATOMY_MODIFIER", 77, 82], ["respiratory tract", "ANATOMY", 83, 100], ["infections", "OBSERVATION", 101, 111]]], ["This is in keeping with a previous study that reported the detection of a viral pathogen by PCR in 72.3 % of children aged \u22645 years [9] , and with Bierbaum et al., who reported viral pathogen detection in children in excess of 80 %, compared to only 20 % in adults presenting with acute respiratory illness [10] .DiscussionSimilar to previous reports [10, 11] , the most frequently detected virus in our study was RSV (48 %).DiscussionFlu A was detected in 6.2 % of the samples and Flu B was detected in 2.3 % of the samples.", [["respiratory", "ANATOMY", 287, 298], ["samples", "ANATOMY", 470, 477], ["samples", "ANATOMY", 517, 524], ["viral pathogen detection", "DISEASE", 177, 201], ["acute respiratory illness", "DISEASE", 281, 306], ["RSV", "DISEASE", 414, 417], ["Flu A", "CHEMICAL", 435, 440], ["Flu B", "CHEMICAL", 482, 487], ["Flu A", "CHEMICAL", 435, 440], ["Flu B", "CHEMICAL", 482, 487], ["children", "ORGANISM", 109, 117], ["children", "ORGANISM", 205, 213], ["RSV", "ORGANISM", 414, 417], ["Flu A", "SIMPLE_CHEMICAL", 435, 440], ["samples", "CANCER", 470, 477], ["Flu B", "GENE_OR_GENE_PRODUCT", 482, 487], ["children", "SPECIES", 109, 117], ["children", "SPECIES", 205, 213], ["RSV", "SPECIES", 414, 417], ["a previous study", "TEST", 24, 40], ["a viral pathogen", "PROBLEM", 72, 88], ["PCR", "TEST", 92, 95], ["viral pathogen detection", "PROBLEM", 177, 201], ["acute respiratory illness", "PROBLEM", 281, 306], ["our study", "TEST", 400, 409], ["RSV", "TEST", 414, 417], ["the samples", "TEST", 466, 477], ["Flu B", "TEST", 482, 487], ["the samples", "TEST", 513, 524], ["acute", "OBSERVATION_MODIFIER", 281, 286], ["respiratory illness", "OBSERVATION", 287, 306], ["virus", "OBSERVATION", 391, 396]]], ["These results are similar to those of Lam et al., who reported a positive rate of 6.3 % for Flu A by PCR and a positive rate of 3.3 % for Flu B [2] .", [["Flu A", "CHEMICAL", 92, 97], ["Flu B", "CHEMICAL", 138, 143], ["Flu B", "CHEMICAL", 138, 143], ["a positive rate", "TEST", 63, 78], ["a positive rate", "TEST", 109, 124]]], ["Some 6-12 % of all children use healthcare services every year because of influenza [12] .", [["influenza", "DISEASE", 74, 83], ["children", "ORGANISM", 19, 27], ["children", "SPECIES", 19, 27], ["influenza", "PROBLEM", 74, 83]]], ["Additionally, many cases of infection with influenza virus are not diagnosed as such [1] .", [["infection", "DISEASE", 28, 37], ["influenza virus", "DISEASE", 43, 58], ["influenza virus", "ORGANISM", 43, 58], ["influenza virus", "SPECIES", 43, 58], ["influenza virus", "SPECIES", 43, 58], ["infection", "PROBLEM", 28, 37], ["influenza virus", "PROBLEM", 43, 58], ["infection", "OBSERVATION", 28, 37], ["influenza virus", "OBSERVATION", 43, 58]]], ["Early confirmation of influenza viruses is helpful because treatment with neuraminidase inhibitors then becomes an option [1] .DiscussionHPIVs are important causes of upper respiratory tract illness and lower respiratory tract illness, especially in children [13, 14] .", [["upper respiratory tract", "ANATOMY", 167, 190], ["lower respiratory tract", "ANATOMY", 203, 226], ["influenza viruses", "DISEASE", 22, 39], ["respiratory tract illness", "DISEASE", 173, 198], ["respiratory tract illness", "DISEASE", 209, 234], ["upper respiratory", "ORGANISM_SUBDIVISION", 167, 184], ["tract", "ORGANISM_SUBDIVISION", 185, 190], ["lower", "ORGANISM_SUBDIVISION", 203, 208], ["respiratory tract", "ORGANISM_SUBDIVISION", 209, 226], ["children", "ORGANISM", 250, 258], ["children", "SPECIES", 250, 258], ["influenza viruses", "PROBLEM", 22, 39], ["neuraminidase inhibitors", "TREATMENT", 74, 98], ["upper respiratory tract illness", "PROBLEM", 167, 198], ["lower respiratory tract illness", "PROBLEM", 203, 234], ["upper", "ANATOMY_MODIFIER", 167, 172], ["respiratory tract", "ANATOMY", 173, 190], ["lower", "ANATOMY_MODIFIER", 203, 208], ["respiratory tract", "ANATOMY", 209, 226]]], ["Collectively, the four types of hPIVs were detected in 8 % of the patients with SARI in the current study.DiscussionSimilar to previous studies, multiplex PCR allowed the detection of HRV, HCoV-OC43, and hMPV, which were not detectable by conventional cell culture isolation or direct detection using immunofluorescence assay.", [["cell", "ANATOMY", 252, 256], ["SARI", "DISEASE", 80, 84], ["hPIVs", "GENE_OR_GENE_PRODUCT", 32, 37], ["patients", "ORGANISM", 66, 74], ["HRV", "ORGANISM", 184, 187], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 189, 198], ["hMPV", "ORGANISM", 204, 208], ["cell", "CELL", 252, 256], ["hPIVs", "PROTEIN", 32, 37], ["patients", "SPECIES", 66, 74], ["HRV", "SPECIES", 184, 187], ["HCoV", "SPECIES", 189, 193], ["hMPV", "SPECIES", 204, 208], ["hPIVs", "TREATMENT", 32, 37], ["SARI", "PROBLEM", 80, 84], ["the current study", "TEST", 88, 105], ["previous studies", "TEST", 127, 143], ["multiplex PCR", "TEST", 145, 158], ["the detection", "TEST", 167, 180], ["HRV", "TEST", 184, 187], ["HCoV", "TEST", 189, 193], ["OC43", "PROBLEM", 194, 198], ["hMPV", "PROBLEM", 204, 208], ["conventional cell culture isolation", "TEST", 239, 274], ["direct detection", "TEST", 278, 294], ["immunofluorescence assay", "TEST", 301, 325], ["four types", "OBSERVATION_MODIFIER", 18, 28], ["hMPV", "OBSERVATION", 204, 208]]], ["The improvement in the diagnostic yield by adding HRV was confirmed in our study, and also reported previously by Gruteke et al. [15] .", [["our study", "TEST", 71, 80], ["improvement", "OBSERVATION_MODIFIER", 4, 15]]], ["These findings are comparable to previous reports [10, 11] .DiscussionIn view of the fact that respiratory tract infections in children occur in close succession during the winter season, it can be assumed that infections actually overlap.", [["respiratory tract", "ANATOMY", 95, 112], ["respiratory tract infections", "DISEASE", 95, 123], ["infections", "DISEASE", 211, 221], ["respiratory tract", "ORGANISM_SUBDIVISION", 95, 112], ["children", "ORGANISM", 127, 135], ["children", "SPECIES", 127, 135], ["respiratory tract infections", "PROBLEM", 95, 123], ["infections", "PROBLEM", 211, 221], ["respiratory tract", "ANATOMY", 95, 112], ["infections", "OBSERVATION", 113, 123], ["infections", "OBSERVATION", 211, 221]]], ["This may provide an explanation for the fact that viral nucleic acids of different viruses in one specimen are found virtually only in childrenfor example, in 8 % of all specimens analyzed by Bierbaum et al. [17] and 46.9 % of the samples in our study.", [["specimen", "ANATOMY", 98, 106], ["specimens", "ANATOMY", 170, 179], ["samples", "ANATOMY", 231, 238], ["nucleic acids", "CHEMICAL", 56, 69], ["viral nucleic acids of different viruses", "PROBLEM", 50, 90], ["all specimens", "TEST", 166, 179], ["the samples", "TEST", 227, 238], ["our study", "TEST", 242, 251]]], ["Co-detections were reported more commonly than single infections in children than older adults (\u226565 years; p = 0.01) [16] .DiscussionCo-infection of RSV with other respiratory viruses is common and can increase the severity of the disease [18] .", [["infections", "DISEASE", 54, 64], ["RSV", "DISEASE", 149, 152], ["respiratory viruses", "DISEASE", 164, 183], ["children", "ORGANISM", 68, 76], ["RSV", "ORGANISM", 149, 152], ["children", "SPECIES", 68, 76], ["RSV", "SPECIES", 149, 152], ["RSV", "PROBLEM", 149, 152], ["other respiratory viruses", "PROBLEM", 158, 183], ["the disease", "PROBLEM", 227, 238], ["RSV", "OBSERVATION", 149, 152], ["viruses", "OBSERVATION", 176, 183], ["disease", "OBSERVATION", 231, 238]]], ["In the current study, co-infection with RSV was present in 52.9 % of the patients who tested positive for RSV.", [["co-infection", "DISEASE", 22, 34], ["RSV", "DISEASE", 106, 109], ["RSV", "ORGANISM", 40, 43], ["patients", "ORGANISM", 73, 81], ["RSV", "ORGANISM", 106, 109], ["patients", "SPECIES", 73, 81], ["RSV", "SPECIES", 40, 43], ["RSV", "SPECIES", 106, 109], ["the current study", "TEST", 3, 20], ["co-infection", "PROBLEM", 22, 34], ["RSV", "PROBLEM", 40, 43], ["RSV", "PROBLEM", 106, 109], ["co-infection", "OBSERVATION", 22, 34], ["RSV", "OBSERVATION", 40, 43]]], ["This may have increased the severity of the disease, resulting in hospital admission.", [["the disease", "PROBLEM", 40, 51], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["severity", "OBSERVATION_MODIFIER", 28, 36], ["disease", "OBSERVATION", 44, 51]]], ["Moreover, 26.9 % of the patients who were admitted to the ICU had RSV in association with other viruses.Detection of viral pathogens among asymptomatic childrenFor a long time, it was assumed that symptomatic infection with respiratory tract viruses was regularly shown by the confirmation of viral nucleic acids in respiratory secretions.", [["respiratory secretions", "ANATOMY", 316, 338], ["RSV", "DISEASE", 66, 69], ["viral pathogens", "DISEASE", 117, 132], ["infection", "DISEASE", 209, 218], ["respiratory tract viruses", "DISEASE", 224, 249], ["nucleic acids", "CHEMICAL", 299, 312], ["patients", "ORGANISM", 24, 32], ["RSV", "ORGANISM", 66, 69], ["children", "ORGANISM", 152, 160], ["secretions", "ORGANISM_SUBSTANCE", 328, 338], ["patients", "SPECIES", 24, 32], ["children", "SPECIES", 152, 160], ["RSV", "SPECIES", 66, 69], ["RSV", "PROBLEM", 66, 69], ["other viruses", "PROBLEM", 90, 103], ["viral pathogens", "PROBLEM", 117, 132], ["symptomatic infection", "PROBLEM", 197, 218], ["respiratory tract viruses", "PROBLEM", 224, 249], ["viral nucleic acids in respiratory secretions", "PROBLEM", 293, 338], ["RSV", "OBSERVATION", 66, 69], ["viruses", "OBSERVATION", 96, 103], ["viral", "OBSERVATION_MODIFIER", 117, 122], ["symptomatic", "OBSERVATION_MODIFIER", 197, 208], ["infection", "OBSERVATION", 209, 218], ["respiratory tract", "ANATOMY", 224, 241], ["viral nucleic acids", "OBSERVATION", 293, 312], ["respiratory secretions", "OBSERVATION", 316, 338]]], ["However, in recent years, there have been increasing indications that this is not necessarily the case [19] .", [["increasing", "OBSERVATION_MODIFIER", 42, 52]]], ["Data are available from only a few case-control studies that examined to what extent specific respiratory viruses cause disease [9, [20] [21] [22] [23] .Detection of viral pathogens among asymptomatic childrenIn the current study, AdV, HBoV, HRV, HEV, and HCoV-OC43 were not only detected in patients admitted with SARI, but were also detected in asymptomatic children.Detection of viral pathogens among asymptomatic childrenThe clinical importance of bocaviruses remains the subject of controversy.", [["respiratory viruses", "DISEASE", 94, 113], ["viral pathogens", "DISEASE", 382, 397], ["[20] [21] [22] [23]", "SIMPLE_CHEMICAL", 132, 151], ["AdV", "ORGANISM", 231, 234], ["HBoV", "ORGANISM", 236, 240], ["HEV", "ORGANISM", 247, 250], ["HCoV-OC43", "ORGANISM", 256, 265], ["patients", "ORGANISM", 292, 300], ["children", "ORGANISM", 360, 368], ["children", "ORGANISM", 417, 425], ["bocaviruses", "CANCER", 452, 463], ["patients", "SPECIES", 292, 300], ["children", "SPECIES", 360, 368], ["children", "SPECIES", 417, 425], ["AdV", "SPECIES", 231, 234], ["HBoV", "SPECIES", 236, 240], ["HRV", "SPECIES", 242, 245], ["HEV", "SPECIES", 247, 250], ["HCoV", "SPECIES", 256, 260], ["specific respiratory viruses cause disease", "PROBLEM", 85, 127], ["viral pathogens", "PROBLEM", 166, 181], ["the current study", "TEST", 212, 229], ["HBoV", "PROBLEM", 236, 240], ["HRV", "TEST", 242, 245], ["HEV", "TEST", 247, 250], ["HCoV", "TEST", 256, 260], ["OC43", "PROBLEM", 261, 265], ["SARI", "PROBLEM", 315, 319], ["viral pathogens", "PROBLEM", 382, 397], ["bocaviruses", "TREATMENT", 452, 463], ["respiratory viruses", "OBSERVATION", 94, 113], ["viral pathogens", "OBSERVATION", 166, 181], ["viral pathogens", "OBSERVATION", 382, 397]]], ["Bocavirus DNA can be confirmed in the respiratory tract of asymptomatic children; a high concentration of these viruses in respiratory specimens seems to be associated with symptoms [19] .", [["respiratory tract", "ANATOMY", 38, 55], ["respiratory specimens", "ANATOMY", 123, 144], ["DNA", "CELLULAR_COMPONENT", 10, 13], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["children", "ORGANISM", 72, 80], ["Bocavirus DNA", "DNA", 0, 13], ["children", "SPECIES", 72, 80], ["Bocavirus", "SPECIES", 0, 9], ["Bocavirus DNA", "PROBLEM", 0, 13], ["these viruses in respiratory specimens", "PROBLEM", 106, 144], ["symptoms", "PROBLEM", 173, 181], ["respiratory tract", "ANATOMY", 38, 55], ["viruses", "OBSERVATION", 112, 119]]], ["Only quantitative monoplex PCR or multiplex PCR can provide information about virus concentration.", [["quantitative monoplex PCR", "TEST", 5, 30], ["multiplex PCR", "TEST", 34, 47], ["virus concentration", "TREATMENT", 78, 97]]], ["Bocavirus was detected by PCR in nasopharyngeal swabs samples of children suffering from acute respiratory tract infection in Saudi Arabia [24] .", [["nasopharyngeal swabs samples", "ANATOMY", 33, 61], ["respiratory tract", "ANATOMY", 95, 112], ["acute respiratory tract infection", "DISEASE", 89, 122], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 33, 53], ["children", "ORGANISM", 65, 73], ["children", "SPECIES", 65, 73], ["Bocavirus", "SPECIES", 0, 9], ["Bocavirus", "PROBLEM", 0, 9], ["PCR", "TEST", 26, 29], ["nasopharyngeal swabs", "TEST", 33, 53], ["acute respiratory tract infection", "PROBLEM", 89, 122], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory tract", "ANATOMY", 95, 112], ["infection", "OBSERVATION", 113, 122]]], ["In our study, HBoV was detected among symptomatic children admitted with SARI, as well as in asymptomatic children.Detection of viral pathogens among asymptomatic childrenSix different human pathogenic coronavirus species (HCoV) are known to date [1] .", [["SARI", "DISEASE", 73, 77], ["HBoV", "ORGANISM", 14, 18], ["children", "ORGANISM", 50, 58], ["children", "ORGANISM", 106, 114], ["childrenSix different", "ORGANISM", 163, 184], ["human pathogenic coronavirus species", "ORGANISM", 185, 221], ["HCoV", "CANCER", 223, 227], ["children", "SPECIES", 50, 58], ["children", "SPECIES", 106, 114], ["human", "SPECIES", 185, 190], ["pathogenic coronavirus", "SPECIES", 191, 213], ["HBoV", "SPECIES", 14, 18], ["human pathogenic coronavirus", "SPECIES", 185, 213], ["HCoV", "SPECIES", 223, 227], ["our study", "TEST", 3, 12], ["HBoV", "PROBLEM", 14, 18], ["viral pathogens", "PROBLEM", 128, 143], ["asymptomatic childrenSix different human pathogenic coronavirus species", "PROBLEM", 150, 221], ["viral pathogens", "OBSERVATION", 128, 143], ["pathogenic coronavirus species", "OBSERVATION", 191, 221]]], ["As a rule, they cause benign disorders of the upper respiratory tract [25] .", [["upper respiratory tract", "ANATOMY", 46, 69], ["disorders of the upper respiratory tract", "DISEASE", 29, 69], ["upper respiratory", "ORGANISM_SUBDIVISION", 46, 63], ["tract", "ORGANISM_SUBDIVISION", 64, 69], ["benign disorders of the upper respiratory tract", "PROBLEM", 22, 69], ["upper", "ANATOMY_MODIFIER", 46, 51], ["respiratory tract", "ANATOMY", 52, 69]]], ["However, after the SARS (severe acute respiratory syndrome) epidemic in 2003 with the SARS CoV, HCoV-NL63 was described in 2004 and HCoVHKU1 in 2005 [21] .", [["SARS", "DISEASE", 19, 23], ["acute respiratory syndrome", "DISEASE", 32, 58], ["SARS", "DISEASE", 86, 90], ["HCoV", "GENE_OR_GENE_PRODUCT", 96, 100], ["SARS CoV", "SPECIES", 86, 94], ["the SARS (severe acute respiratory syndrome", "PROBLEM", 15, 58], ["epidemic", "PROBLEM", 60, 68], ["the SARS CoV", "TEST", 82, 94], ["HCoV", "TEST", 96, 100], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["respiratory syndrome", "OBSERVATION", 38, 58]]], ["The Middle Eastern Respiratory Syndrome (MERS) is caused by MERS-CoV [26] .Detection of viral pathogens among asymptomatic childrenHuman corona viruses (HCoV-NL63, HCoV-OC43, HCoV-229E) were detected in seven patients admitted with SARI.", [["Respiratory Syndrome", "DISEASE", 19, 39], ["MERS", "DISEASE", 41, 45], ["SARI", "DISEASE", 232, 236], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["childrenHuman corona viruses", "ORGANISM", 123, 151], ["HCoV-NL63", "ORGANISM", 153, 162], ["HCoV-OC43", "ORGANISM", 164, 173], ["HCoV-229E", "CELL", 175, 184], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["MERS-CoV", "SPECIES", 60, 68], ["childrenHuman corona viruses", "SPECIES", 123, 151], ["HCoV", "SPECIES", 153, 157], ["HCoV", "SPECIES", 164, 168], ["HCoV-229E", "SPECIES", 175, 184], ["The Middle Eastern Respiratory Syndrome", "PROBLEM", 0, 39], ["viral pathogens", "PROBLEM", 88, 103], ["asymptomatic childrenHuman corona viruses", "PROBLEM", 110, 151], ["HCoV", "TEST", 153, 157], ["HCoV", "TEST", 164, 168], ["HCoV", "TEST", 175, 179], ["SARI", "PROBLEM", 232, 236], ["Middle", "ANATOMY_MODIFIER", 4, 10], ["Respiratory Syndrome", "OBSERVATION", 19, 39], ["viral pathogens", "OBSERVATION", 88, 103], ["corona viruses", "OBSERVATION", 137, 151]]], ["However, HCoV-OC43 was also detected in six asymptomatic children.", [["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 9, 18], ["children", "ORGANISM", 57, 65], ["HCoV", "PROTEIN", 9, 13], ["OC43", "DNA", 14, 18], ["children", "SPECIES", 57, 65], ["HCoV", "SPECIES", 9, 13]]], ["Adenovirus was the third most frequently detected virus in our study population.", [["Adenovirus", "ORGANISM", 0, 10], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus", "PROBLEM", 0, 10], ["virus", "OBSERVATION", 50, 55]]], ["Adenovirus DNA is also often found in the respiratory secretions of asymptomatic children [1] , and was detected among patients as well as asymptomatic children in our study.Detection of viral pathogens among asymptomatic childrenHRVs are frequently found in asymptomatic children [27] , but are also detected in patients with symptoms ranging from mild common colds [28] to serious lower respiratory tract disease [29] .", [["respiratory secretions", "ANATOMY", 42, 64], ["lower respiratory tract", "ANATOMY", 383, 406], ["colds", "DISEASE", 361, 366], ["lower respiratory tract disease", "DISEASE", 383, 414], ["Adenovirus", "ORGANISM", 0, 10], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["children", "ORGANISM", 81, 89], ["patients", "ORGANISM", 119, 127], ["children", "ORGANISM", 152, 160], ["childrenHRVs", "CANCER", 222, 234], ["children", "ORGANISM", 272, 280], ["patients", "ORGANISM", 313, 321], ["tract", "ORGANISM_SUBDIVISION", 401, 406], ["children", "SPECIES", 81, 89], ["patients", "SPECIES", 119, 127], ["children", "SPECIES", 152, 160], ["children", "SPECIES", 272, 280], ["patients", "SPECIES", 313, 321], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus DNA", "PROBLEM", 0, 14], ["our study", "TEST", 164, 173], ["viral pathogens", "PROBLEM", 187, 202], ["symptoms", "PROBLEM", 327, 335], ["mild common colds", "PROBLEM", 349, 366], ["serious lower respiratory tract disease", "PROBLEM", 375, 414], ["viral pathogens", "OBSERVATION", 187, 202], ["mild", "OBSERVATION_MODIFIER", 349, 353], ["respiratory tract", "ANATOMY", 389, 406]]], ["Since the development of molecular assays for the detection of HRVs, the detection rate of HRV in patients with respiratory infections has increased to up to 50 % [30] .", [["respiratory", "ANATOMY", 112, 123], ["respiratory infections", "DISEASE", 112, 134], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["molecular assays", "TEST", 25, 41], ["HRVs", "PROBLEM", 63, 67], ["the detection rate", "TEST", 69, 87], ["HRV", "PROBLEM", 91, 94], ["respiratory infections", "PROBLEM", 112, 134], ["infections", "OBSERVATION", 124, 134]]], ["HRV was only second to RSV in frequency of detection by multiplex PCR in swab samples of children admitted with SARI in our study.", [["swab samples", "ANATOMY", 73, 85], ["SARI", "DISEASE", 112, 116], ["RSV", "ORGANISM", 23, 26], ["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97], ["RSV", "SPECIES", 23, 26], ["HRV", "TEST", 0, 3], ["RSV", "PROBLEM", 23, 26], ["multiplex PCR", "TEST", 56, 69], ["SARI", "PROBLEM", 112, 116], ["our study", "TEST", 120, 129]]], ["However, HRV was also detected in 4/40 controls.", [["HRV", "TEST", 9, 12]]], ["HRVs are frequently detected in asymptomatic children, making it difficult to interpret the clinical significance of a positive PCR finding [9] .", [["HRVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["a positive PCR finding", "PROBLEM", 117, 139]]], ["Moreover, HRVs could be detected until 2-5 weeks after the onset of symptoms [31] .", [["HRVs", "PATHOLOGICAL_FORMATION", 10, 14], ["HRVs", "PROBLEM", 10, 14], ["symptoms", "PROBLEM", 68, 76]]], ["In spite of these facts, Rhedin et al. [9] reported that their data indicate that 39 % [95 % confidence interval (CI): 1 to 62] of acute respiratory infections in their population could be attributed to HRV.Detection of viral pathogens among asymptomatic childrenThe potentially important rate of excreters of viral nucleic acids of specific pathogens that are not directly associated with the acute illness presents a problem.", [["respiratory", "ANATOMY", 137, 148], ["respiratory infections", "DISEASE", 137, 159], ["viral pathogens", "DISEASE", 220, 235], ["nucleic acids", "CHEMICAL", 316, 329], ["children", "ORGANISM", 255, 263], ["children", "SPECIES", 255, 263], ["acute respiratory infections", "PROBLEM", 131, 159], ["HRV", "PROBLEM", 203, 206], ["viral pathogens", "PROBLEM", 220, 235], ["viral nucleic acids", "TREATMENT", 310, 329], ["specific pathogens", "PROBLEM", 333, 351], ["the acute illness", "PROBLEM", 390, 407], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["respiratory", "ANATOMY", 137, 148], ["infections", "OBSERVATION", 149, 159], ["viral pathogens", "OBSERVATION", 220, 235], ["acute", "OBSERVATION_MODIFIER", 394, 399], ["illness", "OBSERVATION", 400, 407]]], ["To date, quantitative conclusions are not reliably established, neither for monoplex PCR nor for multiplex PCR [1] .", [["monoplex PCR", "TEST", 76, 88], ["multiplex PCR", "TEST", 97, 110]]], ["Rhedin et al. showed that the nucleic acids of RSV, hMPV, and parainfluenza virus can be confirmed almost exclusively in symptomatic children and very rarely in asymptomatic children.", [["nucleic acids", "CHEMICAL", 30, 43], ["hMPV, and parainfluenza virus", "DISEASE", 52, 81], ["RSV", "ORGANISM", 47, 50], ["hMPV", "ORGANISM", 52, 56], ["parainfluenza virus", "ORGANISM", 62, 81], ["children", "ORGANISM", 133, 141], ["children", "ORGANISM", 174, 182], ["parainfluenza virus", "SPECIES", 62, 81], ["children", "SPECIES", 133, 141], ["children", "SPECIES", 174, 182], ["RSV", "SPECIES", 47, 50], ["hMPV", "SPECIES", 52, 56], ["parainfluenza virus", "SPECIES", 62, 81], ["the nucleic acids", "TEST", 26, 43], ["RSV", "PROBLEM", 47, 50], ["hMPV", "PROBLEM", 52, 56], ["parainfluenza virus", "PROBLEM", 62, 81], ["hMPV", "OBSERVATION", 52, 56], ["parainfluenza virus", "OBSERVATION", 62, 81]]], ["Their results indicate that a qPCR finding of RSV, hMPV, or PIV is likely to be causative of disease in children with acute respiratory infection, and that detection of several other viruses, such as HBoV, HRV, AdV, HCoV, and HEV, must be interpreted with caution, due to the high detection rates among healthy children [9] .", [["respiratory", "ANATOMY", 124, 135], ["acute respiratory infection", "DISEASE", 118, 145], ["RSV", "ORGANISM", 46, 49], ["hMPV", "ORGANISM", 51, 55], ["children", "ORGANISM", 104, 112], ["HBoV", "ORGANISM", 200, 204], ["AdV", "ORGANISM", 211, 214], ["HCoV", "GENE_OR_GENE_PRODUCT", 216, 220], ["HEV", "ORGANISM", 226, 229], ["children", "ORGANISM", 311, 319], ["children", "SPECIES", 104, 112], ["children", "SPECIES", 311, 319], ["RSV", "SPECIES", 46, 49], ["hMPV", "SPECIES", 51, 55], ["PIV", "SPECIES", 60, 63], ["HBoV", "SPECIES", 200, 204], ["HRV", "SPECIES", 206, 209], ["AdV", "SPECIES", 211, 214], ["HCoV", "SPECIES", 216, 220], ["HEV", "SPECIES", 226, 229], ["a qPCR", "TEST", 28, 34], ["RSV", "PROBLEM", 46, 49], ["hMPV", "PROBLEM", 51, 55], ["PIV", "TREATMENT", 60, 63], ["disease", "PROBLEM", 93, 100], ["acute respiratory infection", "PROBLEM", 118, 145], ["several other viruses", "PROBLEM", 169, 190], ["HBoV", "PROBLEM", 200, 204], ["HRV", "PROBLEM", 206, 209], ["HEV", "PROBLEM", 226, 229], ["RSV", "OBSERVATION", 46, 49], ["is likely to be", "UNCERTAINTY", 64, 79], ["disease", "OBSERVATION", 93, 100], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory", "ANATOMY", 124, 135], ["infection", "OBSERVATION", 136, 145], ["viruses", "OBSERVATION", 183, 190]]], ["The detection of AdV, HBoV, HRV, HCoV-OC43, and HEV among asymptomatic children in the current study and the absence of RSV, hMPV, Flu A, Flu B, hPIV-1-2-3-4, HCoV-NL63, and HCoV-229E in these children support these findings.Detection of viral pathogens among asymptomatic childrenWhereas the detection of some viruses, such as influenza virus and respiratory syncytial virus (RSV), is clearly predictive for respiratory disease [32] [33] [34] , the clinical significance upon the detection of several other viruses needs further investigation.", [["respiratory", "ANATOMY", 409, 420], ["HCoV-229E", "CHEMICAL", 174, 183], ["viral pathogens", "DISEASE", 238, 253], ["influenza virus", "DISEASE", 328, 343], ["respiratory syncytial virus", "DISEASE", 348, 375], ["respiratory disease", "DISEASE", 409, 428], ["AdV", "ORGANISM", 17, 20], ["HBoV", "ORGANISM", 22, 26], ["HRV", "GENE_OR_GENE_PRODUCT", 28, 31], ["HCoV-OC43", "ORGANISM", 33, 42], ["HEV", "ORGANISM", 48, 51], ["children", "ORGANISM", 71, 79], ["RSV", "ORGANISM", 120, 123], ["hMPV", "ORGANISM", 125, 129], ["Flu A", "ORGANISM", 131, 136], ["Flu B", "ORGANISM", 138, 143], ["hPIV", "GENE_OR_GENE_PRODUCT", 145, 149], ["1-2-3-4", "GENE_OR_GENE_PRODUCT", 150, 157], ["HCoV", "GENE_OR_GENE_PRODUCT", 159, 163], ["NL63", "GENE_OR_GENE_PRODUCT", 164, 168], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 174, 183], ["children", "ORGANISM", 193, 201], ["influenza virus", "ORGANISM", 328, 343], ["respiratory syncytial virus", "ORGANISM", 348, 375], ["RSV", "ORGANISM", 377, 380], ["Flu B, hPIV-1-2-3-4, HCoV-NL63, and HCoV-229E", "DNA", 138, 183], ["children", "SPECIES", 71, 79], ["children", "SPECIES", 193, 201], ["influenza virus", "SPECIES", 328, 343], ["respiratory syncytial virus", "SPECIES", 348, 375], ["AdV", "SPECIES", 17, 20], ["HBoV", "SPECIES", 22, 26], ["HCoV", "SPECIES", 33, 37], ["HEV", "SPECIES", 48, 51], ["RSV", "SPECIES", 120, 123], ["hMPV", "SPECIES", 125, 129], ["HCoV", "SPECIES", 159, 163], ["HCoV-229E", "SPECIES", 174, 183], ["influenza virus", "SPECIES", 328, 343], ["respiratory syncytial virus", "SPECIES", 348, 375], ["RSV", "SPECIES", 377, 380], ["The detection", "TEST", 0, 13], ["AdV", "PROBLEM", 17, 20], ["HBoV", "PROBLEM", 22, 26], ["HRV", "TEST", 28, 31], ["HCoV", "TEST", 33, 37], ["OC43", "PROBLEM", 38, 42], ["the current study", "TEST", 83, 100], ["RSV", "PROBLEM", 120, 123], ["hMPV", "PROBLEM", 125, 129], ["hPIV", "TEST", 145, 149], ["HCoV", "TEST", 159, 163], ["HCoV", "TEST", 174, 178], ["viral pathogens", "PROBLEM", 238, 253], ["some viruses", "PROBLEM", 306, 318], ["influenza virus", "PROBLEM", 328, 343], ["respiratory syncytial virus", "PROBLEM", 348, 375], ["respiratory disease", "PROBLEM", 409, 428], ["the detection", "TEST", 477, 490], ["several other viruses", "PROBLEM", 494, 515], ["further investigation", "TEST", 522, 543], ["RSV", "OBSERVATION", 120, 123], ["hMPV", "OBSERVATION", 125, 129], ["viral pathogens", "OBSERVATION", 238, 253], ["viruses", "OBSERVATION", 311, 318], ["respiratory syncytial virus", "OBSERVATION", 348, 375], ["viruses", "OBSERVATION", 508, 515]]], ["The interpretation of a viral detection is complicated by the fact that infections with multiple viruses are common in children with acute respiratory infection and that many viruses have lately been reported to be found also in asymptomatic children [20] .Detection of viral pathogens among asymptomatic childrenMost respiratory tract infections in children are of viral origin, especially during the winter season, which, in Egypt, is from November to February.", [["respiratory", "ANATOMY", 139, 150], ["respiratory tract", "ANATOMY", 318, 335], ["infections", "DISEASE", 72, 82], ["acute respiratory infection", "DISEASE", 133, 160], ["viral pathogens", "DISEASE", 270, 285], ["respiratory tract infections", "DISEASE", 318, 346], ["children", "ORGANISM", 119, 127], ["children", "ORGANISM", 242, 250], ["children", "ORGANISM", 305, 313], ["tract", "ORGANISM_SUBDIVISION", 330, 335], ["children", "ORGANISM", 350, 358], ["children", "SPECIES", 119, 127], ["children", "SPECIES", 242, 250], ["children", "SPECIES", 305, 313], ["children", "SPECIES", 350, 358], ["a viral detection", "TEST", 22, 39], ["infections", "PROBLEM", 72, 82], ["multiple viruses", "PROBLEM", 88, 104], ["acute respiratory infection", "PROBLEM", 133, 160], ["many viruses", "PROBLEM", 170, 182], ["viral pathogens", "PROBLEM", 270, 285], ["Most respiratory tract infections", "PROBLEM", 313, 346], ["viral origin", "PROBLEM", 366, 378], ["viral", "OBSERVATION", 24, 29], ["infections", "OBSERVATION", 72, 82], ["multiple", "OBSERVATION_MODIFIER", 88, 96], ["viruses", "OBSERVATION", 97, 104], ["acute", "OBSERVATION_MODIFIER", 133, 138], ["respiratory", "ANATOMY", 139, 150], ["infection", "OBSERVATION", 151, 160], ["viral pathogens", "OBSERVATION", 270, 285], ["viral origin", "OBSERVATION_MODIFIER", 366, 378]]], ["Almost all the patients in our study received antibiotic therapy during hospital admission.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["our study", "TEST", 27, 36], ["antibiotic therapy", "TREATMENT", 46, 64]]], ["The identification of specific viral pathogens will limit the unnecessary use of antibiotics and will facilitate giving specific antiviral therapy when indicated (e.g., neuraminidase inhibitors in confirmed influenza virus infection).Detection of viral pathogens among asymptomatic childrenBetter understanding of how to interpret viral findings by the use of new technologies is important to improve management decisions, which, in turn, will ameliorate patient outcomes and reduce unnecessary use of antibiotics.ConclusionThis study confirms the high rate of detection of viral nucleic acids by multiplex PCR) among hospitalized children admitted with severe acute respiratory infection, as well as the high rate of detection of multiple viruses.", [["respiratory", "ANATOMY", 667, 678], ["influenza virus infection", "DISEASE", 207, 232], ["nucleic acids", "CHEMICAL", 580, 593], ["acute respiratory infection", "DISEASE", 661, 688], ["influenza virus", "ORGANISM", 207, 222], ["patient", "ORGANISM", 455, 462], ["children", "ORGANISM", 631, 639], ["influenza virus", "SPECIES", 207, 222], ["patient", "SPECIES", 455, 462], ["children", "SPECIES", 631, 639], ["specific viral pathogens", "PROBLEM", 22, 46], ["antibiotics", "TREATMENT", 81, 92], ["specific antiviral therapy", "TREATMENT", 120, 146], ["neuraminidase inhibitors", "TREATMENT", 169, 193], ["influenza virus infection", "PROBLEM", 207, 232], ["viral pathogens", "PROBLEM", 247, 262], ["antibiotics", "TREATMENT", 502, 513], ["This study", "TEST", 524, 534], ["viral nucleic acids", "PROBLEM", 574, 593], ["multiplex PCR", "TEST", 597, 610], ["severe acute respiratory infection", "PROBLEM", 654, 688], ["multiple viruses", "PROBLEM", 731, 747], ["viral pathogens", "OBSERVATION", 247, 262], ["severe", "OBSERVATION_MODIFIER", 654, 660], ["acute", "OBSERVATION_MODIFIER", 661, 666], ["respiratory", "ANATOMY", 667, 678], ["infection", "OBSERVATION", 679, 688], ["multiple", "OBSERVATION_MODIFIER", 731, 739], ["viruses", "OBSERVATION", 740, 747]]], ["Adenovirus, HBoV, HRV, HEV, and HCoV-OC43 were also detected in asymptomatic controls, resulting in challenges in clinical interpretation.", [["Adenovirus", "ORGANISM", 0, 10], ["HBoV", "ORGANISM", 12, 16], ["HRV", "GENE_OR_GENE_PRODUCT", 18, 21], ["HEV", "ORGANISM", 23, 26], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 32, 41], ["Adenovirus", "SPECIES", 0, 10], ["HBoV", "SPECIES", 12, 16], ["HRV", "SPECIES", 18, 21], ["HEV", "SPECIES", 23, 26], ["HCoV", "SPECIES", 32, 36], ["Adenovirus", "PROBLEM", 0, 10], ["HBoV", "PROBLEM", 12, 16], ["HRV", "PROBLEM", 18, 21], ["HEV", "PROBLEM", 23, 26], ["HCoV", "TEST", 32, 36], ["OC43", "PROBLEM", 37, 41], ["HBoV", "OBSERVATION", 12, 16]]], ["Further studies are required to provide quantitative conclusions that will facilitate clinical interpretation and application of the results in the clinical setting.Compliance with ethical standardsFunding source None.Conflict of interestThe authors declare that they have no conflict of interest.Conflict of interestEthical approval Informed verbal consent was obtained from the parents of all the patients and the controls.", [["patients", "ORGANISM", 399, 407], ["patients", "SPECIES", 399, 407], ["Further studies", "TEST", 0, 15], ["clinical interpretation", "TEST", 86, 109], ["ethical standards", "TREATMENT", 181, 198]]], ["The study design conformed to the Revised Helsinki Declaration of Bioethics and was approved by the Scientific Ethics Committee of the Department of Pediatrics, Faculty of Medicine of Cairo University.", [["The study", "TEST", 0, 9]]]], "PMC7418611": [["As of the 7 June, the Johns Hopkins Coronavirus Resource Center reported almost 6.9 million cases of COVID 19 infection with over 398 000 deaths worldwide.", [["COVID", "DISEASE", 101, 106], ["infection", "DISEASE", 110, 119], ["deaths", "DISEASE", 138, 144], ["COVID 19 infection", "PROBLEM", 101, 119], ["infection", "OBSERVATION", 110, 119]]], ["In 2012 GLOBOCAN1 reported that well over two million of the world\u2019s 14 million cancer cases were due to infection, including 640 000 cases of human papilloma virus infection (HPV) the necessary precursor to the development of cervix cancer.", [["cancer", "ANATOMY", 80, 86], ["cervix cancer", "ANATOMY", 227, 240], ["cancer", "DISEASE", 80, 86], ["infection", "DISEASE", 105, 114], ["human papilloma virus infection", "DISEASE", 143, 174], ["cervix cancer", "DISEASE", 227, 240], ["cancer", "CANCER", 80, 86], ["human papilloma virus", "ORGANISM", 143, 164], ["HPV", "ORGANISM", 176, 179], ["cervix cancer", "CANCER", 227, 240], ["human papilloma virus", "SPECIES", 143, 164], ["human papilloma virus", "SPECIES", 143, 164], ["HPV", "SPECIES", 176, 179], ["14 million cancer cases", "PROBLEM", 69, 92], ["infection", "PROBLEM", 105, 114], ["human papilloma virus infection", "PROBLEM", 143, 174], ["cervix cancer", "PROBLEM", 227, 240], ["infection", "OBSERVATION", 105, 114], ["papilloma virus", "OBSERVATION", 149, 164], ["cervix", "ANATOMY", 227, 233], ["cancer", "OBSERVATION", 234, 240]]], ["By 2018, there were approximately 570 000 cases of cervical cancer globally and 311 000 deaths from the disease.2", [["cervical cancer", "ANATOMY", 51, 66], ["cervical cancer", "DISEASE", 51, 66], ["deaths", "DISEASE", 88, 94], ["cervical cancer", "CANCER", 51, 66], ["cervical cancer", "PROBLEM", 51, 66], ["the disease", "PROBLEM", 100, 111], ["cervical", "ANATOMY", 51, 59], ["cancer", "OBSERVATION", 60, 66], ["disease", "OBSERVATION", 104, 111]]]], "PMC7314735": [["IntroductionMultilevel modeling (MLM) extends conventional techniques from the area of Model-Driven Engineering by providing model hierarchies with multiple levels of abstraction.", [["IntroductionMultilevel modeling (MLM)", "PROBLEM", 0, 37], ["multiple", "OBSERVATION_MODIFIER", 148, 156]]], ["The advantages of allowing multiple abstraction levels (e.g. reducing accidental complexity in software models and avoiding synthetic type-instance anti-patterns) and flexible typing (e.g. multiple typing, linguistic extension and deep instantiation), as well as the exact nature of the techniques used for MLM are well studied in the literature [1, 4\u20136, 8, 10, 17].", [["multiple abstraction levels", "TEST", 27, 54], ["synthetic type-instance anti-patterns", "TREATMENT", 124, 161], ["flexible typing", "TEST", 167, 182], ["multiple typing", "TEST", 189, 204], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["abstraction", "OBSERVATION", 36, 47]]], ["Our particular approach [19, 20] to MLM facilitates the separation of concerns by allowing integration of different multilevel modeling hierarchies as separate aspects of the system to be modelled.", [["different multilevel modeling hierarchies", "PROBLEM", 106, 147]]], ["In addition, we enhance reusability of concepts and their behaviour by allowing the definition of flexible transformation rules which are applicable to different hierarchies with a variable number of levels.", [["flexible transformation rules", "PROBLEM", 98, 127], ["flexible transformation", "OBSERVATION", 98, 121], ["variable", "OBSERVATION_MODIFIER", 181, 189]]]], "f25bf6a1e9fe5595582b4fa887b57d02a1eb5443": [["IntroductionRecently, World Health Organization (WHO, https://www.who.int/) declared that the outbreak spread of the novel coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes over 8 million reported cases and more than 4 hundred thousand deaths in 216 countries.", [["coronavirus", "DISEASE", 123, 134], ["acute respiratory syndrome coronavirus", "DISEASE", 142, 180], ["deaths", "DISEASE", 266, 272], ["coronavirus", "ORGANISM", 123, 134], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 135, 182], ["SARS-CoV-2", "ORGANISM", 184, 194], ["coronavirus", "SPECIES", 123, 134], ["syndrome coronavirus", "SPECIES", 160, 180], ["coronavirus severe acute respiratory syndrome coronavirus", "SPECIES", 123, 180], ["SARS-CoV-2", "SPECIES", 184, 194], ["the novel coronavirus severe acute respiratory syndrome coronavirus", "PROBLEM", 113, 180], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["respiratory syndrome", "OBSERVATION", 148, 168]]], ["Most of the coronaviruses cause only mild 3 respiratory distress [1, 2] .", [["respiratory", "ANATOMY", 44, 55], ["coronaviruses", "DISEASE", 12, 25], ["respiratory distress", "DISEASE", 44, 64], ["coronaviruses", "ORGANISM", 12, 25], ["mild 3 respiratory distress", "PROBLEM", 37, 64], ["coronaviruses", "OBSERVATION", 12, 25], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["respiratory distress", "OBSERVATION", 44, 64]]], ["However, three coronaviruses namely the severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, and the Middle East respiratory syndrome coronavirus (MERS-CoV) have been found so far highly pathogenic transmitted from animal to human [3] .", [["acute respiratory syndrome coronavirus", "DISEASE", 47, 85], ["SARS-CoV)", "DISEASE", 87, 96], ["Middle East respiratory syndrome coronavirus", "DISEASE", 118, 162], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 40, 85], ["SARS-CoV", "ORGANISM", 87, 95], ["SARS-CoV-2", "ORGANISM", 98, 108], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 118, 162], ["MERS-CoV", "ORGANISM", 164, 172], ["human", "ORGANISM", 242, 247], ["CoV-2", "SPECIES", 103, 108], ["human", "SPECIES", 242, 247], ["severe acute respiratory syndrome coronavirus", "SPECIES", 40, 85], ["SARS-CoV", "SPECIES", 87, 95], ["SARS-CoV-2", "SPECIES", 98, 108], ["Middle East respiratory syndrome coronavirus", "SPECIES", 118, 162], ["MERS-CoV", "SPECIES", 164, 172], ["human", "SPECIES", 242, 247], ["three coronaviruses", "PROBLEM", 9, 28], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 36, 85], ["SARS", "TEST", 87, 91], ["SARS", "TEST", 98, 102], ["CoV", "TEST", 103, 106], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 114, 162], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["respiratory syndrome coronavirus", "OBSERVATION", 53, 85], ["Middle", "ANATOMY_MODIFIER", 118, 124], ["respiratory syndrome", "OBSERVATION", 130, 150]]], ["The SARS-CoV in 2003 brings about a 10 % case fatality rate (CFR), and MERS presented a CFR of about 34.4% [4] [5] [6] .", [["SARS", "DISEASE", 4, 8], ["SARS-CoV", "ORGANISM", 4, 12], ["SARS-CoV", "SPECIES", 4, 12], ["a CFR", "TEST", 86, 91]]], ["The CFR for the novel coronavirus cannot be stated at the moment, as the pandemic is not over yet, although 3.4% is estimated and one thing is apparent the transmission rate of the infection is higher than the previous outbreaks [7] .IntroductionThe SARS-CoV-2 causes mainly severe acute respiratory distress by attacking lung cells and other complications in the heart, kidney, brain, and spleen and ultimately succumbed to a disastrous effect in coronavirus afflicted patients [8] .", [["respiratory", "ANATOMY", 288, 299], ["lung cells", "ANATOMY", 322, 332], ["heart", "ANATOMY", 364, 369], ["kidney", "ANATOMY", 371, 377], ["brain", "ANATOMY", 379, 384], ["spleen", "ANATOMY", 390, 396], ["infection", "DISEASE", 181, 190], ["SARS", "DISEASE", 250, 254], ["respiratory distress", "DISEASE", 288, 308], ["coronavirus afflicted", "DISEASE", 448, 469], ["coronavirus", "ORGANISM", 22, 33], ["SARS-CoV-2", "ORGANISM", 250, 260], ["lung cells", "CELL", 322, 332], ["heart", "ORGAN", 364, 369], ["kidney", "ORGAN", 371, 377], ["brain", "ORGAN", 379, 384], ["spleen", "ORGAN", 390, 396], ["coronavirus", "ORGANISM", 448, 459], ["patients", "ORGANISM", 470, 478], ["CFR", "PROTEIN", 4, 7], ["lung cells", "CELL_TYPE", 322, 332], ["patients", "SPECIES", 470, 478], ["SARS-CoV", "SPECIES", 250, 258], ["The CFR", "TEST", 0, 7], ["the novel coronavirus", "PROBLEM", 12, 33], ["the infection", "PROBLEM", 177, 190], ["The SARS", "TEST", 246, 254], ["mainly severe acute respiratory distress", "PROBLEM", 268, 308], ["attacking lung cells", "PROBLEM", 312, 332], ["other complications in the heart, kidney, brain, and spleen", "PROBLEM", 337, 396], ["a disastrous effect", "PROBLEM", 425, 444], ["coronavirus", "OBSERVATION", 22, 33], ["infection", "OBSERVATION", 181, 190], ["higher", "OBSERVATION_MODIFIER", 194, 200], ["severe", "OBSERVATION_MODIFIER", 275, 281], ["acute", "OBSERVATION_MODIFIER", 282, 287], ["respiratory distress", "OBSERVATION", 288, 308], ["lung cells", "OBSERVATION", 322, 332], ["complications", "OBSERVATION", 343, 356], ["heart", "ANATOMY", 364, 369], ["kidney", "ANATOMY", 371, 377], ["brain", "ANATOMY", 379, 384], ["spleen", "ANATOMY", 390, 396], ["disastrous", "OBSERVATION_MODIFIER", 427, 437]]], ["In this hour of crisis, there is no available effective standard-of-care present to treat the coronavirus affected patients.", [["coronavirus", "DISEASE", 94, 105], ["coronavirus", "ORGANISM", 94, 105], ["patients", "ORGANISM", 115, 123], ["coronavirus", "SPECIES", 94, 105], ["patients", "SPECIES", 115, 123], ["crisis", "PROBLEM", 16, 22], ["the coronavirus affected patients", "PROBLEM", 90, 123], ["crisis", "OBSERVATION", 16, 22], ["no", "UNCERTAINTY", 33, 35], ["coronavirus", "OBSERVATION", 94, 105]]], ["This makes an urgent need to find out agents to get control over the pandemic.", [["agents", "TREATMENT", 38, 44]]], ["Scientists globally make an effort to do their best to come up with effective therapeutic agents.", [["effective therapeutic agents", "TREATMENT", 68, 96]]], ["So, to design a drug for the virus first we have to see the indispensable processes of the virus, which help them to survive and replicates its copy number.", [["the virus", "PROBLEM", 25, 34], ["the virus", "PROBLEM", 87, 96], ["virus", "OBSERVATION", 91, 96]]], ["The genome of the virus showed a sequence similarity of 96.3% BatCoV RaTG13 and 79% with the SARS-CoV [9, 10] .", [["SARS-CoV", "SPECIES", 93, 101], ["a sequence similarity", "TEST", 31, 52], ["BatCoV RaTG13", "TEST", 62, 75], ["the SARS", "TEST", 89, 97]]], ["SARS-CoV-2 is an enveloped single-stranded positive-sense RNA genome containing viruses.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV-2", "DNA", 0, 10], ["enveloped single-stranded positive-sense RNA genome", "DNA", 17, 68], ["SARS-CoV", "SPECIES", 0, 8], ["viruses", "OBSERVATION", 80, 87]]], ["The RNA consists of 29,891 nucleotides, which transcribed for 6-12 ORFs, can be translated into around 28 identified non-structural and structural proteins (NCBI Reference Sequence: NC_045512.2) [11] .IntroductionSARS-CoV-2 enters into the host cells containing ACE2, such as lung, oral, and nasal mucosa by glycosylated spike protein [12] .", [["cells", "ANATOMY", 245, 250], ["lung", "ANATOMY", 276, 280], ["oral", "ANATOMY", 282, 286], ["nasal mucosa", "ANATOMY", 292, 304], ["nucleotides", "CHEMICAL", 27, 38], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 201, 223], ["host cells", "CELL", 240, 250], ["ACE2", "GENE_OR_GENE_PRODUCT", 262, 266], ["lung", "ORGAN", 276, 280], ["oral", "ORGANISM_SUBDIVISION", 282, 286], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 292, 304], ["glycosylated spike protein [12]", "GENE_OR_GENE_PRODUCT", 308, 339], ["6-12 ORFs", "DNA", 62, 71], ["non-structural and structural proteins", "PROTEIN", 117, 155], ["host cells", "CELL_TYPE", 240, 250], ["ACE2", "PROTEIN", 262, 266], ["glycosylated spike protein", "PROTEIN", 308, 334], ["The RNA", "TEST", 0, 7], ["nucleotides", "TREATMENT", 27, 38], ["IntroductionSARS", "TEST", 201, 217], ["ACE2", "TEST", 262, 266], ["glycosylated spike protein", "TEST", 308, 334], ["lung", "ANATOMY", 276, 280], ["nasal mucosa", "ANATOMY", 292, 304]]], ["Human ACE2 interacts with SARS-CoV-2 spike proteins and facilitates SARS-CoV-2 entry into target cells [13] .", [["cells", "ANATOMY", 97, 102], ["Human", "ORGANISM", 0, 5], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 78], ["cells", "CELL", 97, 102], ["Human ACE2", "PROTEIN", 0, 10], ["SARS-CoV-2 spike proteins", "PROTEIN", 26, 51], ["target cells", "CELL_TYPE", 90, 102], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["spike proteins", "TEST", 37, 51], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76]]], ["The 4 viral glycosylated spike protein composed of S1 and S2 subunits in the coronaviruses which enables them access into the host cell.", [["cell", "ANATOMY", 131, 135], ["S1", "GENE_OR_GENE_PRODUCT", 51, 53], ["S2", "GENE_OR_GENE_PRODUCT", 58, 60], ["coronaviruses", "ORGANISM", 77, 90], ["host cell", "CELL", 126, 135], ["4 viral glycosylated spike protein", "PROTEIN", 4, 38], ["S1 and S2 subunits", "PROTEIN", 51, 69], ["host cell", "CELL_TYPE", 126, 135], ["The 4 viral glycosylated spike protein", "PROBLEM", 0, 38], ["S1 and S2 subunits", "TREATMENT", 51, 69], ["the coronaviruses", "PROBLEM", 73, 90], ["host cell", "OBSERVATION", 126, 135]]], ["The RBD of S1 subunit in SARS-CoV-2 attaches to ACE2, led to the shed of S1 subunit and subsequently triggers the cleavage of the S2 subunit by host protease protein, TMPRSS2, that can cleave S1/S2 protease cleavage site [13] .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["S1", "GENE_OR_GENE_PRODUCT", 73, 75], ["S2", "GENE_OR_GENE_PRODUCT", 130, 132], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 167, 174], ["RBD", "PROTEIN", 4, 7], ["S1 subunit", "PROTEIN", 11, 21], ["ACE2", "PROTEIN", 48, 52], ["S1 subunit", "PROTEIN", 73, 83], ["S2 subunit", "PROTEIN", 130, 140], ["host protease protein", "PROTEIN", 144, 165], ["TMPRSS2", "PROTEIN", 167, 174], ["S1", "PROTEIN", 192, 194], ["S2", "PROTEIN", 195, 197], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["ACE2", "TEST", 48, 52], ["the S2 subunit", "TREATMENT", 126, 140], ["host protease protein", "TREATMENT", 144, 165], ["TMPRSS2", "TEST", 167, 174], ["S1", "ANATOMY", 73, 75]]], ["The cleavage changes the conformation and allowing HR1, HR2 to form 6-HB, which facilitates membrane fusion and virus releases its payload RNA into the cytoplasm.", [["membrane", "ANATOMY", 92, 100], ["cytoplasm", "ANATOMY", 152, 161], ["6-HB", "CHEMICAL", 68, 72], ["HR1", "GENE_OR_GENE_PRODUCT", 51, 54], ["HR2", "GENE_OR_GENE_PRODUCT", 56, 59], ["6-HB", "SIMPLE_CHEMICAL", 68, 72], ["membrane", "CELLULAR_COMPONENT", 92, 100], ["cytoplasm", "ORGANISM_SUBSTANCE", 152, 161], ["HR1", "PROTEIN", 51, 54], ["HR2", "PROTEIN", 56, 59], ["HB", "PROTEIN", 70, 72], ["payload RNA", "RNA", 131, 142], ["The cleavage changes the conformation", "PROBLEM", 0, 37], ["HR1", "TEST", 51, 54], ["membrane fusion", "TREATMENT", 92, 107], ["virus", "PROBLEM", 112, 117], ["membrane fusion", "OBSERVATION", 92, 107]]], ["The first translation product of the RNA genome is polyprotein pp1a and pp1ab.", [["pp1a", "GENE_OR_GENE_PRODUCT", 63, 67], ["pp1ab", "GENE_OR_GENE_PRODUCT", 72, 77], ["RNA genome", "DNA", 37, 47], ["pp1a", "PROTEIN", 63, 67], ["pp1ab", "PROTEIN", 72, 77], ["polyprotein pp1a", "TREATMENT", 51, 67]]], ["Subsequently, 3CL protease (3CLpro) and papain-like protease (PLpro) cleave pp1a and pp1ab to functional proteins required for genome amplification.", [["3CL protease", "GENE_OR_GENE_PRODUCT", 14, 26], ["3CLpro", "GENE_OR_GENE_PRODUCT", 28, 34], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 40, 60], ["PLpro", "GENE_OR_GENE_PRODUCT", 62, 67], ["pp1a", "GENE_OR_GENE_PRODUCT", 76, 80], ["pp1ab", "GENE_OR_GENE_PRODUCT", 85, 90], ["3CL protease", "PROTEIN", 14, 26], ["3CLpro", "PROTEIN", 28, 34], ["papain-like protease", "PROTEIN", 40, 60], ["PLpro", "PROTEIN", 62, 67], ["pp1a", "PROTEIN", 76, 80], ["pp1ab", "PROTEIN", 85, 90], ["3CL protease (3CLpro)", "TREATMENT", 14, 35], ["papain", "TREATMENT", 40, 46], ["protease (PLpro) cleave pp1a", "TREATMENT", 52, 80], ["pp1ab", "TREATMENT", 85, 90], ["functional proteins", "TREATMENT", 94, 113], ["genome amplification", "TREATMENT", 127, 147]]], ["The other structural proteins are produced and the host ER-Golgi system assembles and releases mature virus from infected cells [14, 15] .", [["ER-Golgi system", "ANATOMY", 56, 71], ["cells", "ANATOMY", 122, 127], ["ER", "GENE_OR_GENE_PRODUCT", 56, 58], ["Golgi", "CELLULAR_COMPONENT", 59, 64], ["cells", "CELL", 122, 127], ["structural proteins", "PROTEIN", 10, 29], ["ER", "PROTEIN", 56, 58], ["infected cells", "CELL_TYPE", 113, 127], ["infected cells", "PROBLEM", 113, 127], ["infected cells", "OBSERVATION", 113, 127]]], ["The current understanding strongly recommends targeting the surface protein of the viral particle, which possibly prevents them from entering the host cell.IntroductionSARS-CoV-2 spike protein is a trimeric protein.", [["surface", "ANATOMY", 60, 67], ["cell", "ANATOMY", 151, 155], ["cell", "CELL", 151, 155], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 156, 178], ["surface protein", "PROTEIN", 60, 75], ["host cell", "CELL_TYPE", 146, 155], ["IntroductionSARS-CoV-2 spike protein", "PROTEIN", 156, 192], ["trimeric protein", "PROTEIN", 198, 214], ["the surface protein", "TEST", 56, 75], ["the viral particle", "PROBLEM", 79, 97], ["IntroductionSARS", "TEST", 156, 172], ["CoV", "TEST", 173, 176], ["viral particle", "OBSERVATION", 83, 97], ["possibly prevents", "UNCERTAINTY", 105, 122], ["host cell", "OBSERVATION", 146, 155]]], ["The RBD of each subunit has two types of conformations.", [["RBD", "PROTEIN", 4, 7], ["RBD", "OBSERVATION", 4, 7], ["two types", "OBSERVATION_MODIFIER", 28, 37]]], ["One conformation is \"up\" and the other is \"down\".IntroductionWhen the conformation is \"up\", the viral spike protein could smoothly interact with human ACE2 protein, otherwise, it is inaccessible [16] .", [["human", "ORGANISM", 145, 150], ["ACE2", "GENE_OR_GENE_PRODUCT", 151, 155], ["viral spike protein", "PROTEIN", 96, 115], ["human ACE2 protein", "PROTEIN", 145, 163], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150], ["the viral spike protein", "PROBLEM", 92, 115], ["human ACE2 protein", "TREATMENT", 145, 163]]], ["Comparing the structure of SARS-CoV-2 and SARS-CoV in spike protein, they have similar amino acid sequences and functions [17] .", [["SARS", "DISEASE", 27, 31], ["amino acid", "CHEMICAL", 87, 97], ["amino acid", "CHEMICAL", 87, 97], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["amino acid", "AMINO_ACID", 87, 97], ["spike protein", "PROTEIN", 54, 67], ["SARS-CoV", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["SARS", "PROBLEM", 42, 46], ["CoV in spike protein", "TEST", 47, 67], ["similar amino acid sequences", "TEST", 79, 107]]], ["However, the RBD of SARS-CoV-2 spike protein in the down conformation N packs tightly against the N terminal domain (NTD) of the neighboring protomer, whereas the SARS-CoV-2 in the \"down\" conformation is angled closer to the central cavity of the trimer.", [["SARS", "DISEASE", 20, 24], ["N", "CHEMICAL", 98, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 163, 173], ["RBD", "PROTEIN", 13, 16], ["SARS-CoV-2 spike protein", "PROTEIN", 20, 44], ["N terminal domain", "PROTEIN", 98, 115], ["NTD", "PROTEIN", 117, 120], ["neighboring protomer", "PROTEIN", 129, 149], ["SARS-CoV-2", "PROTEIN", 163, 173], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "TEST", 20, 24], ["CoV", "TEST", 25, 28], ["spike protein", "PROBLEM", 31, 44], ["conformation N packs", "TREATMENT", 57, 77], ["the N terminal domain", "PROBLEM", 94, 115], ["the SARS", "TEST", 159, 167], ["CoV", "TEST", 168, 171], ["angled", "OBSERVATION_MODIFIER", 204, 210], ["central", "ANATOMY_MODIFIER", 225, 232], ["cavity", "ANATOMY_MODIFIER", 233, 239], ["trimer", "ANATOMY_MODIFIER", 247, 253]]], ["Additionally, the binding affinity between SARS-CoV-2 spike protein and ACE2 protein is stronger than SARS-CoV, even 10-20 folds [18] .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 102, 110], ["SARS-CoV-2 spike protein", "PROTEIN", 43, 67], ["ACE2 protein", "PROTEIN", 72, 84], ["SARS-CoV", "SPECIES", 102, 110], ["the binding affinity", "TEST", 14, 34], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51], ["spike protein", "TEST", 54, 67], ["ACE2 protein", "TEST", 72, 84], ["SARS", "TEST", 102, 106], ["CoV", "TEST", 107, 110]]], ["Therefore, we deduce that the structure of SARS-CoV-2 is similar to SARS-CoV, but not the same.", [["SARS", "DISEASE", 43, 47], ["SARS", "DISEASE", 68, 72], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["SARS-CoV", "ORGANISM", 68, 76], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 68, 76], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["SARS", "PROBLEM", 68, 72]]], ["However, the virtual screening of authentic databases and the use of advanced bioinformatics and cheminformatics can reduce the time to come up with the best drug match to the selected target.", [["the virtual screening", "TEST", 9, 30], ["authentic databases", "TEST", 34, 53]]], ["This process of virtual screening has become a gold standard method for the preliminary phase of drug designing.", [["virtual screening", "TEST", 16, 33]]], ["To discover the potential hits against SARS-CoV-2, we have screened the essential entry pathway targeting virus penetration into cells.", [["cells", "ANATOMY", 129, 134], ["SARS", "DISEASE", 39, 43], ["SARS-CoV-2", "ORGANISM", 39, 49], ["cells", "CELL", 129, 134], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "PROBLEM", 39, 43], ["virus penetration into cells", "PROBLEM", 106, 134]]], ["This study aims to find the potential hit compounds from Taiwan Database of Extracts and Compounds (TDEC, https://tdec.kmu.edu.tw/) for and against SARS-CoV-2 spike protein.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 148, 158], ["SARS-CoV-2 spike protein", "PROTEIN", 148, 172], ["SARS-CoV", "SPECIES", 148, 156], ["This study", "TEST", 0, 10], ["the potential hit compounds", "PROBLEM", 24, 51], ["SARS", "PROBLEM", 148, 152], ["CoV", "TEST", 153, 156], ["2 spike protein", "PROBLEM", 157, 172]]], ["We focus on the screen of hit compounds that can interact with viral spike protein and spike-ACE2 complex protein, leading to the prevention of viral payload into the host cytoplasm.", [["cytoplasm", "ANATOMY", 172, 181], ["spike-ACE2", "GENE_OR_GENE_PRODUCT", 87, 97], ["cytoplasm", "ORGANISM_SUBSTANCE", 172, 181], ["viral spike protein", "PROTEIN", 63, 82], ["spike-ACE2 complex protein", "PROTEIN", 87, 113], ["the screen", "TEST", 12, 22], ["hit compounds", "PROBLEM", 26, 39], ["viral spike protein", "PROBLEM", 63, 82], ["ACE2 complex protein", "PROBLEM", 93, 113], ["viral payload into the host cytoplasm", "PROBLEM", 144, 181], ["viral payload", "OBSERVATION", 144, 157], ["host cytoplasm", "OBSERVATION", 167, 181]]], ["We have selected our target mainly in the RBD of spike proteins for viral and host cell interactions.", [["cell", "ANATOMY", 83, 87], ["host cell", "CELL", 78, 87], ["RBD", "PROTEIN", 42, 45], ["spike proteins", "PROTEIN", 49, 63], ["spike proteins", "PROBLEM", 49, 63], ["viral and host cell interactions", "PROBLEM", 68, 100], ["host cell interactions", "OBSERVATION", 78, 100]]], ["It includes much information, such as compounds' structures, physicochemical properties, and biological activities, etc. on pure natural isolates, crude extracts, and synthesized extract from plants, microbes, marine organisms, and Chinese Herbal Medicines.", [["extracts", "ANATOMY", 153, 161], ["extracts", "ORGANISM_SUBSTANCE", 153, 161], ["pure natural isolates", "TREATMENT", 124, 145], ["crude extracts", "TREATMENT", 147, 161], ["Chinese Herbal Medicines", "TREATMENT", 232, 256]]], ["In the present study, an attempt has been made to virtually screen candidates from TDEC for a selected target and did all the high throughput bioinformatics and cheminformatics analysis to get an insight into the interaction of spike protein and hits.", [["TDEC", "CANCER", 83, 87], ["spike protein", "PROTEIN", 228, 241], ["cheminformatics analysis", "TEST", 161, 185], ["spike protein", "PROBLEM", 228, 241], ["hits", "PROBLEM", 246, 250]]], ["6Protein superimpositionThe protein superimposition was performed by PyMOL software (version 0.99rc6) to compare the conformation of spike proteins in two states [20] .", [["6Protein", "SIMPLE_CHEMICAL", 0, 8], ["spike proteins", "PROTEIN", 133, 147], ["The protein superimposition", "TEST", 24, 51], ["spike proteins", "PROBLEM", 133, 147]]], ["One was spike protein in the prefusion ACE2-free conformation, and the other was RBD of spike protein in the ACE2-bound conformation.", [["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["spike protein", "PROTEIN", 8, 21], ["ACE2", "PROTEIN", 39, 43], ["RBD", "PROTEIN", 81, 84], ["spike protein", "PROTEIN", 88, 101], ["ACE2", "PROTEIN", 109, 113], ["spike protein", "PROBLEM", 8, 21], ["RBD", "PROBLEM", 81, 84], ["spike protein", "PROBLEM", 88, 101], ["free conformation", "OBSERVATION", 44, 61]]], ["In this study, the simulated structure of the RBD of spike protein in the prefusion ACE2-free conformation was constructed by homology modeling using the structure of the experimental structure of ACE2-free spike protein resolved by cryogenic electron microscopy (Cryo-EM) as the modeling template (S1A Fig) and the simulated spike protein was able to be obtained from SWISS MODEL website (S1B Fig) [18, 21] .", [["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 197, 201], ["RBD", "PROTEIN", 46, 49], ["spike protein", "PROTEIN", 53, 66], ["ACE2", "PROTEIN", 84, 88], ["ACE2", "PROTEIN", 197, 201], ["spike protein", "PROTEIN", 207, 220], ["this study", "TEST", 3, 13], ["spike protein", "PROBLEM", 53, 66], ["ACE2", "TEST", 197, 201], ["cryogenic electron microscopy", "TEST", 233, 262], ["the simulated spike protein", "PROBLEM", 312, 339], ["RBD", "OBSERVATION", 46, 49], ["experimental structure", "OBSERVATION", 171, 193]]], ["The other was RBD of the spike protein bound with ACE2 protein that was an experimental protein structure resolved by X-ray crystallography and it was able to be downloaded from Protein Data Bank (PDB, https://www.rcsb.org/) (S1C Fig) [22] .", [["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["RBD", "PROTEIN", 14, 17], ["spike protein", "PROTEIN", 25, 38], ["ACE2 protein", "PROTEIN", 50, 62], ["the spike protein bound", "PROBLEM", 21, 44], ["ACE2 protein", "TEST", 50, 62], ["an experimental protein structure", "PROBLEM", 72, 105], ["X-ray crystallography", "TEST", 118, 139]]], ["The protein superimposition calculations were analyzed and shown by PyMOL software.Structure-based virtual screeningThe virtual screenings with molecular docking calculations were performed by AutoDock Vina (version 1.1.2) program within PyRx (version 0.8) software to discover the potential compounds binding into the viral spike protein from the compound database [23, 24] .", [["viral spike protein", "PROTEIN", 319, 338], ["The protein superimposition calculations", "TEST", 0, 40], ["virtual screening", "TEST", 99, 116], ["The virtual screenings", "TEST", 116, 138], ["molecular docking calculations", "TEST", 144, 174], ["the potential compounds binding", "PROBLEM", 278, 309], ["the viral spike protein", "PROBLEM", 315, 338], ["the compound database", "TEST", 344, 365], ["viral spike", "OBSERVATION", 319, 330]]], ["The 2,321 structures of compounds were downloaded (May 9, 2020) from TDEC, and then collected those compounds together and save it as an sdf format file by Discovery Studio 2019 visualizer software (DS 2019) [25] .Structure-based virtual screeningSubsequently, these structures of compounds were optimized by energy minimization with steepest descent algorithm using MMFF94 force field, and then translated and 7 divided to 2,321 individual pdbqt format files by Open Babel program within PyRx software [26] .", [["based virtual screening", "TEST", 224, 247], ["steepest descent algorithm", "TREATMENT", 334, 360]]], ["The experimental structure of spike-ACE2 complex protein resolved by X-ray crystallography was obtained from Protein Data Bank (PDB ID: 6M0J) and the simulated structure of prefusional spike protein was downloaded from SWISS MODEL website [21, 22, 27] .", [["spike-ACE2", "GENE_OR_GENE_PRODUCT", 30, 40], ["ACE2 complex protein", "PROTEIN", 36, 56], ["prefusional spike protein", "PROTEIN", 173, 198], ["spike", "PROBLEM", 30, 35], ["ACE2 complex protein", "PROBLEM", 36, 56], ["X-ray crystallography", "TEST", 69, 90], ["prefusional spike protein", "PROBLEM", 173, 198], ["spike", "OBSERVATION_MODIFIER", 30, 35], ["prefusional spike", "OBSERVATION", 173, 190]]], ["After that, the substrates, including ligands, metal ions, and water molecules existed in both protein structures were all removed and the atoms of residues in both protein structures were modified by added the polar hydrogens and partial charges using DS 2019 software with CHARM force field.Structure-based virtual screeningMoreover, to discover the potential compounds binding into the RBD of spike protein in the prefusion conformation and the site of the connective interface of spike-ACE2 complex protein from the database by virtual screening, dimensions of docking search spaces were respectively set big enough to contain the residues of ACE2 binding site on the RBD of spike proteins.", [["connective", "ANATOMY", 460, 470], ["metal ions", "SIMPLE_CHEMICAL", 47, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 490, 494], ["ACE2", "GENE_OR_GENE_PRODUCT", 647, 651], ["RBD", "PROTEIN", 389, 392], ["spike protein", "PROTEIN", 396, 409], ["spike-ACE2 complex protein", "PROTEIN", 484, 510], ["ACE2 binding site", "PROTEIN", 647, 664], ["RBD", "PROTEIN", 672, 675], ["spike proteins", "PROTEIN", 679, 693], ["metal ions", "TREATMENT", 47, 57], ["water molecules", "TREATMENT", 63, 78], ["residues in both protein structures", "PROBLEM", 148, 183], ["the polar hydrogens", "TREATMENT", 207, 226], ["CHARM force field", "TREATMENT", 275, 292], ["based virtual screening", "TEST", 303, 326], ["spike protein in the prefusion conformation", "PROBLEM", 396, 439], ["ACE2 complex protein", "PROBLEM", 490, 510], ["virtual screening", "TEST", 532, 549], ["docking search spaces", "PROBLEM", 565, 586], ["ACE2 binding site", "PROBLEM", 647, 664], ["spike proteins", "PROBLEM", 679, 693], ["prefusion conformation", "OBSERVATION", 417, 439], ["connective interface", "OBSERVATION", 460, 480]]], ["Therefore, the size of the docking sites was respectively set as follows.", [["size", "OBSERVATION_MODIFIER", 15, 19], ["docking sites", "OBSERVATION", 27, 40]]], ["In experimental spike-ACE2 complex proteinProtein superimpositionA previous report had been shown that once the RBD of SARS-CoV-2 spike protein bound to human ACE2 protein, it can assist virus entry into the cells [17] .Protein superimpositionRecently, the 3D protein structure of the viral spike protein has been resolved by Cryo-EM technique [18] .", [["cells", "ANATOMY", 208, 213], ["SARS", "DISEASE", 119, 123], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 119, 129], ["human", "ORGANISM", 153, 158], ["ACE2", "GENE_OR_GENE_PRODUCT", 159, 163], ["cells", "CELL", 208, 213], ["ACE2", "PROTEIN", 22, 26], ["RBD", "PROTEIN", 112, 115], ["SARS-CoV-2 spike protein", "PROTEIN", 119, 143], ["human ACE2 protein", "PROTEIN", 153, 171], ["3D protein structure", "PROTEIN", 257, 277], ["viral spike protein", "PROTEIN", 285, 304], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["experimental spike", "PROBLEM", 3, 21], ["SARS", "PROBLEM", 119, 123], ["CoV", "TEST", 124, 127], ["spike protein bound", "PROBLEM", 130, 149], ["human ACE2 protein", "TREATMENT", 153, 171], ["Protein superimpositionRecently", "TEST", 220, 251], ["the 3D protein structure", "TEST", 253, 277], ["the viral spike protein", "TEST", 281, 304], ["spike", "OBSERVATION_MODIFIER", 16, 21], ["viral spike", "OBSERVATION", 285, 296]]], ["However, we found that the structure of the spike protein resolved by Cryo-EM was incomplete because it lacked parts of residues in the RBD of spike protein (S1A Fig) .", [["Cryo-EM", "CHEMICAL", 70, 77], ["RBD of spike protein", "GENE_OR_GENE_PRODUCT", 136, 156], ["spike protein", "PROTEIN", 44, 57], ["Cryo", "PROTEIN", 70, 74], ["RBD", "PROTEIN", 136, 139], ["spike protein", "PROTEIN", 143, 156], ["S1A Fig", "PROTEIN", 158, 165], ["the spike protein", "PROBLEM", 40, 57], ["Cryo", "TEST", 70, 74], ["spike protein", "PROBLEM", 143, 156], ["spike", "OBSERVATION_MODIFIER", 44, 49]]], ["Therefore, the structure of the spike protein with the complete amino acid sequences in the prefusion conformation was needed to be constructed by simulation.", [["amino acid", "CHEMICAL", 64, 74], ["amino acid", "CHEMICAL", 64, 74], ["amino acid", "AMINO_ACID", 64, 74], ["spike protein", "PROTEIN", 32, 45], ["the spike protein", "PROBLEM", 28, 45], ["the complete amino acid sequences", "TEST", 51, 84], ["the prefusion conformation", "TREATMENT", 88, 114]]], ["Fortunately, a useful and trusted simulated structure of SARS-CoV-2 spike protein in the prefusion conformation that has been constructed by homology modeling and could be easily downloaded from SWISS-MODEL website (S1B Fig).", [["SARS", "DISEASE", 57, 61], ["SARS-CoV-2 spike protein", "PROTEIN", 57, 81], ["SWISS", "PROTEIN", 195, 200], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["2 spike protein in the prefusion conformation", "PROBLEM", 66, 111], ["prefusion conformation", "OBSERVATION", 89, 111]]], ["Additionally, the viral RBD of spike protein bound with human ACE2 protein, the spike-ACE2 complex protein, was also recently resolved by X-ray crystallography (S1C Fig).", [["human", "ORGANISM", 56, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["spike-ACE2", "GENE_OR_GENE_PRODUCT", 80, 90], ["viral RBD", "PROTEIN", 18, 27], ["spike protein", "PROTEIN", 31, 44], ["human ACE2 protein", "PROTEIN", 56, 74], ["spike-ACE2 complex protein", "PROTEIN", 80, 106], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["the viral RBD of spike protein bound", "PROBLEM", 14, 50], ["human ACE2 protein", "TEST", 56, 74], ["the spike", "TEST", 76, 85], ["ACE2 complex protein", "PROBLEM", 86, 106], ["X-ray crystallography", "TEST", 138, 159], ["viral RBD", "OBSERVATION", 18, 27]]], ["To investigate whether the conformation between the RBD of spike proteins in ACE2-free state and ACE2-bound state have differences or not, the protein superimposition was performed by PyMOL software using the structural aligning method.", [["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 97, 101], ["RBD", "PROTEIN", 52, 55], ["spike proteins", "PROTEIN", 59, 73], ["ACE2", "PROTEIN", 77, 81], ["ACE2", "PROTEIN", 97, 101], ["spike proteins", "TEST", 59, 73], ["ACE2", "TEST", 77, 81], ["ACE2", "TEST", 97, 101], ["the protein superimposition", "TEST", 139, 166]]], ["The data showed that the value of root mean square (RMS) of the two conformations was 1.735 \u00c5 (< 2\u00c5).", [["root", "ANATOMY", 34, 38], ["The data", "TEST", 0, 8]]], ["It meant that the superimposition between both RBD of spike proteins was good (Fig 1) .", [["RBD", "PROTEIN", 47, 50], ["spike proteins", "PROTEIN", 54, 68], ["spike proteins", "TEST", 54, 68]]], ["However, comparing the RBD regions of both spike proteins in the simulation models, it was significantly different in structural conformation (blue ring in Fig 1) .", [["RBD regions", "PROTEIN", 23, 34], ["spike proteins", "PROTEIN", 43, 57], ["both spike proteins", "PROBLEM", 38, 57], ["both spike", "OBSERVATION", 38, 48], ["significantly", "OBSERVATION_MODIFIER", 91, 104], ["different", "OBSERVATION_MODIFIER", 105, 114], ["structural conformation", "OBSERVATION", 118, 141]]], ["The simulation showed that the position of receptor-binding motif (RBM) regional structure in prefusion conformation was close to the RBD core than in the fusion conformation.", [["receptor-binding motif", "PROTEIN", 43, 65], ["RBD core", "PROTEIN", 134, 142], ["The simulation", "TEST", 0, 14], ["receptor-binding motif (RBM) regional structure in prefusion conformation", "PROBLEM", 43, 116], ["prefusion conformation", "OBSERVATION", 94, 116], ["RBD", "OBSERVATION", 134, 137], ["fusion conformation", "OBSERVATION", 155, 174]]], ["Besides, the pose of RBM regional structure in the fusional conformation was more close to ACE2 protein than in the prefusion conformation.", [["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["ACE2 protein", "PROTEIN", 91, 103], ["RBM regional structure in the fusional conformation", "PROBLEM", 21, 72], ["ACE2 protein", "TEST", 91, 103], ["fusional conformation", "OBSERVATION", 51, 72], ["prefusion conformation", "OBSERVATION", 116, 138]]], ["Generally, SAR-CoV-2 RBM contains many contacting residues binding to human ACE2 protein [22] .", [["human", "ORGANISM", 70, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["RBM", "PROTEIN", 21, 24], ["human ACE2 protein", "PROTEIN", 70, 88], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["human ACE2 protein", "TEST", 70, 88]]], ["We concluded that the conformation changing of the RBM regional structure in the spike protein might affect the spike protein binding behavior to human ACE2 protein.Structure-based virtual screeningThe study reported that C-terminal domain (CTD) of SARS-CoV spike protein bound to ACE2 protein with different kinds of angles and its conformations or poses would be changed to well fit the conformation of dynamic ACE2 protein, such as ACE2 unbound-up conformation, ACE2-bound conformation, and ACE2 unbounddown conformation [10] .", [["human", "ORGANISM", 146, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 152, 156], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 249, 257], ["ACE2", "GENE_OR_GENE_PRODUCT", 281, 285], ["ACE2", "GENE_OR_GENE_PRODUCT", 413, 417], ["ACE2", "GENE_OR_GENE_PRODUCT", 435, 439], ["ACE2", "GENE_OR_GENE_PRODUCT", 465, 469], ["ACE2", "GENE_OR_GENE_PRODUCT", 494, 498], ["RBM regional structure", "PROTEIN", 51, 73], ["spike protein", "PROTEIN", 81, 94], ["human ACE2 protein", "PROTEIN", 146, 164], ["C-terminal domain", "PROTEIN", 222, 239], ["CTD", "PROTEIN", 241, 244], ["SARS-CoV spike protein", "PROTEIN", 249, 271], ["ACE2 protein", "PROTEIN", 281, 293], ["ACE2 protein", "PROTEIN", 413, 425], ["ACE2", "PROTEIN", 435, 439], ["ACE2", "PROTEIN", 465, 469], ["ACE2", "PROTEIN", 494, 498], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["SARS-CoV", "SPECIES", 249, 257], ["the RBM regional structure", "PROBLEM", 47, 73], ["the spike protein", "PROBLEM", 77, 94], ["the spike protein binding behavior", "PROBLEM", 108, 142], ["virtual screening", "TEST", 181, 198], ["The study", "TEST", 198, 207], ["C-terminal domain (CTD)", "TEST", 222, 245], ["SARS", "PROBLEM", 249, 253], ["CoV spike protein bound", "PROBLEM", 254, 277], ["ACE2 protein", "TEST", 281, 293], ["dynamic ACE2 protein", "TEST", 405, 425], ["ACE2 unbound", "TEST", 435, 447], ["ACE2", "TEST", 465, 469]]], ["Additionally, we have observed that the conformation of the RBD of SARS-CoV-2 spike protein in the prefusional state is different from in the fusional state (Fig 1) .", [["SARS", "DISEASE", 67, 71], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 67, 77], ["RBD", "PROTEIN", 60, 63], ["SARS-CoV-2 spike protein", "PROTEIN", 67, 91], ["the RBD of SARS", "PROBLEM", 56, 71], ["CoV", "TEST", 72, 75], ["2 spike protein in the prefusional state", "PROBLEM", 76, 116], ["different", "OBSERVATION_MODIFIER", 120, 129]]], ["In other words, we can speculate that the conformation of the dynamic RBD of SARS-CoV-2 spike protein would change to well bind and fit dynamic ACE2 protein.", [["SARS", "DISEASE", 77, 81], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 77, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 144, 148], ["RBD", "PROTEIN", 70, 73], ["SARS-CoV-2 spike protein", "PROTEIN", 77, 101], ["ACE2 protein", "PROTEIN", 144, 156], ["the dynamic RBD of SARS", "PROBLEM", 58, 81], ["CoV", "TEST", 82, 85], ["2 spike protein", "PROBLEM", 86, 101]]], ["Therefore, we could design a strategy that two potential hitting sites could be set as the compound docking sites to prevent the spike protein to bind to ACE2 protein.", [["ACE2", "GENE_OR_GENE_PRODUCT", 154, 158], ["spike protein", "PROTEIN", 129, 142], ["ACE2 protein", "PROTEIN", 154, 166], ["hitting sites", "PROBLEM", 57, 70], ["the compound docking sites", "TREATMENT", 87, 113], ["the spike protein", "PROBLEM", 125, 142], ["ACE2 protein", "TEST", 154, 166]]], ["One was that compounds docked on the RBD of the spike protein to prevent spike protein to bind to the human ACE2 protein, and the other was that compounds docked to the site of the connective interface of the spike-ACE2 complex protein to influence the affinity of binding between dynamic viral spike protein and dynamic human ACE2 protein and to cause nonfunctional changing of structural conformation to prevent viral spike protein from cleaved by human proteases.", [["connective", "ANATOMY", 181, 191], ["human", "ORGANISM", 102, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 108, 112], ["ACE2", "GENE_OR_GENE_PRODUCT", 215, 219], ["human", "ORGANISM", 321, 326], ["ACE2", "GENE_OR_GENE_PRODUCT", 327, 331], ["human", "ORGANISM", 450, 455], ["RBD", "PROTEIN", 37, 40], ["spike protein", "PROTEIN", 48, 61], ["spike protein", "PROTEIN", 73, 86], ["human ACE2 protein", "PROTEIN", 102, 120], ["spike-ACE2 complex protein", "PROTEIN", 209, 235], ["dynamic viral spike protein", "PROTEIN", 281, 308], ["dynamic human ACE2 protein", "PROTEIN", 313, 339], ["viral spike protein", "PROTEIN", 414, 433], ["human proteases", "PROTEIN", 450, 465], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 321, 326], ["human", "SPECIES", 450, 455], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 321, 326], ["human", "SPECIES", 450, 455], ["the spike protein", "PROBLEM", 44, 61], ["spike protein", "PROBLEM", 73, 86], ["the human ACE2 protein", "TREATMENT", 98, 120], ["ACE2 complex protein", "TREATMENT", 215, 235], ["dynamic viral spike protein", "TREATMENT", 281, 308], ["dynamic human ACE2 protein", "TREATMENT", 313, 339], ["nonfunctional changing of structural conformation", "PROBLEM", 353, 402], ["viral spike protein", "PROBLEM", 414, 433], ["connective interface", "OBSERVATION", 181, 201], ["viral spike", "OBSERVATION", 414, 425]]], ["In this study, our aim was going to discover the compounds that not only can bind to the RBD of spike protein in the prefusion conformation but also bind to the site of the connective interface of spike-ACE2 complex protein.", [["connective", "ANATOMY", 173, 183], ["spike-ACE2", "GENE_OR_GENE_PRODUCT", 197, 207], ["RBD", "PROTEIN", 89, 92], ["spike protein", "PROTEIN", 96, 109], ["spike-ACE2 complex protein", "PROTEIN", 197, 223], ["this study", "TEST", 3, 13], ["spike protein in the prefusion conformation", "PROBLEM", 96, 139], ["ACE2 complex protein", "PROBLEM", 203, 223], ["prefusion conformation", "OBSERVATION", 117, 139], ["connective interface", "OBSERVATION", 173, 193]]], ["To discover the potential compounds, the virtual screening with molecular docking calculation was performed by AutoDock Vina program within PyRX software.", [["PyRX", "SIMPLE_CHEMICAL", 140, 144], ["the virtual screening", "TEST", 37, 58], ["molecular docking calculation", "TEST", 64, 93]]], ["All molecular structures prepared for virtual screening were downloaded from TDEC website.", [["virtual screening", "TEST", 38, 55]]], ["The results showed that the numbers of docked compounds (binding energy < -8 kcal/mol) in the prefusion RBD of spike protein and the spike-ACE2 complex protein were respectively 53 and 222.", [["spike-ACE2", "GENE_OR_GENE_PRODUCT", 133, 143], ["prefusion RBD", "PROTEIN", 94, 107], ["spike protein", "PROTEIN", 111, 124], ["ACE2 complex protein", "PROTEIN", 139, 159], ["binding energy", "TEST", 57, 71], ["spike protein", "PROBLEM", 111, 124], ["the spike", "TEST", 129, 138], ["ACE2 complex protein", "TEST", 139, 159]]], ["The binding energies and properties of 39 overlapped compounds were respectively shown in Fig 2, S2 Fig, and S1 Table.", [["binding energies", "OBSERVATION", 4, 20]]], ["Subsequently, once the value of the screening threshold raised and limited to -9 kcal/mol, only compounds TDEC2018CN001781 (Thioflexibilolide A) and TDEC2020CN000246 (Candidine) reached the condition. with amino acid His34, and its interactive distance was 4.71\u00c5 (Fig 5D) .", [["TDEC2018CN001781", "CHEMICAL", 106, 122], ["Thioflexibilolide A", "CHEMICAL", 124, 143], ["TDEC2020CN000246", "CHEMICAL", 149, 165], ["Candidine", "CHEMICAL", 167, 176], ["amino acid", "CHEMICAL", 206, 216], ["TDEC2018CN001781", "CHEMICAL", 106, 122], ["Thioflexibilolide A", "CHEMICAL", 124, 143], ["TDEC2020CN000246", "CHEMICAL", 149, 165], ["Candidine", "CHEMICAL", 167, 176], ["amino acid", "CHEMICAL", 206, 216], ["TDEC2018CN001781", "SIMPLE_CHEMICAL", 106, 122], ["Thioflexibilolide A", "SIMPLE_CHEMICAL", 124, 143], ["TDEC2020CN000246", "SIMPLE_CHEMICAL", 149, 165], ["Candidine", "SIMPLE_CHEMICAL", 167, 176], ["amino acid", "AMINO_ACID", 206, 216], ["His34", "AMINO_ACID", 217, 222], ["amino acid His34", "PROTEIN", 206, 222], ["the screening threshold", "TEST", 32, 55], ["TDEC2020CN000246 (Candidine)", "TREATMENT", 149, 177], ["amino acid His34", "TEST", 206, 222]]], ["The data also showed that candidine could dock with the prefusional RBD of spike protein (cyan cartoon) and its value of binding energy was -9.0 kcal/mol ( Fig 6A) .", [["candidine", "CHEMICAL", 26, 35], ["candidine", "CHEMICAL", 26, 35], ["candidine", "SIMPLE_CHEMICAL", 26, 35], ["prefusional RBD", "PROTEIN", 56, 71], ["spike protein", "PROTEIN", 75, 88], ["cyan cartoon", "PROTEIN", 90, 102], ["The data", "TEST", 0, 8], ["candidine", "TREATMENT", 26, 35], ["the prefusional RBD of spike protein", "PROBLEM", 52, 88], ["binding energy", "TEST", 121, 135]]], ["It also formed many interactions with amino acids in the prefusional RBD of the with amino acid Leu452, and their interactive distances were respectively 3.83\u00c5, 3.95\u00c5, 3.77\u00c5, and 3.55\u00c5.", [["amino acids", "CHEMICAL", 38, 49], ["amino acid", "CHEMICAL", 85, 95], ["amino acids", "CHEMICAL", 38, 49], ["amino acid", "CHEMICAL", 85, 95], ["amino acids", "AMINO_ACID", 38, 49], ["amino acid", "AMINO_ACID", 85, 95], ["Leu452", "AMINO_ACID", 96, 102], ["prefusional RBD", "PROTEIN", 57, 72], ["amino acids", "TEST", 38, 49], ["amino acid Leu452", "TEST", 85, 102]]], ["Moreover, it also formed a pi-pi T-shaped interaction (pinking purple dashed line) with amino acid Phe486, and its interactive distance was 5.39\u00c5 (Fig 6B) .", [["amino acid", "CHEMICAL", 88, 98], ["amino acid", "CHEMICAL", 88, 98], ["amino acid", "AMINO_ACID", 88, 98], ["Phe486", "AMINO_ACID", 99, 105], ["a pi-pi T-shaped interaction", "PROBLEM", 25, 53], ["pinking purple dashed line", "TREATMENT", 55, 81], ["amino acid Phe486", "TEST", 88, 105]]], ["Candidine docked with the site near the connective interface of the 14 RBD of spike-ACE2 complex protein and its value of binding energy was -9.8 kcal/mol (Fig 6C) .", [["Candidine", "CHEMICAL", 0, 9], ["Candidine", "CHEMICAL", 0, 9], ["Candidine", "SIMPLE_CHEMICAL", 0, 9], ["spike-ACE2", "GENE_OR_GENE_PRODUCT", 78, 88], ["14 RBD of spike-ACE2 complex protein", "PROTEIN", 68, 104], ["Candidine", "TREATMENT", 0, 9], ["ACE2 complex protein", "PROBLEM", 84, 104], ["binding energy", "TEST", 122, 136], ["connective interface", "OBSERVATION", 40, 60], ["14 RBD", "OBSERVATION_MODIFIER", 68, 74]]], ["Besides, it also formed many interactions with amino acids in the space near the connective interface of the RBD of spike-ACE2 complex protein.", [["connective interface", "ANATOMY", 81, 101], ["amino acids", "CHEMICAL", 47, 58], ["amino acids", "CHEMICAL", 47, 58], ["amino acids", "AMINO_ACID", 47, 58], ["spike-ACE2", "GENE_OR_GENE_PRODUCT", 116, 126], ["RBD", "PROTEIN", 109, 112], ["spike-ACE2 complex protein", "PROTEIN", 116, 142], ["amino acids", "TREATMENT", 47, 58], ["ACE2 complex protein", "PROBLEM", 122, 142], ["connective interface", "OBSERVATION", 81, 101], ["RBD", "OBSERVATION", 109, 112]]], ["The results showed that it formed an electrostatic hydrogen-bonding interaction (green dashed line) with amino acid Glu37, and its interactive distance was 2.25\u00c5.", [["amino acid", "CHEMICAL", 105, 115], ["hydrogen", "CHEMICAL", 51, 59], ["amino acid", "CHEMICAL", 105, 115], ["Glu37", "CHEMICAL", 116, 121], ["amino acid", "AMINO_ACID", 105, 115], ["Glu37", "AMINO_ACID", 116, 121], ["an electrostatic hydrogen-bonding interaction", "PROBLEM", 34, 79], ["green dashed line", "TREATMENT", 81, 98], ["amino acid Glu37", "TEST", 105, 121], ["electrostatic hydrogen", "OBSERVATION", 37, 59]]], ["Besides, it also formed a hydrophobic pi-sigma interaction (dark purple dashed line) with amino acid Asn33, and its interactive distance was 3.94\u00c5 (Fig 6D) . vaccines for coronaviruses [13, 30] .", [["amino acid", "CHEMICAL", 90, 100], ["coronaviruses", "DISEASE", 171, 184], ["amino acid", "CHEMICAL", 90, 100], ["amino acid", "AMINO_ACID", 90, 100], ["Asn33", "AMINO_ACID", 101, 106], ["coronaviruses", "ORGANISM", 171, 184], ["amino acid Asn33", "PROTEIN", 90, 106], ["a hydrophobic pi-sigma interaction", "PROBLEM", 24, 58], ["dark purple dashed line", "TREATMENT", 60, 83], ["amino acid Asn33", "TREATMENT", 90, 106], ["vaccines", "TREATMENT", 158, 166], ["coronaviruses", "PROBLEM", 171, 184], ["hydrophobic pi-sigma", "OBSERVATION", 26, 46]]], ["The predictions obtained from virtual screening such as binding energy, possible flexibility in conformation, are still very useful to lead the way of drug discovery or drug repurposing.", [["virtual screening", "TEST", 30, 47]]], ["As represented in Fig 4, we have started with 2,321 compounds taken from TDEC and applied the filters to get compound which can bind to the target structures with high affinity.", [["TDEC", "CHEMICAL", 73, 77], ["TDEC", "SIMPLE_CHEMICAL", 73, 77], ["TDEC", "TREATMENT", 73, 77], ["the filters", "TREATMENT", 90, 101], ["high affinity", "PROBLEM", 163, 176], ["high affinity", "OBSERVATION", 163, 176]]], ["Notably, we got the two natural products, thioflexibilolide A and candidine, which passed all the filters applied with the strong binding energy respectively -9.2 kcal/mol and -9.0 kcal/mol on the prefusion spike protein and -9.8 kcal/mol and -8.9 kcal/mol on the spike-ACE2 complex protein (Fig 5 and Fig 6) .", [["thioflexibilolide A", "CHEMICAL", 42, 61], ["candidine", "CHEMICAL", 66, 75], ["thioflexibilolide A", "CHEMICAL", 42, 61], ["candidine", "CHEMICAL", 66, 75], ["thioflexibilolide A", "SIMPLE_CHEMICAL", 42, 61], ["candidine", "SIMPLE_CHEMICAL", 66, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 270, 274], ["prefusion spike protein", "PROTEIN", 197, 220], ["ACE2 complex protein", "PROTEIN", 270, 290], ["Fig 5 and Fig 6", "PROTEIN", 292, 307], ["thioflexibilolide A", "TREATMENT", 42, 61], ["candidine", "TREATMENT", 66, 75], ["the prefusion spike protein", "TEST", 193, 220], ["the spike", "TEST", 260, 269], ["ACE2 complex protein (Fig", "TREATMENT", 270, 295]]], ["Among them, hit compounds were able to influence the interaction between viral RBD of the spike protein and the human ACE2 protein in two dynamic proteins.", [["human", "ORGANISM", 112, 117], ["ACE2", "GENE_OR_GENE_PRODUCT", 118, 122], ["viral RBD", "PROTEIN", 73, 82], ["spike protein", "PROTEIN", 90, 103], ["human ACE2 protein", "PROTEIN", 112, 130], ["dynamic proteins", "PROTEIN", 138, 154], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["viral RBD", "PROBLEM", 73, 82], ["the spike protein", "TEST", 86, 103], ["the human ACE2 protein", "TEST", 108, 130]]], ["Besides, we also found among these 39 compounds that Dioscin, Actinomycin D and Saikosaponin C had been reported that they had antivirus activity against others virus (S2 Table) .", [["Dioscin", "CHEMICAL", 53, 60], ["Actinomycin D", "CHEMICAL", 62, 75], ["Saikosaponin C", "CHEMICAL", 80, 94], ["Dioscin", "CHEMICAL", 53, 60], ["Actinomycin D", "CHEMICAL", 62, 75], ["Saikosaponin C", "CHEMICAL", 80, 94], ["Dioscin", "SIMPLE_CHEMICAL", 53, 60], ["Actinomycin D", "SIMPLE_CHEMICAL", 62, 75], ["Saikosaponin C", "SIMPLE_CHEMICAL", 80, 94], ["Dioscin", "TREATMENT", 53, 60], ["Actinomycin D", "TREATMENT", 62, 75], ["Saikosaponin C", "PROBLEM", 80, 94], ["antivirus activity", "TREATMENT", 127, 145]]], ["Although, those compounds that we discovered from the database may have the potential ability to prevent the binding between viral spike protein and human ACE2 protein, the efficacy of compounds were still needed to be further verified by bioassay.Structure-based virtual screeningThioflexibilolide A and candidine were natural products respectively isolated from soft coral Sinularia flexibilis and Phaius mishmensis [31, 32] .", [["Thioflexibilolide A", "CHEMICAL", 281, 300], ["candidine", "CHEMICAL", 305, 314], ["Thioflexibilolide A", "CHEMICAL", 281, 300], ["candidine", "CHEMICAL", 305, 314], ["human", "ORGANISM", 149, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 155, 159], ["Thioflexibilolide A", "SIMPLE_CHEMICAL", 281, 300], ["candidine", "SIMPLE_CHEMICAL", 305, 314], ["Sinularia flexibilis", "ORGANISM", 375, 395], ["Phaius mishmensis", "ORGANISM", 400, 417], ["viral spike protein", "PROTEIN", 125, 144], ["human ACE2 protein", "PROTEIN", 149, 167], ["human", "SPECIES", 149, 154], ["Sinularia flexibilis", "SPECIES", 375, 395], ["Phaius mishmensis", "SPECIES", 400, 417], ["human", "SPECIES", 149, 154], ["Sinularia flexibilis", "SPECIES", 375, 395], ["Phaius mishmensis", "SPECIES", 400, 417], ["the binding", "PROBLEM", 105, 116], ["viral spike protein", "PROBLEM", 125, 144], ["human ACE2 protein", "TREATMENT", 149, 167], ["Thioflexibilolide A and candidine", "TREATMENT", 281, 314], ["natural products", "TREATMENT", 320, 336], ["soft coral", "OBSERVATION_MODIFIER", 364, 374]]], ["In chemical structure, the structure of candidine is more solid than thioflexibilolide A. It it might be caused that the RBM of spike protein is major composed of chain type of structure rather than \u03b1-helix or \u03b2-sheet structure (S1 Fig).", [["candidine", "CHEMICAL", 40, 49], ["candidine", "CHEMICAL", 40, 49], ["thioflexibilolide", "CHEMICAL", 69, 86], ["candidine", "SIMPLE_CHEMICAL", 40, 49], ["\u03b1-helix", "SIMPLE_CHEMICAL", 199, 206], ["RBM", "PROTEIN", 121, 124], ["spike protein", "PROTEIN", 128, 141], ["\u03b1-helix", "PROTEIN", 199, 206], ["\u03b2-sheet structure", "PROTEIN", 210, 227], ["candidine", "TREATMENT", 40, 49], ["the RBM of spike protein", "PROBLEM", 117, 141], ["chemical structure", "OBSERVATION", 3, 21], ["more solid", "OBSERVATION_MODIFIER", 53, 63], ["chain type", "OBSERVATION_MODIFIER", 163, 173]]], ["Besides, we also deduce that two compounds bind to side face respectively with the RBM of the ACE2-free spike protein and the connective interface of spike-ACE2 complex protein probably affect the affinity of binding between viral spike protein and human ACE2 protein or influence its conformation changing to prevent spike protein to be cleaved by host protease like TMPRSS2 (Fig 5 and Fig 6) .Structure-based virtual screeningTo rapidly develop useful drugs against SARS-CoV-2, computer-aid drug screening was performed in many studies.", [["connective interface", "ANATOMY", 126, 146], ["SARS", "DISEASE", 468, 472], ["ACE2", "GENE_OR_GENE_PRODUCT", 94, 98], ["spike-ACE2", "GENE_OR_GENE_PRODUCT", 150, 160], ["human", "ORGANISM", 249, 254], ["ACE2", "GENE_OR_GENE_PRODUCT", 255, 259], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 368, 375], ["RBM", "PROTEIN", 83, 86], ["ACE2", "PROTEIN", 94, 98], ["spike protein", "PROTEIN", 104, 117], ["ACE2 complex protein", "PROTEIN", 156, 176], ["viral spike protein", "PROTEIN", 225, 244], ["human ACE2 protein", "PROTEIN", 249, 267], ["spike protein", "PROTEIN", 318, 331], ["host protease", "PROTEIN", 349, 362], ["TMPRSS2", "PROTEIN", 368, 375], ["Fig 5 and Fig 6", "PROTEIN", 377, 392], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["SARS-CoV", "SPECIES", 468, 476], ["the ACE2", "TEST", 90, 98], ["the connective interface of spike", "PROBLEM", 122, 155], ["ACE2 complex protein", "PROBLEM", 156, 176], ["the affinity of binding", "PROBLEM", 193, 216], ["viral spike protein", "TREATMENT", 225, 244], ["human ACE2 protein", "TREATMENT", 249, 267], ["spike protein", "PROBLEM", 318, 331], ["TMPRSS2 (Fig", "TREATMENT", 368, 380], ["virtual screening", "TEST", 411, 428], ["useful drugs", "TREATMENT", 447, 459], ["SARS", "TEST", 468, 472], ["CoV", "TEST", 473, 476], ["computer-aid drug screening", "TEST", 480, 507]]], ["SARS-CoV spike protein were homology proteins with greater than 70% similar sequences and have the same function for binding ACE2.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["SARS-CoV spike protein", "PROTEIN", 0, 22], ["homology proteins", "PROTEIN", 28, 45], ["ACE2", "PROTEIN", 125, 129], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV spike protein", "TEST", 5, 22], ["homology proteins", "TEST", 28, 45]]], ["However, the previous report also showed that the binding affinity between SARS-CoV-2 spike protein and ACE2 was higher than SARS-CoV spike protein approximately 10-20 folds [18, 39] .Structure-based virtual screeningThese reports suggested that it is highly similar but not the same in partial structure or conformation in the spike proteins between SARS-CoV-2 and SARS-CoV.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 75, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 125, 133], ["SARS-CoV-2", "ORGANISM", 351, 361], ["SARS-CoV", "ORGANISM", 366, 374], ["SARS-CoV-2 spike protein", "PROTEIN", 75, 99], ["ACE2", "PROTEIN", 104, 108], ["SARS-CoV spike protein", "PROTEIN", 125, 147], ["spike proteins", "PROTEIN", 328, 342], ["SARS-CoV", "SPECIES", 125, 133], ["SARS-CoV", "SPECIES", 351, 359], ["SARS-CoV", "SPECIES", 366, 374], ["the binding affinity", "PROBLEM", 46, 66], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["spike protein", "TEST", 86, 99], ["ACE2", "TEST", 104, 108], ["SARS", "TEST", 125, 129], ["CoV spike protein", "TEST", 130, 147], ["virtual screening", "TEST", 200, 217], ["the spike proteins", "TEST", 324, 342], ["SARS", "TEST", 351, 355], ["CoV", "TEST", 356, 359], ["SARS", "PROBLEM", 366, 370]]], ["Moreover, spike-ACE2 complex protein was constructed by protein-protein docking may not good enough to directly exhibit the protein-protein binding situation in fact.", [["spike-ACE2", "GENE_OR_GENE_PRODUCT", 10, 20], ["spike-ACE2 complex protein", "PROTEIN", 10, 36], ["spike", "PROBLEM", 10, 15], ["ACE2 complex protein", "TREATMENT", 16, 36], ["protein-protein docking", "TREATMENT", 56, 79], ["the protein", "TEST", 120, 131]]], ["Recently, the RBD of SARS-CoV-2 spike protein in the prefusion conformation (PDB ID:Structure-based virtual screening6VSB) and the complex protein that SARS-CoV-2 spike protein's RBD bound with ACE2 protein had already been resolved (PDB ID: 6M0J) respectively by Cryo-EM and X-ray crystallography with high resolution [18, 22] .", [["SARS", "DISEASE", 21, 25], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 152, 162], ["RBD", "GENE_OR_GENE_PRODUCT", 179, 182], ["ACE2", "GENE_OR_GENE_PRODUCT", 194, 198], ["RBD", "PROTEIN", 14, 17], ["SARS-CoV-2 spike protein", "PROTEIN", 21, 45], ["prefusion conformation", "PROTEIN", 53, 75], ["PDB ID:Structure-based virtual screening6VSB", "PROTEIN", 77, 121], ["complex protein", "PROTEIN", 131, 146], ["SARS-CoV-2 spike protein", "PROTEIN", 152, 176], ["RBD", "PROTEIN", 179, 182], ["ACE2 protein", "PROTEIN", 194, 206], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["2 spike protein", "PROBLEM", 30, 45], ["virtual screening6VSB", "TEST", 100, 121], ["the complex protein", "TEST", 127, 146], ["SARS", "TEST", 152, 156], ["CoV", "TEST", 157, 160], ["2 spike protein's RBD bound", "PROBLEM", 161, 188], ["ACE2 protein", "TEST", 194, 206], ["X-ray crystallography", "TEST", 276, 297]]], ["Therefore, the two new resolving protein structures were likely more close to the structural situations in fact.Structure-based virtual screeningIn other words, it could raise the accuracy in structure-based virtual screening with docking calculation because of those structures resolved with high resolution that is why we did that in this study.Structure-based virtual screeningDeveloping the viral spike antibody is one of the good strategies to fight against SARS-CoV-2.", [["SARS", "DISEASE", 463, 467], ["SARS-CoV-2", "ORGANISM", 463, 473], ["viral spike antibody", "PROTEIN", 395, 415], ["SARS-CoV", "SPECIES", 463, 471], ["the two new resolving protein structures", "PROBLEM", 11, 51], ["virtual screening", "TEST", 128, 145], ["virtual screening", "TEST", 208, 225], ["docking calculation", "TEST", 231, 250], ["this study", "TEST", 336, 346], ["virtual screening", "TEST", 363, 380], ["the viral spike antibody", "TEST", 391, 415], ["SARS", "TEST", 463, 467], ["CoV", "TEST", 468, 471], ["new", "OBSERVATION_MODIFIER", 19, 22], ["resolving", "OBSERVATION_MODIFIER", 23, 32], ["protein structures", "OBSERVATION", 33, 51], ["viral spike", "OBSERVATION", 395, 406]]], ["It could bind to the RBD of spike protein to neutralize SARS-CoV-2 had been reported [40, 41] .", [["RBD", "PROTEIN", 21, 24], ["spike protein", "PROTEIN", 28, 41], ["spike protein", "TEST", 28, 41], ["neutralize SARS", "TEST", 45, 60], ["CoV", "TEST", 61, 64]]], ["Herein, we reported that the 39 potential compounds against SARS-CoV-2 spike protein may have the advantage of avoiding to induce ADE.Structure-based virtual screeningACE2 was a type I transmembrane protein and it functioned as a carboxypeptidase to mediate homeostasis of renin-angiotensin system (RAS), such as blood volume, lung and cardiovascular regulating functions, by cleaving angiotensin II (Ang II) to Ang(1-7) [43] .", [["blood", "ANATOMY", 313, 318], ["lung", "ANATOMY", 327, 331], ["cardiovascular", "ANATOMY", 336, 350], ["ADE", "DISEASE", 130, 133], ["angiotensin", "CHEMICAL", 279, 290], ["angiotensin II", "CHEMICAL", 385, 399], ["Ang II", "CHEMICAL", 401, 407], ["Ang(1-7)", "CHEMICAL", 412, 420], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 60, 70], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 230, 246], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 273, 297], ["RAS", "GENE_OR_GENE_PRODUCT", 299, 302], ["blood", "ORGANISM_SUBSTANCE", 313, 318], ["lung", "ORGAN", 327, 331], ["cardiovascular", "ANATOMICAL_SYSTEM", 336, 350], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 385, 399], ["Ang II", "GENE_OR_GENE_PRODUCT", 401, 407], ["Ang(1-7", "GENE_OR_GENE_PRODUCT", 412, 419], ["SARS-CoV-2 spike protein", "PROTEIN", 60, 84], ["type I transmembrane protein", "PROTEIN", 178, 206], ["carboxypeptidase", "PROTEIN", 230, 246], ["renin", "PROTEIN", 273, 278], ["angiotensin II", "PROTEIN", 385, 399], ["Ang II", "PROTEIN", 401, 407], ["SARS-CoV", "SPECIES", 60, 68], ["SARS", "PROBLEM", 60, 64], ["CoV", "TEST", 65, 68], ["2 spike protein", "PROBLEM", 69, 84], ["a type I transmembrane protein", "PROBLEM", 176, 206], ["a carboxypeptidase", "TREATMENT", 228, 246], ["renin-angiotensin system", "TREATMENT", 273, 297], ["blood volume", "TEST", 313, 325], ["lung and cardiovascular regulating functions", "PROBLEM", 327, 371], ["cleaving angiotensin II (Ang II)", "TREATMENT", 376, 408], ["lung", "ANATOMY", 327, 331], ["cardiovascular", "ANATOMY", 336, 350]]], ["ACE2 was higher expressed in the small intestine, kidneys, testicles, adipose tissue, and thyroid and moderate in the lungs, liver, adrenal glands, and rectum and lower in the blood, blood vessels, spleen, brain, muscle, and bone marrow [44, 45] .", [["small intestine", "ANATOMY", 33, 48], ["kidneys", "ANATOMY", 50, 57], ["testicles", "ANATOMY", 59, 68], ["adipose tissue", "ANATOMY", 70, 84], ["thyroid", "ANATOMY", 90, 97], ["lungs", "ANATOMY", 118, 123], ["liver", "ANATOMY", 125, 130], ["adrenal glands", "ANATOMY", 132, 146], ["rectum", "ANATOMY", 152, 158], ["blood", "ANATOMY", 176, 181], ["blood vessels", "ANATOMY", 183, 196], ["spleen", "ANATOMY", 198, 204], ["brain", "ANATOMY", 206, 211], ["muscle", "ANATOMY", 213, 219], ["bone marrow", "ANATOMY", 225, 236], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["small intestine", "ORGAN", 33, 48], ["kidneys", "ORGAN", 50, 57], ["testicles", "ORGAN", 59, 68], ["adipose tissue", "TISSUE", 70, 84], ["thyroid", "ORGAN", 90, 97], ["lungs", "ORGAN", 118, 123], ["liver", "ORGAN", 125, 130], ["adrenal glands", "ORGAN", 132, 146], ["rectum", "ORGAN", 152, 158], ["blood", "ORGANISM_SUBSTANCE", 176, 181], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 183, 196], ["spleen", "ORGAN", 198, 204], ["brain", "ORGAN", 206, 211], ["muscle", "ORGAN", 213, 219], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 225, 236], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TEST", 0, 4], ["adipose tissue, and thyroid and moderate in the lungs, liver, adrenal glands, and rectum and lower in the blood, blood vessels, spleen, brain, muscle, and bone marrow", "PROBLEM", 70, 236], ["higher", "OBSERVATION", 9, 15], ["small", "ANATOMY_MODIFIER", 33, 38], ["intestine", "ANATOMY", 39, 48], ["kidneys", "ANATOMY", 50, 57], ["testicles", "ANATOMY", 59, 68], ["adipose tissue", "OBSERVATION", 70, 84], ["thyroid", "ANATOMY", 90, 97], ["moderate", "OBSERVATION_MODIFIER", 102, 110], ["lungs", "ANATOMY", 118, 123], ["liver", "ANATOMY", 125, 130], ["adrenal glands", "ANATOMY", 132, 146], ["rectum", "ANATOMY", 152, 158], ["lower", "ANATOMY_MODIFIER", 163, 168], ["blood", "ANATOMY", 176, 181], ["blood vessels", "ANATOMY", 183, 196], ["spleen", "ANATOMY", 198, 204], ["brain", "ANATOMY", 206, 211], ["muscle", "ANATOMY", 213, 219], ["bone marrow", "ANATOMY", 225, 236]]], ["On the other hand, gender and age characters could affect ACE2 expression under inflammatory conditions in the skin, lung, brain, and thyroid [44] .", [["skin", "ANATOMY", 111, 115], ["lung", "ANATOMY", 117, 121], ["brain", "ANATOMY", 123, 128], ["thyroid", "ANATOMY", 134, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["skin", "ORGAN", 111, 115], ["lung", "ORGAN", 117, 121], ["brain", "ORGAN", 123, 128], ["thyroid", "ORGAN", 134, 141], ["ACE2", "PROTEIN", 58, 62], ["ACE2 expression under inflammatory conditions in the skin, lung, brain", "PROBLEM", 58, 128], ["inflammatory", "OBSERVATION", 80, 92], ["skin", "ANATOMY", 111, 115], ["lung", "ANATOMY", 117, 121], ["brain", "ANATOMY", 123, 128], ["thyroid", "ANATOMY", 134, 141]]], ["Recent studies also showed that gender could affect SARS-CoV-2 infection susceptibility and virus clearance [17] .", [["infection", "DISEASE", 63, 72], ["SARS-CoV-2", "ORGANISM", 52, 62], ["SARS-CoV", "SPECIES", 52, 60], ["Recent studies", "TEST", 0, 14], ["SARS", "PROBLEM", 52, 56], ["CoV", "TEST", 57, 60], ["2 infection susceptibility", "PROBLEM", 61, 87], ["virus clearance", "TEST", 92, 107]]], ["Besides, another report also pointed out that COVID-19 patients' symptoms including dysfunctions in diarrhea, taste, and smell; injuries in the liver, kidney, and heart may have a close relationship with ACE2 expression [46] .", [["liver", "ANATOMY", 144, 149], ["kidney", "ANATOMY", 151, 157], ["heart", "ANATOMY", 163, 168], ["diarrhea", "DISEASE", 100, 108], ["injuries", "DISEASE", 128, 136], ["patients", "ORGANISM", 55, 63], ["liver", "ORGAN", 144, 149], ["kidney", "ORGAN", 151, 157], ["heart", "ORGAN", 163, 168], ["ACE2", "GENE_OR_GENE_PRODUCT", 204, 208], ["ACE2", "PROTEIN", 204, 208], ["patients", "SPECIES", 55, 63], ["COVID", "TEST", 46, 51], ["patients' symptoms", "PROBLEM", 55, 73], ["dysfunctions", "PROBLEM", 84, 96], ["diarrhea", "PROBLEM", 100, 108], ["taste", "PROBLEM", 110, 115], ["smell", "PROBLEM", 121, 126], ["injuries in the liver, kidney, and heart", "PROBLEM", 128, 168], ["diarrhea", "OBSERVATION", 100, 108], ["injuries", "OBSERVATION", 128, 136], ["liver", "ANATOMY", 144, 149], ["kidney", "ANATOMY", 151, 157], ["heart", "ANATOMY", 163, 168]]], ["Herein, our results showed the 39 potential compounds could prevent the binding between viral spike protein and human ACE2 protein in silico.", [["human", "ORGANISM", 112, 117], ["ACE2", "GENE_OR_GENE_PRODUCT", 118, 122], ["viral spike protein", "PROTEIN", 88, 107], ["human ACE2 protein", "PROTEIN", 112, 130], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["the binding", "PROBLEM", 68, 79], ["viral spike protein", "TEST", 88, 107], ["human ACE2 protein in silico", "PROBLEM", 112, 140]]], ["It 20 is speculated that those potential compounds could fight against COVID-19 and lower the expression in the above symptoms for humans.Structure-based virtual screeningNatural products proved to be beneficial due to the contribution from a long time to develop effective drugs for several diseases [47] .", [["COVID-19", "CHEMICAL", 71, 79], ["COVID-19", "GENE_OR_GENE_PRODUCT", 71, 79], ["humans", "ORGANISM", 131, 137], ["humans", "SPECIES", 131, 137], ["humans", "SPECIES", 131, 137], ["COVID", "TEST", 71, 76], ["the above symptoms", "PROBLEM", 108, 126], ["effective drugs", "TREATMENT", 264, 279], ["several diseases", "PROBLEM", 284, 300]]], ["Therefore, we have tried our endemic TDEC which is very rich and diverse in natural product resources derived from traditional medicine, domestic microbes, and marine organisms.Structure-based virtual screeningthioflexibilolide A is well-known for its neuroprotective and anti-inflammatory activities derived from soft corals, whereas about gravicycle is reported non-toxic after its in vitro toxicity assessment in the cell [48] .", [["cell", "ANATOMY", 420, 424], ["TDEC", "CHEMICAL", 37, 41], ["screeningthioflexibilolide", "CHEMICAL", 201, 227], ["toxicity", "DISEASE", 393, 401], ["screeningthioflexibilolide", "CHEMICAL", 201, 227], ["TDEC", "CANCER", 37, 41], ["screeningthioflexibilolide", "SIMPLE_CHEMICAL", 201, 227], ["gravicycle", "SIMPLE_CHEMICAL", 341, 351], ["cell", "CELL", 420, 424], ["our endemic TDEC", "TREATMENT", 25, 41], ["traditional medicine", "TREATMENT", 115, 135], ["domestic microbes", "TREATMENT", 137, 154], ["marine organisms", "PROBLEM", 160, 176], ["Structure", "TEST", 177, 186], ["vitro toxicity assessment", "TEST", 387, 412], ["soft corals", "OBSERVATION_MODIFIER", 314, 325]]], ["The results we are reporting here about the compounds which are screened by employing virtual screening with molecular docking approach from the database for disabling SARS-CoV-2 spike protein's RBD from its interaction with ACE2 receptor of the host cell is very first of its kind as far as possibly know.", [["cell", "ANATOMY", 251, 255], ["SARS", "DISEASE", 168, 172], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 168, 178], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 225, 238], ["host cell", "CELL", 246, 255], ["SARS-CoV-2 spike protein", "PROTEIN", 168, 192], ["RBD", "PROTEIN", 195, 198], ["ACE2 receptor", "PROTEIN", 225, 238], ["virtual screening", "TEST", 86, 103], ["disabling SARS", "PROBLEM", 158, 172], ["CoV", "TEST", 173, 176], ["2 spike protein's RBD", "PROBLEM", 177, 198], ["ACE2 receptor", "TREATMENT", 225, 238], ["host cell", "OBSERVATION", 246, 255]]], ["The compounds perform well to get the filter into potential drug candidate during our screening process, and we strongly recommend our compound for further in vitro and in vivo investigation.ConclusionThe study carried out intending to come up with potential drugs for COVID-19Conclusiontherapy.", [["COVID-19Conclusiontherapy", "SIMPLE_CHEMICAL", 269, 294], ["the filter", "TREATMENT", 34, 44], ["vivo investigation", "TEST", 172, 190], ["The study", "TEST", 201, 210], ["potential drugs", "TREATMENT", 249, 264], ["COVID-19Conclusiontherapy", "TREATMENT", 269, 294]]], ["Here in this piece of work, we virtually screened more than 2000 drugs against the target spike protein's RBD.", [["RBD", "DISEASE", 106, 109], ["target spike protein", "PROTEIN", 83, 103], ["RBD", "PROTEIN", 106, 109], ["drugs", "TREATMENT", 65, 70], ["the target spike protein's RBD", "PROBLEM", 79, 109]]], ["After data mining and filtering out the unfitted compounds, we finally found two compounds named thioflexibilolide A and candidine.", [["thioflexibilolide A", "CHEMICAL", 97, 116], ["candidine", "CHEMICAL", 121, 130], ["thioflexibilolide A", "CHEMICAL", 97, 116], ["candidine", "CHEMICAL", 121, 130], ["thioflexibilolide A", "SIMPLE_CHEMICAL", 97, 116], ["candidine", "SIMPLE_CHEMICAL", 121, 130], ["candidine", "TREATMENT", 121, 130]]], ["As per our result, we found these two compounds bind with strong affinity to the selected target of the viral protein.", [["viral protein", "PROTEIN", 104, 117], ["viral protein", "OBSERVATION", 104, 117]]], ["We believed that these two compounds could be potential drugs for SARS-CoV-2.", [["SARS", "DISEASE", 66, 70], ["CoV-2", "ORGANISM", 71, 76], ["SARS-CoV", "SPECIES", 66, 74], ["SARS", "PROBLEM", 66, 70]]], ["The two 34 S1 Sinularia flexibilis [31] TDEC2020CN000246 -9.0 -9.8 Phaius mishmensis [32, 51] TDEC2019CA001707 -8.9 -8.3ConclusionTripterygium wilfordii [52] TDEC2019CA001572 -8.8 -8.9ConclusionDioscorea nipponica [53] TDEC2019CN000617 -8.8 -8.3ConclusionSolanum torvum [54] TDEC2018CN001906 -8.7 -8.0 Sinularia crassa [55] TDEC2018CN000709 -8.6 -8.1 Streptomyces sindenensis [56] TDEC2019CA001664 -8.6 -9.1 Bupleurum chinense [57] TDEC2019CA001644 -8.5 -9.1 Cunninghamia lanceolata [58] TDEC2019CN000295 -8.", [["Dioscorea nipponica [53] TDEC2019CN000617 -8.8 -8.3ConclusionSolanum torvum [54] TDEC2018CN001906 -8.7 -8.0 Sinularia crassa [55] TDEC2018CN000709 -8.6 -8.1 Streptomyces sindenensis [56] TDEC2019CA001664 -8.6 -9.1 Bupleurum chinense [57] TDEC2019CA001644 -8.5 -9.1 Cunninghamia lanceolata", "CHEMICAL", 194, 482], ["Dioscorea", "ORGANISM", 194, 203], ["torvum", "ORGANISM", 263, 269], ["Sinularia crassa", "ORGANISM", 302, 318], ["sindenensis", "ORGANISM", 364, 375], ["Sinularia flexibilis", "SPECIES", 14, 34], ["Phaius mishmensis", "SPECIES", 67, 84], ["Tripterygium wilfordii", "SPECIES", 130, 152], ["Dioscorea nipponica", "SPECIES", 194, 213], ["ConclusionSolanum torvum", "SPECIES", 245, 269], ["Sinularia crassa", "SPECIES", 302, 318], ["Streptomyces sindenensis", "SPECIES", 351, 375], ["Bupleurum chinense", "SPECIES", 408, 426], ["Cunninghamia lanceolata", "SPECIES", 459, 482], ["Sinularia flexibilis", "SPECIES", 14, 34], ["Phaius mishmensis", "SPECIES", 67, 84], ["Tripterygium wilfordii", "SPECIES", 130, 152], ["Dioscorea nipponica", "SPECIES", 194, 213], ["Sinularia crassa", "SPECIES", 302, 318], ["Streptomyces sindenensis", "SPECIES", 351, 375], ["Bupleurum chinense", "SPECIES", 408, 426], ["Cunninghamia lanceolata", "SPECIES", 459, 482], ["flexibilis", "TEST", 24, 34], ["TDEC2020CN000246", "TEST", 40, 56], ["Phaius mishmensis", "TEST", 67, 84], ["TDEC2019CA001707", "TEST", 94, 110], ["ConclusionTripterygium wilfordii", "TEST", 120, 152], ["TDEC2019CA001572", "TEST", 158, 174], ["Dioscorea", "TEST", 194, 203], ["nipponica", "TEST", 204, 213], ["TDEC2019CN000617", "TEST", 219, 235], ["ConclusionSolanum torvum", "TEST", 245, 269], ["TDEC2018CN001906", "TEST", 275, 291], ["Sinularia crassa", "TEST", 302, 318], ["TDEC2018CN000709", "TEST", 324, 340], ["Streptomyces sindenensis", "TEST", 351, 375], ["TDEC2019CA001664", "TEST", 381, 397], ["Bupleurum chinense", "TEST", 408, 426], ["TDEC2019CA001644", "TEST", 432, 448], ["Cunninghamia lanceolata", "TEST", 459, 482]]], ["[76, 77] TDEC2018CN002008 -8.0 -8.8ConclusionSinularia brassica [61] TDEC2018CN002161 -8.0 -8.6ConclusionSinularia brassica [61] TDEC2019CN000527 -8.0 -8.7ConclusionAnnona montana [63] TDEC2019CN000665 -8.0 -8.5 Paraminabea acronocephala [62] TDEC2019CN000667 -8.0 -8.1 Paraminabea acronocephala [62] TDEC2019CN000203 -8.0 -8.6ConclusionSapindus mukorossi [63] S2 [82, 83]", [["[63] TDEC2019CN000665", "SIMPLE_CHEMICAL", 180, 201], ["Annona montana", "SPECIES", 165, 179], ["Paraminabea acronocephala", "SPECIES", 212, 237], ["Paraminabea acronocephala", "SPECIES", 270, 295], ["Annona montana", "SPECIES", 165, 179], ["TDEC2018CN002008", "TEST", 9, 25], ["brassica", "TEST", 55, 63], ["TDEC2018CN002161", "TEST", 69, 85], ["brassica", "TEST", 115, 123], ["TDEC2019CN000527", "TEST", 129, 145], ["Annona montana", "TEST", 165, 179], ["TDEC2019CN000665", "TEST", 185, 201], ["Paraminabea acronocephala", "TEST", 212, 237], ["TDEC2019CN000667", "TEST", 243, 259], ["Paraminabea", "TEST", 270, 281], ["acronocephala", "TEST", 282, 295], ["TDEC2019CN000203", "TEST", 301, 317], ["ConclusionSapindus mukorossi", "TEST", 327, 355]]]], "429c5b39ce887f0383dcfe255e64bac5e794521a": [["OpinionGastrointestinal manifestations of coronavirus disease 2019 (COVID-19) are immediately reminiscent of previous coronavirus outbreaks and should raise concern about faecal shedding as a mode of transmission in hospital settings.", [["faecal", "ANATOMY", 171, 177], ["coronavirus disease", "DISEASE", 42, 61], ["coronavirus outbreaks", "DISEASE", 118, 139], ["coronavirus", "ORGANISM", 118, 129], ["faecal", "ORGANISM_SUBSTANCE", 171, 177], ["coronavirus disease", "PROBLEM", 42, 61], ["COVID", "TEST", 68, 73], ["previous coronavirus outbreaks", "PROBLEM", 109, 139], ["faecal shedding", "PROBLEM", 171, 186], ["coronavirus disease", "OBSERVATION", 42, 61], ["coronavirus", "OBSERVATION", 118, 129]]], ["Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), the coronavirus that caused SARS, was primarily transmitted by droplets and personal contact.", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["coronavirus", "DISEASE", 66, 77], ["SARS", "DISEASE", 90, 94], ["Severe acute respiratory syndrome coronavirus 1", "ORGANISM", 0, 47], ["SARS-CoV-1", "ORGANISM", 49, 59], ["coronavirus", "ORGANISM", 66, 77], ["coronavirus 1", "SPECIES", 34, 47], ["Severe acute respiratory syndrome coronavirus 1", "SPECIES", 0, 47], ["SARS-CoV-1", "SPECIES", 49, 59], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["SARS-CoV", "TEST", 49, 57], ["the coronavirus", "PROBLEM", 62, 77], ["SARS", "PROBLEM", 90, 94], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["SARS", "OBSERVATION", 90, 94]]], ["However, analysis of a community cluster of SARS in Hong Kong that originated from an index patient with diarrhoea suggested that faecal shedding and air movement of contaminated bio-aerosols was a major contributor to the 187-person outbreak [1] .OpinionSimilarly, airborne SARS probably contributed to another large hospital outbreak [2] .", [["faecal", "ANATOMY", 130, 136], ["SARS", "DISEASE", 44, 48], ["diarrhoea", "DISEASE", 105, 114], ["SARS", "DISEASE", 275, 279], ["patient", "ORGANISM", 92, 99], ["faecal", "ORGANISM_SUBSTANCE", 130, 136], ["patient", "SPECIES", 92, 99], ["SARS", "PROBLEM", 44, 48], ["diarrhoea", "PROBLEM", 105, 114], ["faecal shedding", "PROBLEM", 130, 145], ["air movement of contaminated bio-aerosols", "PROBLEM", 150, 191], ["airborne SARS", "PROBLEM", 266, 279]]], ["Bioaerosols containing live pathogens can be produced by toilet flushing [3] , and 95% of droplets produced by flushing are small enough to present an airborne infection concern (\u2264 2 \u00b5m) [4] .", [["Bioaerosols", "CHEMICAL", 0, 11], ["infection", "DISEASE", 160, 169], ["Bioaerosols", "TREATMENT", 0, 11], ["droplets", "TREATMENT", 90, 98], ["an airborne infection", "PROBLEM", 148, 169], ["small", "OBSERVATION_MODIFIER", 124, 129], ["airborne", "OBSERVATION_MODIFIER", 151, 159], ["infection", "OBSERVATION", 160, 169]]], ["Months into the COVID-19 pandemic, it is well recognized that COVID-19 patients have gastrointestinal symptoms including diarrhoea and shed virus in stool [5] .", [["gastrointestinal", "ANATOMY", 85, 101], ["gastrointestinal symptoms", "DISEASE", 85, 110], ["diarrhoea", "DISEASE", 121, 130], ["patients", "ORGANISM", 71, 79], ["gastrointestinal", "ORGAN", 85, 101], ["stool", "ORGANISM_SUBSTANCE", 149, 154], ["patients", "SPECIES", 71, 79], ["COVID", "TEST", 62, 67], ["gastrointestinal symptoms", "PROBLEM", 85, 110], ["diarrhoea", "PROBLEM", 121, 130], ["shed virus in stool", "PROBLEM", 135, 154], ["gastrointestinal", "ANATOMY", 85, 101]]], ["Faecal shedding seems to occur in patients without gastrointestinal symptoms [6] , which could enable asymptomatic individuals with no respiratory symptoms to be a source of faecal transmission.OpinionWhile research on this route is ongoing, the potential for transmission should not be underestimated: recently published data from China reported presumed transmission of SARS-CoV-2 from one patient with gastrointestinal symptoms to 10 healthcare workers and four other patients [7] .Page 4 of 7Faecal bio-aerosol transmission may be overlooked in a hospital setting because it is not a commonly discussed source of pathogenic aerosols.", [["Faecal", "ANATOMY", 0, 6], ["gastrointestinal", "ANATOMY", 51, 67], ["respiratory", "ANATOMY", 135, 146], ["faecal", "ANATOMY", 174, 180], ["gastrointestinal", "ANATOMY", 405, 421], ["faecal transmission", "DISEASE", 174, 193], ["SARS", "DISEASE", 372, 376], ["gastrointestinal symptoms", "DISEASE", 405, 430], ["Faecal", "ORGANISM_SUBSTANCE", 0, 6], ["patients", "ORGANISM", 34, 42], ["gastrointestinal", "ORGAN", 51, 67], ["faecal", "ORGANISM_SUBSTANCE", 174, 180], ["SARS-CoV-2", "ORGANISM", 372, 382], ["patient", "ORGANISM", 392, 399], ["gastrointestinal", "ORGAN", 405, 421], ["patients", "ORGANISM", 471, 479], ["patients", "SPECIES", 34, 42], ["CoV-2", "SPECIES", 377, 382], ["patient", "SPECIES", 392, 399], ["patients", "SPECIES", 471, 479], ["SARS-CoV", "SPECIES", 372, 380], ["Faecal shedding", "PROBLEM", 0, 15], ["gastrointestinal symptoms", "PROBLEM", 51, 76], ["respiratory symptoms", "PROBLEM", 135, 155], ["faecal transmission", "PROBLEM", 174, 193], ["SARS", "PROBLEM", 372, 376], ["CoV", "TEST", 377, 380], ["gastrointestinal symptoms", "PROBLEM", 405, 430], ["pathogenic aerosols", "PROBLEM", 617, 636], ["gastrointestinal", "ANATOMY", 405, 421], ["pathogenic", "OBSERVATION_MODIFIER", 617, 627], ["aerosols", "OBSERVATION", 628, 636]]], ["Inoculation by exposure to contaminated surfaces is the typically understood route of transmission for a pathogen with demonstrated gastrointestinal shedding.", [["gastrointestinal", "ANATOMY", 132, 148], ["gastrointestinal", "ORGANISM_SUBDIVISION", 132, 148], ["a pathogen", "PROBLEM", 103, 113], ["gastrointestinal shedding", "PROBLEM", 132, 157], ["gastrointestinal", "ANATOMY", 132, 148]]], ["However, toilet flushing also generates droplet nuclei that are small enough to both contaminate surfaces and become airborne [4] .", [["droplet nuclei", "ANATOMY", 40, 54], ["toilet flushing", "TREATMENT", 9, 24], ["droplet nuclei", "PROBLEM", 40, 54], ["droplet nuclei", "OBSERVATION", 40, 54], ["small", "OBSERVATION_MODIFIER", 64, 69]]], ["While little to no research is available on the production of infectious bio-aerosols containing specific pathogens, including SARS-CoV-2, the presence of pathogens such as Clostridioides difficile in hospital air is substantially increased by toilet flushing [8] .", [["Clostridioides difficile", "DISEASE", 173, 197], ["SARS-CoV-2", "ORGANISM", 127, 137], ["Clostridioides difficile", "ORGANISM", 173, 197], ["Clostridioides difficile", "SPECIES", 173, 197], ["SARS-CoV", "SPECIES", 127, 135], ["Clostridioides difficile", "SPECIES", 173, 197], ["infectious bio-aerosols", "PROBLEM", 62, 85], ["specific pathogens", "PROBLEM", 97, 115], ["SARS-CoV", "TEST", 127, 135], ["pathogens", "PROBLEM", 155, 164], ["Clostridioides difficile in hospital air", "PROBLEM", 173, 213], ["toilet flushing", "TREATMENT", 244, 259], ["pathogens", "OBSERVATION", 155, 164], ["increased", "OBSERVATION_MODIFIER", 231, 240]]], ["Already, evidence of SARS-CoV-2 contamination of surface and air samples outside of isolation rooms [9] , and experimental data showing that SARS-CoV-2 can live in aerosols for 3 hours [10] , should raise concerns about this mode of transmission and prompt additional research.Page 4 of 7Additional research on this topic is needed, but the questions that are immediately relevant to infection control are:Page 4 of 7\u2022 Does toilet flushing produce bio-aerosolized and viable SARS-CoV-2 to a similar or lesser degree compared to clinical aerosolizing procedures, such as nebulizer treatments?Page 4 of 7\u2022 Under certain conditions, could bio-aerosols containing viable SARS-CoV-2 be recirculated in the ventilation systems of healthcare facilities and public buildings?Page 4 of 7\u2022 Given that bio-aerosols penetrate alveolar tissue, does exposure to bio-aerosols from toilets cause more severe disease than contact with respiratory droplets, and could this route of exposure put healthcare workers, hospitalized patients, and environmental services staff at higher risk of severe or critical disease?Page 4 of 7These questions have not yet been answered.", [["surface", "ANATOMY", 49, 56], ["air samples", "ANATOMY", 61, 72], ["alveolar tissue", "ANATOMY", 814, 829], ["respiratory droplets", "ANATOMY", 918, 938], ["SARS", "DISEASE", 21, 25], ["SARS", "DISEASE", 141, 145], ["infection", "DISEASE", 384, 393], ["SARS", "DISEASE", 667, 671], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["surface", "CELLULAR_COMPONENT", 49, 56], ["bio-aerosols", "SIMPLE_CHEMICAL", 791, 803], ["alveolar tissue", "TISSUE", 814, 829], ["patients", "ORGANISM", 1010, 1018], ["patients", "SPECIES", 1010, 1018], ["SARS-CoV", "SPECIES", 475, 483], ["SARS", "PROBLEM", 21, 25], ["CoV", "TEST", 26, 29], ["air samples", "TEST", 61, 72], ["experimental data", "TEST", 110, 127], ["SARS", "PROBLEM", 141, 145], ["clinical aerosolizing procedures", "TREATMENT", 528, 560], ["nebulizer treatments", "TREATMENT", 570, 590], ["bio-aerosols penetrate alveolar tissue", "PROBLEM", 791, 829], ["bio-aerosols", "TREATMENT", 848, 860], ["more severe disease", "PROBLEM", 880, 899], ["severe or critical disease", "PROBLEM", 1071, 1097], ["evidence of", "UNCERTAINTY", 9, 20], ["SARS", "OBSERVATION", 21, 25], ["air", "OBSERVATION", 61, 64], ["lesser degree", "OBSERVATION_MODIFIER", 502, 515], ["alveolar tissue", "OBSERVATION", 814, 829], ["severe", "OBSERVATION_MODIFIER", 885, 891], ["disease", "OBSERVATION", 892, 899], ["severe", "OBSERVATION_MODIFIER", 1071, 1077], ["critical", "OBSERVATION_MODIFIER", 1081, 1089], ["disease", "OBSERVATION", 1090, 1097]]], ["However, given the urgent and emerging nature of this illness, the apparent increased infectiousness of SARS-CoV-2 compared to earlier coronaviruses, and the lack of clinical experience with this pathogen, it would be prudent for hospitals to exercise precautions as part of infection control initiatives.", [["SARS", "DISEASE", 104, 108], ["infection", "DISEASE", 275, 284], ["SARS-CoV-2", "ORGANISM", 104, 114], ["SARS-CoV", "SPECIES", 104, 112], ["this illness", "PROBLEM", 49, 61], ["the apparent increased infectiousness of SARS", "PROBLEM", 63, 108], ["CoV", "TEST", 109, 112], ["earlier coronaviruses", "PROBLEM", 127, 148], ["this pathogen", "PROBLEM", 191, 204], ["exercise precautions", "TREATMENT", 243, 263], ["infection control initiatives", "TREATMENT", 275, 304], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["infectiousness", "OBSERVATION", 86, 100], ["infection", "OBSERVATION", 275, 284]]], ["Precautions may be simple: for example, hospitals may advise covering toilets or using non-flushing commodes, and ensuring robust environmental decontamination protocols.", [["Precautions", "TREATMENT", 0, 11], ["non-flushing commodes", "TREATMENT", 87, 108]]], ["Implementing these precautions now based on information that was previously learned from SARS can help healthcare facilities prevent similar patterns of transmission for SARS-CoV-2.", [["SARS", "DISEASE", 89, 93], ["SARS", "DISEASE", 170, 174], ["SARS-CoV-2", "ORGANISM", 170, 180], ["SARS-CoV", "SPECIES", 170, 178], ["these precautions", "TREATMENT", 13, 30], ["SARS", "PROBLEM", 170, 174]]], ["This is not the first coronavirus outbreak that global hospital systems have encountered, and it is not likely to be the last.", [["coronavirus", "DISEASE", 22, 33], ["not likely to be", "UNCERTAINTY", 100, 116]]], ["Management of COVID-19 should be guided by the wealth of information available from previous outbreaks, which clearly demonstrated faecal shedding and the potential for bio-aerosolization of the pathogen.", [["faecal", "ANATOMY", 131, 137], ["COVID-19", "CHEMICAL", 14, 22], ["COVID-19", "CHEMICAL", 14, 22], ["faecal", "ORGANISM_SUBSTANCE", 131, 137], ["COVID", "TEST", 14, 19], ["faecal shedding", "PROBLEM", 131, 146], ["bio-aerosolization of the pathogen", "PROBLEM", 169, 203], ["pathogen", "OBSERVATION", 195, 203]]], ["Faecal bio-aerosol transmission is particularly concerning for healthcare workers, who are already at higher risk of infection from SARS-CoV-2 than the general public, especially with shortages of personal protective equipment.", [["Faecal", "ANATOMY", 0, 6], ["infection", "DISEASE", 117, 126], ["SARS", "DISEASE", 132, 136], ["Faecal", "ORGANISM_SUBSTANCE", 0, 6], ["SARS-CoV", "SPECIES", 132, 140], ["Faecal bio-aerosol transmission", "TEST", 0, 31], ["infection", "PROBLEM", 117, 126], ["SARS", "PROBLEM", 132, 136], ["personal protective equipment", "TREATMENT", 197, 226], ["infection", "OBSERVATION", 117, 126]]], ["Exercising simple precautions and raising awareness about all routes of transmission, including faecal bio-aerosols, will help hospitals control both nosocomial infection and healthcare worker exposure.", [["nosocomial infection", "DISEASE", 150, 170], ["simple precautions", "TREATMENT", 11, 29], ["faecal bio-aerosols", "TREATMENT", 96, 115], ["both nosocomial infection", "PROBLEM", 145, 170], ["nosocomial", "OBSERVATION_MODIFIER", 150, 160], ["infection", "OBSERVATION", 161, 170]]]], "8ff7438ebf5bd7ffc431dccd7fdffd45b0a8d778": [["I enjoyed reading the recent clinical recommendations on airway management for thoracic surgical patients during the COVID-19 pandemic [1] .", [["airway", "ANATOMY", 57, 63], ["thoracic", "ANATOMY", 79, 87], ["airway", "MULTI-TISSUE_STRUCTURE", 57, 63], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["airway management", "TREATMENT", 57, 74], ["thoracic surgical patients", "TREATMENT", 79, 105], ["the COVID", "TEST", 113, 122], ["airway", "ANATOMY", 57, 63], ["thoracic", "ANATOMY", 79, 87]]], ["However, as a clinically practising thoracic anaesthetist of 28 years, I would like to make the following comments.", [["thoracic", "ANATOMY", 36, 44], ["thoracic", "ANATOMY", 36, 44]]], ["It was previously common practice to extubate the patient's trachea while they were still anaesthetised; that is, deep.", [["trachea", "ANATOMY", 60, 67], ["patient", "ORGANISM", 50, 57], ["trachea", "ORGAN", 60, 67], ["patient", "SPECIES", 50, 57], ["trachea", "ANATOMY", 60, 67], ["deep", "ANATOMY_MODIFIER", 114, 118]]], ["This minimised coughing due to the tracheal tube, which is common when extubating patients awake.", [["tracheal tube", "ANATOMY", 35, 48], ["coughing", "DISEASE", 15, 23], ["tracheal tube", "MULTI-TISSUE_STRUCTURE", 35, 48], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["This minimised coughing", "PROBLEM", 0, 23], ["the tracheal tube", "TREATMENT", 31, 48], ["coughing", "OBSERVATION", 15, 23], ["tracheal", "ANATOMY", 35, 43], ["tube", "OBSERVATION", 44, 48]]]], "PMC7150199": [["IntroductionViruses are ultramicroscopic, acellular, metabolically inert nucleoprotein particles of either deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), with or without a lipid envelop [1], [2].", [["deoxyribonucleic acid", "CHEMICAL", 107, 128], ["ribonucleic acid", "CHEMICAL", 138, 154], ["deoxyribonucleic acid", "SIMPLE_CHEMICAL", 107, 128], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["ribonucleic acid", "SIMPLE_CHEMICAL", 138, 154], ["ribonucleic acid", "RNA", 138, 154], ["IntroductionViruses", "TREATMENT", 0, 19], ["ultramicroscopic", "TREATMENT", 24, 40], ["acellular, metabolically inert nucleoprotein particles", "TREATMENT", 42, 96], ["deoxyribonucleic acid (DNA", "TREATMENT", 107, 133], ["ribonucleic acid (RNA", "PROBLEM", 138, 159], ["a lipid envelop", "TREATMENT", 178, 193]]], ["They are obligate intracellular parasites, utilize the host\u2019s cell machineries to propagate, and cause ailments as benign as a common wart, as irritating as a cold, or as deadly as the bloody African fever [2].", [["intracellular", "ANATOMY", 18, 31], ["cell", "ANATOMY", 62, 66], ["wart", "ANATOMY", 134, 138], ["fever", "DISEASE", 200, 205], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 31], ["cell", "CELL", 62, 66], ["intracellular parasites", "PROBLEM", 18, 41], ["the host\u2019s cell machineries", "TREATMENT", 51, 78], ["ailments", "PROBLEM", 103, 111], ["the bloody African fever", "PROBLEM", 181, 205]]], ["Entry of a virus into the specific host cell depends on the precise attachment or fitting of the viral surface molecules with the molecules of the host cell.", [["cell", "ANATOMY", 40, 44], ["surface", "ANATOMY", 103, 110], ["cell", "ANATOMY", 152, 156], ["host cell", "CELL", 35, 44], ["host cell", "CELL", 147, 156], ["viral surface molecules", "PROTEIN", 97, 120], ["host cell", "CELL_TYPE", 147, 156], ["a virus", "PROBLEM", 9, 16], ["the viral surface molecules", "PROBLEM", 93, 120], ["virus", "OBSERVATION", 11, 16], ["host cell", "OBSERVATION", 35, 44], ["viral surface molecules", "OBSERVATION", 97, 120], ["host cell", "OBSERVATION", 147, 156]]], ["Each viral strain is unique in its surface antigenic structure, host cell receptors, and life cycle, and thus adopts various invasion strategies to infect every form of life.", [["surface", "ANATOMY", 35, 42], ["cell", "ANATOMY", 69, 73], ["host cell", "CELL", 64, 73], ["host cell receptors", "PROTEIN", 64, 83], ["Each viral strain", "PROBLEM", 0, 17], ["host cell receptors", "TREATMENT", 64, 83], ["various invasion strategies", "TREATMENT", 117, 144], ["viral strain", "OBSERVATION", 5, 17], ["host cell receptors", "OBSERVATION", 64, 83], ["invasion", "OBSERVATION", 125, 133]]], ["Due to their genetic variation, mode of transmission, effective replication, and the ability to persist within the host, viruses can cause widespread diseases from bacteria to humans [3], [4], [5], [6].IntroductionThus, the development of antiviral drugs requires great efforts.", [["humans", "ORGANISM", 176, 182], ["[4]", "SIMPLE_CHEMICAL", 188, 191], ["[5]", "SIMPLE_CHEMICAL", 193, 196], ["[6]", "SIMPLE_CHEMICAL", 198, 201], ["humans", "SPECIES", 176, 182], ["humans", "SPECIES", 176, 182], ["effective replication", "TREATMENT", 54, 75], ["viruses", "PROBLEM", 121, 128], ["widespread diseases", "PROBLEM", 139, 158], ["bacteria to humans", "PROBLEM", 164, 182], ["IntroductionThus", "TREATMENT", 202, 218], ["antiviral drugs", "TREATMENT", 239, 254], ["antiviral drugs", "OBSERVATION", 239, 254]]], ["Several reports on the discovery of new drugs from traditional medicines [7], [8], [9], [10], [11], [12] indicated the use of medicinal plants as a potential source for antiviral drug development [1], [7], [8], [9].", [["[7]", "SIMPLE_CHEMICAL", 73, 76], ["[8], [9]", "SIMPLE_CHEMICAL", 78, 86], ["[10]", "SIMPLE_CHEMICAL", 88, 92], ["[11]", "SIMPLE_CHEMICAL", 94, 98], ["[12]", "SIMPLE_CHEMICAL", 100, 104], ["[7]", "SIMPLE_CHEMICAL", 201, 204], ["[8]", "SIMPLE_CHEMICAL", 206, 209], ["[9]", "SIMPLE_CHEMICAL", 211, 214], ["new drugs", "TREATMENT", 36, 45], ["traditional medicines", "TREATMENT", 51, 72], ["medicinal plants", "TREATMENT", 126, 142], ["antiviral drug development", "TREATMENT", 169, 195]]], ["Several reports indicated that a wide variety of phytochemicals, including alkaloids, flavonoids, terpenoids, polyphenolics, coumarins, lignans, have therapeutic applications [4], [5], [6], [7], [8], [9], [10], [11], [12] due to their interferences on viral entry or replication, along with their antioxidative properties [6], [9], [13].", [["alkaloids, flavonoids, terpenoids, polyphenolics, coumarins, lignans", "CHEMICAL", 75, 143], ["[5], [6], [7], [8], [9], [10], [11], [12]", "CHEMICAL", 180, 221], ["flavonoids", "CHEMICAL", 86, 96], ["terpenoids", "CHEMICAL", 98, 108], ["polyphenolics", "CHEMICAL", 110, 123], ["coumarins", "CHEMICAL", 125, 134], ["lignans", "CHEMICAL", 136, 143], ["alkaloids", "SIMPLE_CHEMICAL", 75, 84], ["flavonoids", "SIMPLE_CHEMICAL", 86, 96], ["terpenoids", "SIMPLE_CHEMICAL", 98, 108], ["polyphenolics", "SIMPLE_CHEMICAL", 110, 123], ["coumarins", "SIMPLE_CHEMICAL", 125, 134], ["lignans", "SIMPLE_CHEMICAL", 136, 143], ["[4]", "SIMPLE_CHEMICAL", 175, 178], ["[5], [6], [7], [8], [9], [10], [11], [12]", "SIMPLE_CHEMICAL", 180, 221], ["[9]", "SIMPLE_CHEMICAL", 327, 330], ["[13]", "SIMPLE_CHEMICAL", 332, 336], ["a wide variety of phytochemicals", "PROBLEM", 31, 63], ["alkaloids", "TREATMENT", 75, 84], ["flavonoids", "TREATMENT", 86, 96], ["terpenoids", "TREATMENT", 98, 108], ["polyphenolics", "TREATMENT", 110, 123], ["coumarins", "TREATMENT", 125, 134], ["lignans", "TREATMENT", 136, 143], ["therapeutic applications", "TREATMENT", 150, 174], ["their interferences", "PROBLEM", 229, 248], ["viral entry", "PROBLEM", 252, 263], ["their antioxidative properties", "TREATMENT", 291, 321]]], ["Different in vitro and in vivo bioassays on phytochemicals lead to the identification of potential antiviral molecules.", [["antiviral molecules", "PROTEIN", 99, 118], ["phytochemicals", "TREATMENT", 44, 58], ["potential antiviral molecules", "PROBLEM", 89, 118], ["antiviral molecules", "OBSERVATION", 99, 118]]], ["In this chapter, we will summarize the scientific approaches used to validate potential \u201cantiviral leads\u201d against selected genetically and functionally diverse viral families, from crude extracts to pure compounds.", [["extracts", "ANATOMY", 187, 195], ["extracts", "ORGANISM_SUBSTANCE", 187, 195], ["potential \u201cantiviral leads", "TREATMENT", 78, 104]]], ["In-depth studies on some common in vitro antiviral assays with testing of efficacies, modes, and molecular mechanisms of action will be described here with in vivo methods against a few selected viruses.IntroductionViral infection control strategies include (1) public health measures to minimize the risk of infection, (2) vaccination to the exposed individuals, and (3) antiinfective drugs for infected individuals.", [["infection", "DISEASE", 221, 230], ["infection", "DISEASE", 309, 318], ["depth studies", "TEST", 3, 16], ["vitro antiviral assays", "TEST", 35, 57], ["a few selected viruses", "PROBLEM", 180, 202], ["IntroductionViral infection control strategies", "TREATMENT", 203, 249], ["public health measures", "TREATMENT", 262, 284], ["infection", "PROBLEM", 309, 318], ["vaccination", "TREATMENT", 324, 335], ["antiinfective drugs", "TREATMENT", 372, 391], ["infected individuals", "PROBLEM", 396, 416], ["viruses", "OBSERVATION", 195, 202], ["infection", "OBSERVATION", 221, 230], ["infection", "OBSERVATION", 309, 318]]], ["Public health measures such as safe drinking water can prevent Polio and Rota virus infections, while pest control can prevent arthropod and rodent-borne yellow fever, dengue, encephalitis, and hanta and arena viruses.", [["Polio and Rota virus infections", "DISEASE", 63, 94], ["yellow fever", "DISEASE", 154, 166], ["dengue", "DISEASE", 168, 174], ["encephalitis", "DISEASE", 176, 188], ["hanta and arena viruses", "DISEASE", 194, 217], ["Rota virus", "ORGANISM", 73, 83], ["arena viruses", "ORGANISM", 204, 217], ["rodent", "SPECIES", 141, 147], ["yellow fever", "SPECIES", 154, 166], ["Rota virus", "SPECIES", 73, 83], ["Public health measures", "TREATMENT", 0, 22], ["Polio and Rota virus infections", "PROBLEM", 63, 94], ["pest control", "TREATMENT", 102, 114], ["borne yellow fever", "PROBLEM", 148, 166], ["dengue", "PROBLEM", 168, 174], ["encephalitis", "PROBLEM", 176, 188], ["hanta and arena viruses", "PROBLEM", 194, 217], ["encephalitis", "OBSERVATION", 176, 188], ["arena", "ANATOMY", 204, 209], ["viruses", "OBSERVATION", 210, 217]]], ["However, to provide these benefits to the people of underdeveloped and developing world is a challenge.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48]]], ["A second challenge is to discover means to control airborne respiratory infections.", [["respiratory", "ANATOMY", 60, 71], ["respiratory infections", "DISEASE", 60, 82], ["A second challenge", "TREATMENT", 0, 18], ["airborne respiratory infections", "PROBLEM", 51, 82], ["airborne", "OBSERVATION_MODIFIER", 51, 59], ["respiratory infections", "OBSERVATION", 60, 82]]], ["As public health measures are never totally effective, vaccination is a second strategy.", [["public health measures", "TREATMENT", 3, 25], ["vaccination", "TREATMENT", 55, 66], ["a second strategy", "TREATMENT", 70, 87]]], ["Although vaccines dramatically decreased the incidence of polio, yellow fever, rabies, measles, mumps, rubella, and hepatitis B, they are not yet effective in human immunodeficiency virus (HIV), herpes simplex virus (HSV), hepatitis C virus (HCV), influenza, including common cold, caused by 100+ strains of Rhinoviruses.", [["polio", "DISEASE", 58, 63], ["yellow fever", "DISEASE", 65, 77], ["rabies", "DISEASE", 79, 85], ["measles, mumps, rubella, and hepatitis B", "DISEASE", 87, 127], ["human immunodeficiency virus (HIV), herpes simplex virus (HSV), hepatitis C virus (HCV), influenza", "DISEASE", 159, 257], ["Rhinoviruses", "DISEASE", 308, 320], ["yellow fever", "ORGANISM", 65, 77], ["rabies", "ORGANISM", 79, 85], ["hepatitis B", "ORGANISM", 116, 127], ["human immunodeficiency virus", "ORGANISM", 159, 187], ["HIV", "ORGANISM", 189, 192], ["herpes simplex virus (HSV),", "ORGANISM", 195, 222], ["hepatitis C virus", "ORGANISM", 223, 240], ["HCV", "ORGANISM", 242, 245], ["Rhinoviruses", "CANCER", 308, 320], ["human immunodeficiency virus (HIV", "SPECIES", 159, 192], ["herpes simplex virus", "SPECIES", 195, 215], ["hepatitis C virus", "SPECIES", 223, 240], ["hepatitis B", "SPECIES", 116, 127], ["human immunodeficiency virus", "SPECIES", 159, 187], ["HIV", "SPECIES", 189, 192], ["herpes simplex virus", "SPECIES", 195, 215], ["HSV", "SPECIES", 217, 220], ["hepatitis C virus", "SPECIES", 223, 240], ["HCV", "SPECIES", 242, 245], ["vaccines", "TREATMENT", 9, 17], ["polio", "PROBLEM", 58, 63], ["yellow fever", "PROBLEM", 65, 77], ["rabies", "PROBLEM", 79, 85], ["measles", "PROBLEM", 87, 94], ["mumps", "PROBLEM", 96, 101], ["rubella", "PROBLEM", 103, 110], ["hepatitis B", "PROBLEM", 116, 127], ["human immunodeficiency virus", "PROBLEM", 159, 187], ["HIV", "PROBLEM", 189, 192], ["herpes simplex virus", "PROBLEM", 195, 215], ["HSV", "PROBLEM", 217, 220], ["hepatitis C virus (HCV)", "PROBLEM", 223, 246], ["influenza", "PROBLEM", 248, 257], ["common cold", "PROBLEM", 269, 280], ["Rhinoviruses", "PROBLEM", 308, 320], ["polio", "OBSERVATION_MODIFIER", 58, 63], ["hepatitis", "OBSERVATION", 116, 125], ["Rhinoviruses", "OBSERVATION", 308, 320]]], ["Developing a polyvalent vaccine against all these viruses is also a challenge.", [["a polyvalent vaccine", "TREATMENT", 11, 31], ["viruses", "OBSERVATION", 50, 57]]], ["Moreover, Alpha and Filovirus (Ebola) cause devastating epidemics with sporadic outbreaks, and it is difficult to vaccinate the entire population to eradicate them.", [["Ebola", "DISEASE", 31, 36], ["Alpha", "GENE_OR_GENE_PRODUCT", 10, 15], ["Ebola", "ORGANISM", 31, 36], ["Alpha and Filovirus (Ebola)", "TREATMENT", 10, 37], ["devastating epidemics", "PROBLEM", 44, 65], ["sporadic outbreaks", "PROBLEM", 71, 89], ["devastating", "OBSERVATION_MODIFIER", 44, 55]]], ["Thus, infection can and will occur despite the best effort of humankind.", [["infection", "DISEASE", 6, 15], ["infection", "PROBLEM", 6, 15], ["infection", "OBSERVATION", 6, 15]]], ["Hence, for antiviral drug development, scientists are looking into the features of an ideal antiviral drug that (1) effectively inhibits some essential viral processes, (2) prevents the development of drug-resistant viruses, (3) has broad activity (single drug against any of the 100+ common cold viruses), and (4) has minimum or no effect on the host system.", [["antiviral drug development", "TREATMENT", 11, 37], ["an ideal antiviral drug", "TREATMENT", 83, 106], ["some essential viral processes", "PROBLEM", 137, 167], ["drug-resistant viruses", "PROBLEM", 201, 223], ["common cold viruses", "PROBLEM", 285, 304], ["effect on the host system", "PROBLEM", 333, 358], ["viral processes", "OBSERVATION", 152, 167], ["resistant viruses", "OBSERVATION", 206, 223]]], ["The first feature is obvious while the remaining depend on the viral process being targeted.Rationale for Antiviral Drug DevelopmentTill 2014, only 37 antivirals are approved by the US Food and Drug Administration, although many viral diseases have no effective drug(s).", [["viral diseases", "DISEASE", 229, 243], ["the viral process", "PROBLEM", 59, 76], ["Antiviral Drug DevelopmentTill", "TREATMENT", 106, 136], ["antivirals", "TREATMENT", 151, 161], ["Drug Administration", "TREATMENT", 194, 213], ["many viral diseases", "PROBLEM", 224, 243], ["obvious", "OBSERVATION_MODIFIER", 21, 28], ["viral", "OBSERVATION", 63, 68], ["viral diseases", "OBSERVATION", 229, 243]]], ["Moreover, several viral diseases require long-term treatment that usually leads to the development of drug-resistant viruses.", [["viral diseases", "DISEASE", 18, 32], ["drug-resistant viruses", "DISEASE", 102, 124], ["several viral diseases", "PROBLEM", 10, 32], ["long-term treatment", "TREATMENT", 41, 60], ["drug-resistant viruses", "PROBLEM", 102, 124], ["several", "OBSERVATION_MODIFIER", 10, 17], ["viral diseases", "OBSERVATION", 18, 32], ["long-term treatment", "OBSERVATION_MODIFIER", 41, 60], ["resistant viruses", "OBSERVATION", 107, 124]]], ["The existing antiviral nucleoside analogs act as antimetabolites in DNA synthesis and prevent viral replication in infected cells, and the related nucleotide analogs are used against hepatitis B virus (HBV), HCV, HSV, and HIV.", [["cells", "ANATOMY", 124, 129], ["nucleoside", "CHEMICAL", 23, 33], ["nucleotide", "CHEMICAL", 147, 157], ["hepatitis B virus (HBV), HCV, HSV, and HIV", "DISEASE", 183, 225], ["nucleoside", "CHEMICAL", 23, 33], ["nucleotide", "CHEMICAL", 147, 157], ["nucleoside analogs", "SIMPLE_CHEMICAL", 23, 41], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["cells", "CELL", 124, 129], ["hepatitis B virus", "ORGANISM", 183, 200], ["HBV", "ORGANISM", 202, 205], ["HCV", "ORGANISM", 208, 211], ["HSV", "ORGANISM", 213, 216], ["HIV", "ORGANISM", 222, 225], ["infected cells", "CELL_TYPE", 115, 129], ["hepatitis B virus", "SPECIES", 183, 200], ["HIV", "SPECIES", 222, 225], ["hepatitis B virus", "SPECIES", 183, 200], ["HBV", "SPECIES", 202, 205], ["HCV", "SPECIES", 208, 211], ["HSV", "SPECIES", 213, 216], ["HIV", "SPECIES", 222, 225], ["The existing antiviral nucleoside analogs", "TREATMENT", 0, 41], ["antimetabolites in DNA synthesis", "TREATMENT", 49, 81], ["viral replication in infected cells", "PROBLEM", 94, 129], ["the related nucleotide analogs", "TREATMENT", 135, 165], ["hepatitis B virus", "PROBLEM", 183, 200], ["HBV", "PROBLEM", 202, 205], ["HCV", "PROBLEM", 208, 211], ["HSV", "PROBLEM", 213, 216], ["HIV", "PROBLEM", 222, 225], ["viral replication", "OBSERVATION", 94, 111], ["infected cells", "OBSERVATION", 115, 129]]], ["In infected cells, these analogs are incorporated into the replicating DNA strand and phosphorylated as a chain terminator to stop viral DNA polymerase activity, and affect the mitochondrial DNA, leading to adverse effects such as bone marrow suppression.", [["cells", "ANATOMY", 12, 17], ["mitochondrial", "ANATOMY", 177, 190], ["bone marrow", "ANATOMY", 231, 242], ["bone marrow suppression", "DISEASE", 231, 254], ["cells", "CELL", 12, 17], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["mitochondrial", "CELLULAR_COMPONENT", 177, 190], ["DNA", "CELLULAR_COMPONENT", 191, 194], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 231, 242], ["replicating DNA strand", "DNA", 59, 81], ["viral DNA polymerase", "PROTEIN", 131, 151], ["mitochondrial DNA", "DNA", 177, 194], ["infected cells", "PROBLEM", 3, 17], ["a chain terminator", "TREATMENT", 104, 122], ["viral DNA polymerase activity", "PROBLEM", 131, 160], ["the mitochondrial DNA", "PROBLEM", 173, 194], ["adverse effects", "PROBLEM", 207, 222], ["bone marrow suppression", "TREATMENT", 231, 254], ["infected cells", "OBSERVATION", 3, 17], ["mitochondrial DNA", "OBSERVATION", 177, 194], ["bone marrow suppression", "OBSERVATION", 231, 254]]], ["Another family of synthetic nucleoside analog reverse-transcriptase (RT) inhibitors help to design drugs with preferential activity, while some nucleoside analogs can act as nucleoside analog reverse-transcriptase inhibitors and polymerase inhibitors for HBV.", [["nucleoside", "CHEMICAL", 28, 38], ["nucleoside", "CHEMICAL", 144, 154], ["nucleoside", "CHEMICAL", 174, 184], ["nucleoside", "CHEMICAL", 28, 38], ["nucleoside", "CHEMICAL", 144, 154], ["nucleoside", "CHEMICAL", 174, 184], ["nucleoside analogs", "SIMPLE_CHEMICAL", 144, 162], ["nucleoside", "SIMPLE_CHEMICAL", 174, 184], ["HBV", "ORGANISM", 255, 258], ["reverse-transcriptase", "PROTEIN", 46, 67], ["reverse-transcriptase", "PROTEIN", 192, 213], ["HBV", "SPECIES", 255, 258], ["synthetic nucleoside analog", "TREATMENT", 18, 45], ["transcriptase (RT) inhibitors", "TREATMENT", 54, 83], ["design drugs", "TREATMENT", 92, 104], ["preferential activity", "TREATMENT", 110, 131], ["some nucleoside analogs", "TREATMENT", 139, 162], ["nucleoside analog reverse", "TREATMENT", 174, 199], ["transcriptase inhibitors", "TREATMENT", 200, 224], ["polymerase inhibitors", "TREATMENT", 229, 250], ["HBV", "PROBLEM", 255, 258]]], ["Thus, antiviral nucleotides analogs repress viral reproduction by interfering with viral nucleic acid replication, compete with natural deoxynucleotide triphosphates (dNTP)/NTP substrates, and incorporate into the nascent viral nucleic acid leading to chain termination or mutagenesis (Table 8.1).Rationale for Antiviral Drug DevelopmentExtensive long-term clinical use of antivirals, such as acyclovir, the reference treatment for herpes viruses [14], results in the emergence of drug-resistant strains [15], due to mutations in viral thymidine kinase and/or DNA polymerase[16], along with renal impairment [17], [18].", [["renal", "ANATOMY", 591, 596], ["nucleic acid", "CHEMICAL", 89, 101], ["deoxynucleotide triphosphates", "CHEMICAL", 136, 165], ["dNTP", "CHEMICAL", 167, 171], ["NTP", "CHEMICAL", 173, 176], ["nucleic acid", "CHEMICAL", 228, 240], ["acyclovir", "CHEMICAL", 393, 402], ["herpes viruses", "DISEASE", 432, 446], ["thymidine", "CHEMICAL", 536, 545], ["renal impairment", "DISEASE", 591, 607], ["nucleotides", "CHEMICAL", 16, 27], ["deoxynucleotide triphosphates", "CHEMICAL", 136, 165], ["dNTP", "CHEMICAL", 167, 171], ["NTP", "CHEMICAL", 173, 176], ["acyclovir", "CHEMICAL", 393, 402], ["thymidine", "CHEMICAL", 536, 545], ["natural deoxynucleotide triphosphates", "SIMPLE_CHEMICAL", 128, 165], ["dNTP", "SIMPLE_CHEMICAL", 167, 171], ["NTP", "SIMPLE_CHEMICAL", 173, 176], ["acyclovir", "SIMPLE_CHEMICAL", 393, 402], ["herpes viruses", "ORGANISM", 432, 446], ["viral thymidine kinase", "GENE_OR_GENE_PRODUCT", 530, 552], ["DNA", "CELLULAR_COMPONENT", 560, 563], ["renal", "ORGAN", 591, 596], ["viral thymidine kinase", "PROTEIN", 530, 552], ["DNA polymerase", "PROTEIN", 560, 574], ["antiviral nucleotides analogs", "TREATMENT", 6, 35], ["viral reproduction", "TREATMENT", 44, 62], ["viral nucleic acid replication", "TREATMENT", 83, 113], ["natural deoxynucleotide triphosphates", "TREATMENT", 128, 165], ["dNTP)/NTP substrates", "TREATMENT", 167, 187], ["the nascent viral nucleic acid", "TREATMENT", 210, 240], ["Antiviral Drug", "TREATMENT", 311, 325], ["antivirals", "TREATMENT", 373, 383], ["acyclovir", "TREATMENT", 393, 402], ["the reference treatment", "TREATMENT", 404, 427], ["herpes viruses", "PROBLEM", 432, 446], ["resistant strains", "PROBLEM", 486, 503], ["viral thymidine kinase", "TREATMENT", 530, 552], ["DNA polymerase", "PROBLEM", 560, 574], ["renal impairment", "PROBLEM", 591, 607], ["renal", "ANATOMY", 591, 596], ["impairment", "OBSERVATION", 597, 607]]], ["As antiviral drugs are virus specific and target oriented, they require appropriate diagnosis before therapeutic intervention.", [["antiviral drugs", "TREATMENT", 3, 18], ["virus", "TREATMENT", 23, 28], ["therapeutic intervention", "TREATMENT", 101, 125]]], ["Another factor is the availability of suitable vaccines and their degree of effectiveness against a particular virus, as vaccination is the most effective approach for the prevention of a disease.", [["suitable vaccines", "TREATMENT", 38, 55], ["a particular virus", "PROBLEM", 98, 116], ["vaccination", "TREATMENT", 121, 132], ["a disease", "PROBLEM", 186, 195], ["disease", "OBSERVATION", 188, 195]]], ["However, in diseases such as hepatitis B, infected patients provide a large market for chemotherapy.", [["hepatitis B", "DISEASE", 29, 40], ["hepatitis B", "ORGANISM", 29, 40], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["hepatitis B", "SPECIES", 29, 40], ["diseases", "PROBLEM", 12, 20], ["hepatitis B", "PROBLEM", 29, 40], ["chemotherapy", "TREATMENT", 87, 99], ["diseases", "OBSERVATION", 12, 20], ["hepatitis", "OBSERVATION", 29, 38], ["large", "OBSERVATION_MODIFIER", 70, 75]]], ["Therefore, there is an unmatched need for readily available antiviral drugs at affordable prices with minimal side effects.", [["antiviral drugs", "TREATMENT", 60, 75], ["affordable prices", "TREATMENT", 79, 96], ["minimal side effects", "PROBLEM", 102, 122]]], ["Hence, traditional medicines are explored as novel antiviral agents, as many of these ancient medicaments, containing diverse plant metabolites, have potent antiviral activities [10], [11], [12], [19], [20].Development of Effective AntiViral DrugsDespite continuous advancement in medical science, viral diseases are a major cause of death around the globe.", [["viral diseases", "DISEASE", 298, 312], ["death", "DISEASE", 334, 339], ["[11], [12], [19], [20]", "SIMPLE_CHEMICAL", 184, 206], ["globe", "ORGAN", 351, 356], ["traditional medicines", "TREATMENT", 7, 28], ["novel antiviral agents", "TREATMENT", 45, 67], ["these ancient medicaments", "TREATMENT", 80, 105], ["diverse plant metabolites", "TREATMENT", 118, 143], ["Effective AntiViral DrugsDespite continuous advancement", "TREATMENT", 222, 277], ["viral diseases", "PROBLEM", 298, 312], ["death", "PROBLEM", 334, 339], ["Effective", "OBSERVATION_MODIFIER", 222, 231], ["AntiViral", "OBSERVATION", 232, 241], ["viral diseases", "OBSERVATION", 298, 312], ["globe", "ANATOMY", 351, 356]]], ["The development of an antiviral drug depends on the unique features of host\u2013virus interactions, as viruses are acellular and host- and route-specific, and infect only by their nucleic acid(s) that regulate the host cell DNA for multiplication.", [["cell", "ANATOMY", 215, 219], ["nucleic acid", "CHEMICAL", 176, 188], ["host\u2013virus", "GENE_OR_GENE_PRODUCT", 71, 81], ["host cell", "CELL", 210, 219], ["DNA", "CELLULAR_COMPONENT", 220, 223], ["an antiviral drug", "TREATMENT", 19, 36], ["host\u2013virus interactions", "PROBLEM", 71, 94], ["multiplication", "PROBLEM", 228, 242], ["antiviral drug", "OBSERVATION", 22, 36], ["host cell DNA", "OBSERVATION", 210, 223]]], ["Being an obligate intracellular parasite, viral replication depends on the metabolic pathways of the host.", [["intracellular", "ANATOMY", 18, 31], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 31], ["an obligate intracellular parasite", "PROBLEM", 6, 40], ["viral replication", "TREATMENT", 42, 59], ["obligate", "OBSERVATION_MODIFIER", 9, 17], ["intracellular parasite", "OBSERVATION", 18, 40], ["viral replication", "OBSERVATION", 42, 59]]], ["Thus, designing an effective antiviral drug to target virus-specific enzymes or replication steps without affecting the host cell is very difficult [20].", [["cell", "ANATOMY", 125, 129], ["cell", "CELL", 125, 129], ["an effective antiviral drug", "TREATMENT", 16, 43], ["target virus", "PROBLEM", 47, 59], ["specific enzymes", "TEST", 60, 76], ["replication steps", "PROBLEM", 80, 97], ["host cell", "OBSERVATION", 120, 129]]], ["Advancement in molecular biology and genetics helps to design a rational approach for developing antiviral agents by targeting specific sites/steps of the viral life cycle, including (1) inactivation of the extracellular virus particles, (2) prevention of viral attachment or fusion, (3) entry or penetration, (4) replication of viral genome, (5) synthesis of viral-specific proteins or intermediates, and (6) assembly or release of new virions.", [["extracellular", "ANATOMY", 207, 220], ["virions", "ANATOMY", 437, 444], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 207, 220], ["viral genome", "DNA", 329, 341], ["viral-specific proteins", "PROTEIN", 360, 383], ["a rational approach", "TREATMENT", 62, 81], ["antiviral agents", "TREATMENT", 97, 113], ["the extracellular virus particles", "TREATMENT", 203, 236], ["viral attachment or fusion", "TREATMENT", 256, 282], ["penetration", "PROBLEM", 297, 308], ["viral genome", "PROBLEM", 329, 341], ["synthesis of viral-specific proteins", "PROBLEM", 347, 383], ["new virions", "PROBLEM", 433, 444], ["extracellular virus", "ANATOMY", 207, 226], ["viral genome", "OBSERVATION", 329, 341], ["new", "OBSERVATION_MODIFIER", 433, 436], ["virions", "OBSERVATION", 437, 444]]], ["However, the most desirable target is the inhibition of major viral enzymes essential for replication and spread of the disease.", [["major viral enzymes", "PROTEIN", 56, 75], ["major viral enzymes", "TEST", 56, 75], ["replication", "PROBLEM", 90, 101], ["the disease", "PROBLEM", 116, 127], ["disease", "OBSERVATION", 120, 127]]], ["Most of the well-studied inhibitors of HIV, HSV, or Influenza viruses target the host cell binding (T-20, betulinic acid), uncoating of capsid (amantadine, pleconaril), viral replication (RT inhibitors: zidovudine, abacavir, nevirapine), viral enzymes integrase or DNA/RNA polymerase (acyclovir, cidofovir, ribavirin), proteinases of polyprotein precursors, and assembly or maturation (indinavir, ritonavir, rimantadine).", [["cell", "ANATOMY", 86, 90], ["T-20, betulinic acid", "CHEMICAL", 100, 120], ["amantadine", "CHEMICAL", 144, 154], ["pleconaril", "CHEMICAL", 156, 166], ["zidovudine", "CHEMICAL", 203, 213], ["abacavir", "CHEMICAL", 215, 223], ["nevirapine", "CHEMICAL", 225, 235], ["acyclovir", "CHEMICAL", 285, 294], ["cidofovir", "CHEMICAL", 296, 305], ["ribavirin", "CHEMICAL", 307, 316], ["indinavir", "CHEMICAL", 386, 395], ["ritonavir", "CHEMICAL", 397, 406], ["rimantadine", "CHEMICAL", 408, 419], ["betulinic acid", "CHEMICAL", 106, 120], ["amantadine", "CHEMICAL", 144, 154], ["pleconaril", "CHEMICAL", 156, 166], ["zidovudine", "CHEMICAL", 203, 213], ["abacavir", "CHEMICAL", 215, 223], ["nevirapine", "CHEMICAL", 225, 235], ["acyclovir", "CHEMICAL", 285, 294], ["cidofovir", "CHEMICAL", 296, 305], ["ribavirin", "CHEMICAL", 307, 316], ["indinavir", "CHEMICAL", 386, 395], ["ritonavir", "CHEMICAL", 397, 406], ["rimantadine", "CHEMICAL", 408, 419], ["HIV", "ORGANISM", 39, 42], ["HSV", "ORGANISM", 44, 47], ["Influenza viruses", "ORGANISM", 52, 69], ["cell", "CELL", 86, 90], ["T-20", "SIMPLE_CHEMICAL", 100, 104], ["betulinic acid", "SIMPLE_CHEMICAL", 106, 120], ["amantadine", "SIMPLE_CHEMICAL", 144, 154], ["pleconaril", "SIMPLE_CHEMICAL", 156, 166], ["zidovudine", "SIMPLE_CHEMICAL", 203, 213], ["abacavir", "SIMPLE_CHEMICAL", 215, 223], ["nevirapine", "SIMPLE_CHEMICAL", 225, 235], ["DNA", "CELLULAR_COMPONENT", 265, 268], ["acyclovir", "SIMPLE_CHEMICAL", 285, 294], ["cidofovir", "SIMPLE_CHEMICAL", 296, 305], ["ribavirin", "SIMPLE_CHEMICAL", 307, 316], ["indinavir", "SIMPLE_CHEMICAL", 386, 395], ["ritonavir", "SIMPLE_CHEMICAL", 397, 406], ["rimantadine", "SIMPLE_CHEMICAL", 408, 419], ["viral enzymes", "PROTEIN", 238, 251], ["DNA/RNA polymerase", "PROTEIN", 265, 283], ["proteinases", "PROTEIN", 319, 330], ["polyprotein precursors", "PROTEIN", 334, 356], ["HIV", "SPECIES", 39, 42], ["Influenza", "SPECIES", 52, 61], ["HIV", "SPECIES", 39, 42], ["HSV", "SPECIES", 44, 47], ["Influenza viruses", "SPECIES", 52, 69], ["HIV", "PROBLEM", 39, 42], ["HSV", "PROBLEM", 44, 47], ["Influenza viruses", "PROBLEM", 52, 69], ["T", "TEST", 100, 101], ["betulinic acid", "TEST", 106, 120], ["capsid (amantadine", "TREATMENT", 136, 154], ["pleconaril", "TREATMENT", 156, 166], ["viral replication (RT inhibitors", "TREATMENT", 169, 201], ["zidovudine", "TREATMENT", 203, 213], ["abacavir", "TREATMENT", 215, 223], ["nevirapine", "TREATMENT", 225, 235], ["viral enzymes integrase", "TREATMENT", 238, 261], ["DNA/RNA polymerase", "TREATMENT", 265, 283], ["acyclovir", "TREATMENT", 285, 294], ["cidofovir", "TREATMENT", 296, 305], ["ribavirin", "TREATMENT", 307, 316], ["proteinases", "TREATMENT", 319, 330], ["polyprotein precursors", "TREATMENT", 334, 356], ["indinavir", "TREATMENT", 386, 395], ["ritonavir", "TREATMENT", 397, 406], ["rimantadine", "TREATMENT", 408, 419]]], ["On the basis of these strategies, several compounds were tested on different viruses, but only 40 licensed antivirals are approved till 2014 [1], [5].", [["these strategies", "TREATMENT", 16, 32], ["several compounds", "PROBLEM", 34, 51], ["different viruses", "PROBLEM", 67, 84], ["antivirals", "TREATMENT", 107, 117]]], ["Moreover, studies on viral genomics, gene functions, and regulations led to the rational designing of gene-based drugs that induce protective antiviral immunity, interference with viral replication, gene expression, or viral messenger RNAs with limited delivery to the sites of replication and nuclease degradation [13].Medicinal Plants as a Source of Antiviral Drugs: an OverviewThe history of human civilization revealed that almost all ancient cultures rely upon medicinal plants for treating ailments of the body and mind, and about 80% of the world population uses traditional medicine for primary health care [4].", [["sites", "ANATOMY", 269, 274], ["body", "ANATOMY", 512, 516], ["human", "ORGANISM", 395, 400], ["body", "ORGANISM_SUBDIVISION", 512, 516], ["viral messenger RNAs", "RNA", 219, 239], ["nuclease", "PROTEIN", 294, 302], ["human", "SPECIES", 395, 400], ["human", "SPECIES", 395, 400], ["viral genomics", "TEST", 21, 35], ["gene-based drugs", "TREATMENT", 102, 118], ["protective antiviral immunity", "TREATMENT", 131, 160], ["viral replication", "TREATMENT", 180, 197], ["viral messenger RNAs", "PROBLEM", 219, 239], ["nuclease degradation", "PROBLEM", 294, 314], ["Antiviral Drugs", "TREATMENT", 352, 367], ["medicinal plants", "TREATMENT", 466, 482], ["traditional medicine", "TREATMENT", 570, 590]]], ["The discovery of synthetic drugs with better efficacy and quick recovery in many diseases leads to several adverse effects during long-term clinical use, particularly in chronic or \u201cdifficult-to-treat\u201d diseases.", [["synthetic drugs", "TREATMENT", 17, 32], ["many diseases", "PROBLEM", 76, 89], ["\u201d diseases", "PROBLEM", 200, 210], ["diseases", "OBSERVATION", 81, 89], ["chronic", "OBSERVATION_MODIFIER", 170, 177]]], ["Thus, there has been a huge upsurge in the use of natural products for preventing and treating serious viral diseases.", [["viral diseases", "DISEASE", 103, 117], ["natural products", "TREATMENT", 50, 66], ["serious viral diseases", "PROBLEM", 95, 117], ["huge", "OBSERVATION_MODIFIER", 23, 27], ["upsurge", "OBSERVATION_MODIFIER", 28, 35]]], ["About 40% of the modern-day anticancer and antimicrobial drugs have their roots in traditional medicine [4], [5], [20], but till 2014, we have barely analyzed the tip of iceberg to design more drugs from plants.", [["anticancer", "ANATOMY", 28, 38], ["roots", "ANATOMY", 74, 79], ["anticancer", "CANCER", 28, 38], ["roots", "ORGAN", 74, 79], ["[5]", "SIMPLE_CHEMICAL", 109, 112], ["[20]", "SIMPLE_CHEMICAL", 114, 118], ["the modern-day anticancer", "TREATMENT", 13, 38], ["antimicrobial drugs", "TREATMENT", 43, 62], ["traditional medicine", "TREATMENT", 83, 103]]], ["Hence, it is of utmost importance to search for phytochemicals with antiviral potential from unexplored plants used in ethnomedicine, before we lose our herbal resources due to rapid anthropogenic activities including industrialization and urbanization [1], [8].Medicinal Plants as a Source of Antiviral Drugs: an OverviewMany viruses have unique features in their structure or replication cycle that may act as the potential target for designing new antivirals, as evident with acyclovir (acycloguanosine), which blocks certain enzymes of herpes viruses responsible for triggering disease.", [["acyclovir", "CHEMICAL", 479, 488], ["acycloguanosine", "CHEMICAL", 490, 505], ["herpes viruses", "DISEASE", 540, 554], ["acyclovir", "CHEMICAL", 479, 488], ["acycloguanosine", "CHEMICAL", 490, 505], ["acyclovir", "SIMPLE_CHEMICAL", 479, 488], ["acycloguanosine", "SIMPLE_CHEMICAL", 490, 505], ["herpes viruses", "ORGANISM", 540, 554], ["ethnomedicine", "TREATMENT", 119, 132], ["rapid anthropogenic activities", "PROBLEM", 177, 207], ["Antiviral Drugs", "TREATMENT", 294, 309], ["new antivirals", "TREATMENT", 447, 461], ["acyclovir (acycloguanosine)", "TREATMENT", 479, 506], ["herpes viruses", "PROBLEM", 540, 554], ["triggering disease", "PROBLEM", 571, 589], ["herpes viruses", "OBSERVATION", 540, 554]]], ["Due to the structural diversity and broad range of bioactivities, ethnomedicines can serve as a source of complementary antivirals by inhibiting some specific enzymes or steps of viral replication or cellular factors (Table 8.2) of many DNA/RNA viruses [5].Medicinal Plants as a Source of Antiviral Drugs: an OverviewAyurveda and traditional Chinese medicine, in particular, use several medicinal plants to reduce disease severity, and many of them have antiviral activity [1], [5], [7], [8], [21].", [["cellular", "ANATOMY", 200, 208], ["cellular", "CELL", 200, 208], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["[5], [7]", "SIMPLE_CHEMICAL", 478, 486], ["[8]", "SIMPLE_CHEMICAL", 488, 491], ["[21]", "SIMPLE_CHEMICAL", 493, 497], ["enzymes", "PROTEIN", 159, 166], ["cellular factors", "PROTEIN", 200, 216], ["the structural diversity", "PROBLEM", 7, 31], ["broad range of bioactivities", "TREATMENT", 36, 64], ["ethnomedicines", "TREATMENT", 66, 80], ["complementary antivirals", "TREATMENT", 106, 130], ["viral replication", "PROBLEM", 179, 196], ["cellular factors", "PROBLEM", 200, 216], ["many DNA/RNA viruses", "PROBLEM", 232, 252], ["Antiviral Drugs", "TREATMENT", 289, 304], ["traditional Chinese medicine", "TREATMENT", 330, 358], ["several medicinal plants", "TREATMENT", 379, 403], ["disease severity", "PROBLEM", 414, 430], ["antiviral activity", "TEST", 454, 472], ["broad", "OBSERVATION_MODIFIER", 36, 41], ["viral replication", "OBSERVATION", 179, 196], ["RNA viruses", "OBSERVATION", 241, 252]]], ["Research on the antiviral potentials of plants was first started in 1952, and 12 out of 288 plants were found to be effective against influenza [4], [5].", [["influenza", "DISEASE", 134, 143], ["influenza", "PROBLEM", 134, 143]]], ["During the past 40 years, numerous broad-based screening programs for the antiviral activity of medicinal plants have been initiated using in vitro and in vivo assays.", [["numerous broad-based screening programs", "TREATMENT", 26, 65], ["the antiviral activity", "TREATMENT", 70, 92], ["medicinal plants", "TREATMENT", 96, 112], ["antiviral activity", "OBSERVATION", 74, 92]]], ["Out of 100 British Colombian medicinal plants, only a few showed activities against corona viruses, respiratory syncytial virus (RSV), para influenza, and HSV [22], while the marine algae Spirulina showed antimutagenic, immunomodulatory, and antiviral activities [23], [24].", [["respiratory syncytial virus (RSV), para influenza", "DISEASE", 100, 149], ["corona viruses", "ORGANISM", 84, 98], ["respiratory syncytial virus", "ORGANISM", 100, 127], ["RSV", "ORGANISM", 129, 132], ["HSV", "ORGANISM", 155, 158], ["algae Spirulina", "ORGANISM", 182, 197], ["respiratory syncytial virus", "SPECIES", 100, 127], ["corona viruses", "SPECIES", 84, 98], ["respiratory syncytial virus", "SPECIES", 100, 127], ["RSV", "SPECIES", 129, 132], ["HSV", "SPECIES", 155, 158], ["corona viruses", "PROBLEM", 84, 98], ["respiratory syncytial virus", "PROBLEM", 100, 127], ["para influenza", "PROBLEM", 135, 149], ["HSV", "PROBLEM", 155, 158], ["the marine algae Spirulina", "TEST", 171, 197], ["immunomodulatory", "TREATMENT", 220, 236], ["antiviral activities", "TEST", 242, 262], ["respiratory syncytial", "ANATOMY", 100, 121]]], ["Interestingly, Cyanovirin N, an 11-kDa protein of blue green algae, inactivates HIV-1 by binding with its glycoprotein120 [25], while sulfated polysaccharides of seaweeds and alga showed anti-HIV and anti-HSV activities [26].", [["seaweeds", "ANATOMY", 162, 170], ["alga", "ANATOMY", 175, 179], ["Cyanovirin N", "CHEMICAL", 15, 27], ["Cyanovirin N", "CHEMICAL", 15, 27], ["Cyanovirin N", "SIMPLE_CHEMICAL", 15, 27], ["blue green algae", "ORGANISM", 50, 66], ["HIV-1", "ORGANISM", 80, 85], ["sulfated polysaccharides", "SIMPLE_CHEMICAL", 134, 158], ["seaweeds", "SIMPLE_CHEMICAL", 162, 170], ["alga", "ORGANISM_SUBDIVISION", 175, 179], ["anti-HIV", "CANCER", 187, 195], ["anti-HSV", "SIMPLE_CHEMICAL", 200, 208], ["HIV-1", "SPECIES", 80, 85], ["blue green algae", "SPECIES", 50, 66], ["HIV-1", "SPECIES", 80, 85], ["anti-HSV", "SPECIES", 200, 208], ["Cyanovirin", "TEST", 15, 25], ["blue green algae", "PROBLEM", 50, 66], ["HIV", "TEST", 80, 83], ["its glycoprotein", "TEST", 102, 118], ["sulfated polysaccharides of seaweeds", "TREATMENT", 134, 170], ["anti-HIV", "TREATMENT", 187, 195], ["anti-HSV activities", "TREATMENT", 200, 219]]], ["A list of selected medicinal plants and their compounds having antiviral activities against common viral diseases is presented in Table 8.3, and the structures of some important compounds are depicted in Figure 8.1.Indirect Assays ::: In vitro Assay ::: Methods for the Validation of Antiviral Activity of PlantsIndirect assays are the first step for screening a large number of extracts or phytocompounds at a time, as virus infection and multiplication result in a cytopathic effect (CPE) due to the release of infectious virion or induction of apoptosis.", [["extracts", "ANATOMY", 379, 387], ["viral diseases", "DISEASE", 99, 113], ["infection", "DISEASE", 426, 435], ["extracts", "ORGANISM_SUBSTANCE", 379, 387], ["phytocompounds", "SIMPLE_CHEMICAL", 391, 405], ["selected medicinal plants", "TREATMENT", 10, 35], ["antiviral activities", "TREATMENT", 63, 83], ["common viral diseases", "PROBLEM", 92, 113], ["Indirect Assays", "TEST", 215, 230], ["Methods", "TREATMENT", 254, 261], ["Antiviral Activity of Plants", "TREATMENT", 284, 312], ["screening", "TEST", 351, 360], ["virus infection", "PROBLEM", 420, 435], ["multiplication", "PROBLEM", 440, 454], ["a cytopathic effect (CPE", "PROBLEM", 465, 489], ["infectious virion", "PROBLEM", 513, 530], ["apoptosis", "PROBLEM", 547, 556], ["large", "OBSERVATION_MODIFIER", 363, 368], ["infectious", "OBSERVATION", 513, 523]]], ["Inhibition of CPE in the presence of a test extract or phytocompound may be due to the inhibition of viral replication.", [["extract", "ANATOMY", 44, 51], ["CPE", "CHEMICAL", 14, 17], ["phytocompound", "CHEMICAL", 55, 68], ["phytocompound", "SIMPLE_CHEMICAL", 55, 68], ["CPE", "PROBLEM", 14, 17], ["a test extract", "PROBLEM", 37, 51], ["phytocompound", "PROBLEM", 55, 68], ["viral replication", "TREATMENT", 101, 118], ["CPE", "OBSERVATION", 14, 17], ["viral replication", "OBSERVATION", 101, 118]]], ["Till 2014, various indirect assays have been developed, validated, and modified for individual viruses.Visual Observation of CPE ::: In vitro Assay ::: Methods for the Validation of Antiviral Activity of PlantsVisual observation of CPE under an inverted microscope is usually carried out by infecting a semiconfluent cell monolayer with a susceptible virus in the presence or absence of a test drug, in a microtiter plate (Figure 8.2).Visual Observation of CPE ::: In vitro Assay ::: Methods for the Validation of Antiviral Activity of PlantsThis initial evaluation is usually done at a twofold concentration (with a 10-fold difference, e.g., 1 and 10 ng/ml or \u03bcg/ml).", [["cell monolayer", "ANATOMY", 317, 331], ["cell monolayer", "CELL", 317, 331], ["semiconfluent cell monolayer", "CELL_LINE", 303, 331], ["various indirect assays", "TEST", 11, 34], ["individual viruses", "PROBLEM", 84, 102], ["Methods", "TREATMENT", 152, 159], ["CPE", "PROBLEM", 232, 235], ["an inverted microscope", "TEST", 242, 264], ["a semiconfluent cell monolayer", "PROBLEM", 301, 331], ["a susceptible virus", "PROBLEM", 337, 356], ["a test drug", "TEST", 387, 398], ["a microtiter plate", "TEST", 403, 421], ["Methods", "TREATMENT", 484, 491], ["This initial evaluation", "TEST", 542, 565], ["viruses", "OBSERVATION", 95, 102]]], ["An 18 h culture (80\u201390% confluency) of an appropriate cell line should be added with the test drug or placebo, immediately after the virus infection.", [["cell line", "ANATOMY", 54, 63], ["infection", "DISEASE", 139, 148], ["cell line", "CELL", 54, 63], ["cell line", "CELL_LINE", 54, 63], ["An 18 h culture", "TEST", 0, 15], ["an appropriate cell line", "TREATMENT", 39, 63], ["the test drug", "TREATMENT", 85, 98], ["placebo", "TREATMENT", 102, 109], ["the virus infection", "PROBLEM", 129, 148], ["cell line", "OBSERVATION", 54, 63]]], ["When the drug effect was tested as pretreatment, cells need to be treated with the test drug for 15\u2013180 min before virus infection, and incubated for a standard time to induce viral CPE.", [["cells", "ANATOMY", 49, 54], ["infection", "DISEASE", 121, 130], ["cells", "CELL", 49, 54], ["the drug effect", "PROBLEM", 5, 20], ["the test drug", "TREATMENT", 79, 92], ["virus infection", "PROBLEM", 115, 130], ["viral CPE", "PROBLEM", 176, 185], ["viral CPE", "OBSERVATION", 176, 185]]], ["After every 24 h until the end of the experiment, the plate needs to be visualized microscopically for changes in cell morphology, compared to that for the control cells.", [["cell", "ANATOMY", 114, 118], ["cells", "ANATOMY", 164, 169], ["cell", "CELL", 114, 118], ["cells", "CELL", 164, 169], ["control cells", "CELL_TYPE", 156, 169], ["changes in cell morphology", "PROBLEM", 103, 129], ["cell morphology", "OBSERVATION", 114, 129]]], ["Here, the uninfected cell monolayer treated with the test drug will provide an idea of the maximum dose of drug causing minimum cell toxicity, as enlargement, granularity, rounding off, detachment, etc., and the degree of cytotoxicity as T (100% toxic), PVH (partially very heavy toxic, 80%), PH (partially heavy toxic, 60%), P (partial toxic 40%), PS (partial slightly toxic, 20%), or 0 (nontoxic, 0%).", [["cell monolayer", "ANATOMY", 21, 35], ["cell", "ANATOMY", 128, 132], ["toxicity", "DISEASE", 133, 141], ["detachment", "DISEASE", 186, 196], ["PH", "DISEASE", 293, 295], ["cell monolayer", "CELL", 21, 35], ["cell", "CELL", 128, 132], ["PVH", "SIMPLE_CHEMICAL", 254, 257], ["uninfected cell monolayer", "CELL_LINE", 10, 35], ["the uninfected cell monolayer", "TREATMENT", 6, 35], ["the test drug", "TREATMENT", 49, 62], ["drug", "TREATMENT", 107, 111], ["minimum cell toxicity", "PROBLEM", 120, 141], ["enlargement", "PROBLEM", 146, 157], ["granularity", "PROBLEM", 159, 170], ["detachment", "PROBLEM", 186, 196], ["cytotoxicity", "PROBLEM", 222, 234], ["T", "TEST", 238, 239], ["PVH", "PROBLEM", 254, 257], ["PH", "TEST", 293, 295], ["partially heavy toxic", "PROBLEM", 297, 318], ["P", "TEST", 326, 327], ["partial toxic", "TEST", 329, 342], ["PS", "TEST", 349, 351], ["partial slightly toxic", "PROBLEM", 353, 375], ["uninfected cell monolayer", "OBSERVATION", 10, 35], ["minimum cell toxicity", "OBSERVATION", 120, 141], ["enlargement", "OBSERVATION", 146, 157], ["granularity", "OBSERVATION_MODIFIER", 159, 170], ["detachment", "OBSERVATION", 186, 196], ["toxic", "OBSERVATION_MODIFIER", 370, 375]]], ["A 50% cell inhibitory or cytotoxic concentration (CC50) and 50% end point of virus inhibitory or effective concentration (EC50) can be determined from a graph plotted with the concentration versus cellular effect due to virus infection, while the selectivity or therapeutic index (SI or TI) is calculated as CC50/EC50.MTT or MTS Assay ::: In vitro Assay ::: Methods for the Validation of Antiviral Activity of PlantsAnother rapid and sensitive in vitro assay for the evaluation of antiviral agents is based on the spectrophotometric assessment of the viability of virus-infected or mock-infected cells, via the in situ reduction of a tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) or 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS); this has an equal sensitivity to that of the plaque reduction assay [10], [11], [84].", [["cell", "ANATOMY", 6, 10], ["cellular", "ANATOMY", 197, 205], ["cells", "ANATOMY", 596, 601], ["plaque", "ANATOMY", 861, 867], ["infection", "DISEASE", 226, 235], ["tetrazolium", "CHEMICAL", 634, 645], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 650, 710], ["MTT", "CHEMICAL", 712, 715], ["3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 720, 808], ["MTS", "CHEMICAL", 810, 813], ["MTT", "CHEMICAL", 318, 321], ["tetrazolium", "CHEMICAL", 634, 645], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 650, 710], ["MTT", "CHEMICAL", 712, 715], ["3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 720, 808], ["MTS", "CHEMICAL", 810, 813], ["cell", "CELL", 6, 10], ["cellular", "CELL", 197, 205], ["cells", "CELL", 596, 601], ["tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 634, 710], ["MTT", "SIMPLE_CHEMICAL", 712, 715], ["3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "SIMPLE_CHEMICAL", 720, 808], ["MTS", "SIMPLE_CHEMICAL", 810, 813], ["plaque", "PATHOLOGICAL_FORMATION", 861, 867], ["[11]", "SIMPLE_CHEMICAL", 890, 894], ["mock-infected cells", "CELL_TYPE", 582, 601], ["cytotoxic concentration", "TEST", 25, 48], ["CC50", "TEST", 50, 54], ["virus inhibitory", "PROBLEM", 77, 93], ["a graph", "TEST", 151, 158], ["the concentration", "TREATMENT", 172, 189], ["cellular effect", "PROBLEM", 197, 212], ["virus infection", "PROBLEM", 220, 235], ["Methods", "TREATMENT", 358, 365], ["Antiviral Activity of Plants", "TREATMENT", 388, 416], ["vitro assay", "TEST", 447, 458], ["the evaluation", "TEST", 463, 477], ["antiviral agents", "TREATMENT", 481, 497], ["the spectrophotometric assessment", "TEST", 510, 543], ["virus", "PROBLEM", 564, 569], ["infected cells", "PROBLEM", 587, 601], ["a tetrazolium dye", "TREATMENT", 632, 649], ["dimethylthiazol", "TREATMENT", 657, 672], ["diphenyltetrazolium bromide (MTT)", "TREATMENT", 683, 716], ["dimethylthiazol", "TREATMENT", 727, 742], ["carboxymethoxyphenyl)", "TREATMENT", 754, 775], ["tetrazolium (MTS)", "TREATMENT", 797, 814], ["virus infection", "OBSERVATION", 220, 235], ["plaque", "OBSERVATION", 861, 867]]], ["The mechanism is based on the conversion of a yellow water-soluble dye MTT or MTS to a purple colored insoluble formazan crystal by the mitochondrial enzymes of the viable cells.", [["mitochondrial", "ANATOMY", 136, 149], ["cells", "ANATOMY", 172, 177], ["MTT", "CHEMICAL", 71, 74], ["MTS", "CHEMICAL", 78, 81], ["formazan", "CHEMICAL", 112, 120], ["MTT", "CHEMICAL", 71, 74], ["MTS", "CHEMICAL", 78, 81], ["formazan", "CHEMICAL", 112, 120], ["MTT", "SIMPLE_CHEMICAL", 71, 74], ["MTS", "SIMPLE_CHEMICAL", 78, 81], ["formazan crystal", "SIMPLE_CHEMICAL", 112, 128], ["mitochondrial", "CELLULAR_COMPONENT", 136, 149], ["cells", "CELL", 172, 177], ["mitochondrial enzymes", "PROTEIN", 136, 157], ["a yellow water-soluble dye MTT", "TREATMENT", 44, 74], ["a purple colored insoluble formazan crystal", "PROBLEM", 85, 128], ["the mitochondrial enzymes", "TEST", 132, 157], ["viable cells", "OBSERVATION", 165, 177]]], ["The quantitation of the amount of formazan produced in each well is then determined spectrophotometrically at 490 nm, and the same is subtracted from the background absorption of the plate at 650 nm.", [["formazan", "CHEMICAL", 34, 42], ["formazan", "CHEMICAL", 34, 42], ["formazan", "SIMPLE_CHEMICAL", 34, 42], ["quantitation", "OBSERVATION_MODIFIER", 4, 16], ["amount", "OBSERVATION_MODIFIER", 24, 30], ["formazan", "OBSERVATION", 34, 42], ["plate", "ANATOMY", 183, 188]]], ["The cytotoxicity of the test drug needs to be evaluated in the same plate, and for data analysis, a statistical software program is used to determine the efficacy (EC50), cell toxicity (CC50), and SI or TI of the test drug.", [["cell", "ANATOMY", 171, 175], ["toxicity", "DISEASE", 176, 184], ["cell", "CELL", 171, 175], ["the test drug", "TEST", 20, 33], ["data analysis", "TEST", 83, 96], ["cell toxicity", "PROBLEM", 171, 184], ["the test drug", "TEST", 209, 222]]], ["This method allowed the screening of a larger number of extract/compounds at the same time with a simplified procedure.MTT or MTS Assay ::: In vitro Assay ::: Methods for the Validation of Antiviral Activity of Plants", [["MTT", "CHEMICAL", 119, 122], ["the screening", "TEST", 20, 33], ["extract/compounds", "TREATMENT", 56, 73], ["a simplified procedure", "TREATMENT", 96, 118], ["Methods", "TREATMENT", 159, 166], ["Antiviral Activity of Plants", "TREATMENT", 189, 217], ["larger", "OBSERVATION_MODIFIER", 39, 45]]]], "PMC7263271": [["The first reports of severe uveitis and occlusive retinal vasculitis associated with the use of brolucizumab (Beovu; Novartis, East Hanover, New Jersey, USA) appeared in early February of 2020, and more have appeared since then.", [["retinal", "ANATOMY", 50, 57], ["uveitis", "DISEASE", 28, 35], ["occlusive retinal vasculitis", "DISEASE", 40, 68], ["brolucizumab", "CHEMICAL", 96, 108], ["brolucizumab", "CHEMICAL", 96, 108], ["retinal", "MULTI-TISSUE_STRUCTURE", 50, 57], ["brolucizumab", "SIMPLE_CHEMICAL", 96, 108], ["severe uveitis", "PROBLEM", 21, 35], ["occlusive retinal vasculitis", "PROBLEM", 40, 68], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["uveitis", "OBSERVATION", 28, 35], ["occlusive", "OBSERVATION_MODIFIER", 40, 49], ["retinal", "ANATOMY", 50, 57], ["vasculitis", "OBSERVATION", 58, 68]]], ["Novartis sent information on the postapproval development to users on February 25 and updates have followed.1 Twenty-six cases associated with 70,000 injections and 37,000 treated patients were reported by March 27, 2020, in a report by the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee.2 Although the ASRS ReST committee report was not publicly available, the American Academy of Ophthalmology (AAO) has provided an available audio report on these recent developments surrounding brolucizumab-induced inflammation.3 Neither the Novartis warning nor the latest ASRS ReST committee's report from April 7 recommended that brolucizumab injections be stopped, but they did recommend careful evaluation for inflammation and continued vigilance in monitoring brolucizumab treatment outcomes.", [["brolucizumab", "CHEMICAL", 534, 546], ["inflammation", "DISEASE", 555, 567], ["brolucizumab", "CHEMICAL", 673, 685], ["inflammation", "DISEASE", 755, 767], ["brolucizumab", "CHEMICAL", 806, 818], ["brolucizumab", "CHEMICAL", 534, 546], ["brolucizumab", "CHEMICAL", 673, 685], ["brolucizumab", "CHEMICAL", 806, 818], ["patients", "ORGANISM", 180, 188], ["brolucizumab", "SIMPLE_CHEMICAL", 534, 546], ["brolucizumab", "SIMPLE_CHEMICAL", 673, 685], ["brolucizumab", "SIMPLE_CHEMICAL", 806, 818], ["patients", "SPECIES", 180, 188], ["induced inflammation", "PROBLEM", 547, 567], ["brolucizumab injections", "TREATMENT", 673, 696], ["careful evaluation", "TEST", 732, 750], ["inflammation", "PROBLEM", 755, 767], ["monitoring brolucizumab treatment outcomes", "TREATMENT", 795, 837], ["inflammation", "OBSERVATION", 555, 567]]], ["However, for many of us, these recommendations did not go far enough, and we have stopped using brolucizumab because of the associated inflammation.", [["brolucizumab", "CHEMICAL", 96, 108], ["inflammation", "DISEASE", 135, 147], ["brolucizumab", "CHEMICAL", 96, 108], ["brolucizumab", "SIMPLE_CHEMICAL", 96, 108], ["brolucizumab", "TREATMENT", 96, 108], ["the associated inflammation", "PROBLEM", 120, 147], ["inflammation", "OBSERVATION", 135, 147]]], ["Our patients have alternatives without incurring this risk.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]]], "9129d78b0d47b31ff06bb44bf06444e601e6ac95": [["INTRODUCTIONThe pandemic of severe acute respiratory syndrome (SARS) between 2002 and 2003.", [["acute respiratory syndrome", "DISEASE", 35, 61], ["SARS", "DISEASE", 63, 67], ["severe acute respiratory syndrome", "PROBLEM", 28, 61], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory syndrome", "OBSERVATION", 41, 61]]], ["This disease caused by SARS coronavirus (SARS-CoV) led to close to 800 deaths and more than 8,000 infections, which concluded approximately 10 percent of overall fatality rate.", [["SARS coronavirus", "DISEASE", 23, 39], ["SARS", "DISEASE", 41, 45], ["deaths", "DISEASE", 71, 77], ["infections", "DISEASE", 98, 108], ["SARS coronavirus", "ORGANISM", 23, 39], ["SARS-CoV", "ORGANISM", 41, 49], ["SARS coronavirus", "SPECIES", 23, 39], ["SARS-CoV", "SPECIES", 41, 49], ["This disease", "PROBLEM", 0, 12], ["SARS coronavirus", "PROBLEM", 23, 39], ["8,000 infections", "PROBLEM", 92, 108], ["disease", "OBSERVATION", 5, 12]]], ["Alarmingly, the fatality rate among older adults exceeded 50 percent [1] .", [["the fatality rate", "TEST", 12, 29]]], ["In preparation for future pandemics and accidental and/or intentional releases of SARS-CoV, intensive efforts have been made to develop vaccines against SARS-CoV.INTRODUCTIONFor the past two decades, several different antigens have been identified and developed as SARS-CoV vaccine candidates.INTRODUCTIONInitially, whole inactivated virus (WIV) or modified vaccinia virus Ankara expressing SARS vaccines were developed [1] , however, eosinophilic immunopathology was observed in mice and non-human primates immunized with these viral-vectored vaccines [2] [3] [4] [5] [6] [7] .", [["SARS", "DISEASE", 82, 86], ["SARS", "DISEASE", 391, 395], ["SARS-CoV", "ORGANISM", 82, 90], ["SARS-CoV", "ORGANISM", 265, 273], ["whole inactivated virus", "ORGANISM", 316, 339], ["vaccinia virus Ankara", "ORGANISM", 358, 379], ["eosinophilic", "PATHOLOGICAL_FORMATION", 435, 447], ["mice", "ORGANISM", 480, 484], ["non-human primates", "ORGANISM", 489, 507], ["[2] [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 553, 576], ["antigens", "PROTEIN", 218, 226], ["vaccinia virus", "SPECIES", 358, 372], ["mice", "SPECIES", 480, 484], ["SARS-CoV", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 265, 273], ["WIV", "SPECIES", 341, 344], ["vaccinia virus", "SPECIES", 358, 372], ["mice", "SPECIES", 480, 484], ["future pandemics", "TREATMENT", 19, 35], ["SARS", "PROBLEM", 82, 86], ["vaccines", "TREATMENT", 136, 144], ["several different antigens", "PROBLEM", 200, 226], ["SARS-CoV vaccine candidates", "TREATMENT", 265, 292], ["whole inactivated virus (WIV)", "TREATMENT", 316, 345], ["modified vaccinia virus Ankara expressing SARS vaccines", "TREATMENT", 349, 404], ["eosinophilic immunopathology", "PROBLEM", 435, 463], ["non-human primates immunized", "TREATMENT", 489, 517], ["these viral-vectored vaccines", "TREATMENT", 523, 552], ["eosinophilic", "OBSERVATION_MODIFIER", 435, 447], ["immunopathology", "OBSERVATION", 448, 463]]], ["Even though historically there have been reports that alum adjuvanted vaccines could induces enhancement, such as in the 1960's with the RSV vaccine or even with WIV and S proteins, [8] later, it was shown that alum-adjuvanted WIV elicited less immunopathology than WIV alone [8] . suggesting that alum might reduce immune enhancement, a process possibly linked to mixed Th1, Th17, and Th2 responses [7, 9] .", [["alum", "CHEMICAL", 54, 58], ["alum", "CHEMICAL", 211, 215], ["WIV", "CHEMICAL", 227, 230], ["immunopathology", "DISEASE", 245, 260], ["alum", "CHEMICAL", 298, 302], ["alum", "CHEMICAL", 54, 58], ["alum", "CHEMICAL", 211, 215], ["alum", "CHEMICAL", 298, 302], ["alum", "SIMPLE_CHEMICAL", 54, 58], ["RSV", "ORGANISM", 137, 140], ["alum", "SIMPLE_CHEMICAL", 211, 215], ["WIV", "SIMPLE_CHEMICAL", 227, 230], ["alum", "SIMPLE_CHEMICAL", 298, 302], ["Th1", "GENE_OR_GENE_PRODUCT", 371, 374], ["Th17", "GENE_OR_GENE_PRODUCT", 376, 380], ["WIV and S proteins", "PROTEIN", 162, 180], ["RSV", "SPECIES", 137, 140], ["WIV", "SPECIES", 162, 165], ["WIV", "SPECIES", 227, 230], ["WIV", "SPECIES", 266, 269], ["alum adjuvanted vaccines", "TREATMENT", 54, 78], ["the RSV vaccine", "TREATMENT", 133, 148], ["WIV and S proteins", "TEST", 162, 180], ["alum-adjuvanted WIV", "TREATMENT", 211, 230], ["alum", "TREATMENT", 298, 302], ["immune enhancement", "PROBLEM", 316, 334], ["alum", "OBSERVATION", 298, 302]]], ["Additional evidence emerged that the virus N protein had a key but not exclusive role in immune enhancement [3, 7] .", [["virus N protein", "PROTEIN", 37, 52], ["the virus N protein", "TEST", 33, 52], ["immune enhancement", "OBSERVATION", 89, 107]]], ["Based on these studies, the recombinant S protein of SARS-CoV was used as a vaccine candidate [1] , but the full-length S-protein also induced immunopathology, with epitopes outside of the receptor-binding domain (RBD) of the S protein implicated in eliciting this phenomenon [10, 11] .", [["SARS-CoV", "ORGANISM", 53, 61], ["S-protein", "GENE_OR_GENE_PRODUCT", 120, 129], ["recombinant S protein", "PROTEIN", 28, 49], ["full-length S-protein", "PROTEIN", 108, 129], ["epitopes", "PROTEIN", 165, 173], ["receptor-binding domain", "PROTEIN", 189, 212], ["RBD", "PROTEIN", 214, 217], ["S protein", "PROTEIN", 226, 235], ["SARS-CoV", "SPECIES", 53, 61], ["these studies", "TEST", 9, 22], ["SARS", "PROBLEM", 53, 57], ["CoV", "PROBLEM", 58, 61], ["immunopathology", "PROBLEM", 143, 158], ["epitopes", "TREATMENT", 165, 173], ["the S protein", "TREATMENT", 222, 235]]], ["Therefore, the RBD of the S protein was selected as a substitute for the full-length S protein [12] [13] [14] [15] [16] [17] .INTRODUCTIONRecombinant RBD formulated with Sigma's adjuvant system \u00ae (consisting of Monophosphoryl-lipid A/Trehalose dicorynomycolate adjuvant, a skewet Th1/Th2 adjuvant) or with Freund's adjuvant (Freund's complete in prime and Freund's incomplete in boost; a Th1/Th2 balanced adjuvant scheme) was shown to elicit neutralizing antibodies and highly protective immunity in the vaccinated animals, while significantly reducing or eliminating eosinophilic immunopathology [14, [16] [17] [18] [19] .", [["[12] [13] [14] [15] [16] [17", "CHEMICAL", 95, 123], ["Monophosphoryl-lipid A", "CHEMICAL", 211, 233], ["Trehalose dicorynomycolate", "CHEMICAL", 234, 260], ["immunopathology", "DISEASE", 581, 596], ["Monophosphoryl", "CHEMICAL", 211, 225], ["[12] [13] [14] [15] [16] [17] .INTRODUCTIONRecombinant RBD", "SIMPLE_CHEMICAL", 95, 153], ["Sigma", "SIMPLE_CHEMICAL", 170, 175], ["\u00ae", "SIMPLE_CHEMICAL", 194, 195], ["Monophosphoryl-lipid A", "SIMPLE_CHEMICAL", 211, 233], ["Trehalose dicorynomycolate", "SIMPLE_CHEMICAL", 234, 260], ["Freund", "ORGANISM", 306, 312], ["Freund", "ORGANISM", 325, 331], ["Freund", "ORGANISM", 356, 362], ["RBD", "PROTEIN", 15, 18], ["S protein", "PROTEIN", 26, 35], ["full-length S protein", "PROTEIN", 73, 94], ["neutralizing antibodies", "PROTEIN", 442, 465], ["the S protein", "TREATMENT", 22, 35], ["the full-length S protein", "TEST", 69, 94], ["Sigma's adjuvant system", "TREATMENT", 170, 193], ["Monophosphoryl-lipid A/Trehalose dicorynomycolate adjuvant", "TREATMENT", 211, 269], ["a skewet Th1/Th2 adjuvant", "TREATMENT", 271, 296], ["Freund's adjuvant", "TREATMENT", 306, 323], ["Freund's", "TREATMENT", 325, 333], ["a Th1/Th2 balanced adjuvant scheme", "TREATMENT", 386, 420], ["neutralizing antibodies", "PROBLEM", 442, 465], ["eosinophilic immunopathology", "PROBLEM", 568, 596]]], ["In our previous studies [20] . we developed a production process for several tag-free yeast-expressed recombinant RBD constructs.INTRODUCTIONSuch studies down-selected several candidates and ultimately identifying one, RBD219-N1 (residues 319-536), as a promising vaccine candidate, due to its ability to induce in immunized mice a stronger anti-RBD-specific antibody response and neutralizing antibodies when adjuvanted with aluminum hydroxide (Alhydrogel \u00ae ).", [["aluminum hydroxide", "CHEMICAL", 426, 444], ["Alhydrogel \u00ae", "CHEMICAL", 446, 458], ["aluminum hydroxide", "CHEMICAL", 426, 444], ["Alhydrogel", "CHEMICAL", 446, 456], ["RBD", "GENE_OR_GENE_PRODUCT", 114, 117], ["mice", "ORGANISM", 325, 329], ["anti-RBD", "CANCER", 341, 349], ["aluminum hydroxide", "SIMPLE_CHEMICAL", 426, 444], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 446, 458], ["tag-free yeast-expressed recombinant RBD constructs", "DNA", 77, 128], ["anti-RBD", "PROTEIN", 341, 349], ["neutralizing antibodies", "PROTEIN", 381, 404], ["yeast", "SPECIES", 86, 91], ["mice", "SPECIES", 325, 329], ["yeast", "SPECIES", 86, 91], ["mice", "SPECIES", 325, 329], ["a production process", "PROBLEM", 44, 64], ["several tag", "PROBLEM", 69, 80], ["free yeast", "PROBLEM", 81, 91], ["INTRODUCTIONSuch studies", "TEST", 129, 153], ["RBD219", "TEST", 219, 225], ["neutralizing antibodies", "TREATMENT", 381, 404], ["aluminum hydroxide", "TREATMENT", 426, 444], ["RBD constructs", "OBSERVATION", 114, 128]]], ["The protein production process was transferred to the Pilot Bioproduction Facility (PBF) at Walter Reed Army Institute of Research (WRAIR), and the clinical .", [["protein production", "OBSERVATION", 4, 22]]], ["CC-BY-NC-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a In this work, the RBD219-N1 formulated with Alhydrogel \u00ae resulted in significantly increased antigen-specific IgG titers and neutralizing antibody responses when compared to other RBD constructs.", [["RBD219-N1", "CHEMICAL", 47, 56], ["Alhydrogel \u00ae", "CHEMICAL", 73, 85], ["RBD219-N1", "CHEMICAL", 47, 56], ["RBD219-N1", "SIMPLE_CHEMICAL", 47, 56], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 73, 85], ["IgG", "GENE_OR_GENE_PRODUCT", 139, 142], ["IgG", "PROTEIN", 139, 142], ["RBD constructs", "DNA", 209, 223], ["the RBD219", "TEST", 43, 53], ["Alhydrogel", "TREATMENT", 73, 83], ["significantly increased antigen", "PROBLEM", 98, 129], ["specific IgG titers", "TEST", 130, 149], ["neutralizing antibody responses", "TEST", 154, 185], ["significantly", "OBSERVATION_MODIFIER", 98, 111], ["increased", "OBSERVATION_MODIFIER", 112, 121]]], ["After challenge with SARS-CoV, 100% of mice immunized with RBD219-N1 survived, while only 89% of mice immunized with other RBD constructs and less than 70% of the mice immunized with SARS-CoV spike protein survived and none survived in the control group.", [["SARS-CoV", "ORGANISM", 21, 29], ["mice", "ORGANISM", 39, 43], ["RBD219-N1", "CELL", 59, 68], ["mice", "ORGANISM", 97, 101], ["mice", "ORGANISM", 163, 167], ["SARS-CoV", "ORGANISM", 183, 191], ["RBD constructs", "DNA", 123, 137], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 163, 167], ["SARS-CoV", "SPECIES", 21, 29], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 163, 167], ["SARS-CoV", "SPECIES", 183, 191], ["SARS", "PROBLEM", 21, 25], ["CoV", "TEST", 26, 29], ["RBD219", "TEST", 59, 65], ["other RBD constructs", "PROBLEM", 117, 137], ["SARS", "PROBLEM", 183, 187], ["CoV spike protein", "PROBLEM", 188, 205]]], ["The alum formulated RBD minimized immune enhancement compared with other adjuvants formulations with either the RBD or full-length S protein.INTRODUCTIONFinally, an Alhydrogel \u00ae dose-ranging study further indicated that by formulating RBD219-N1 with Alhydrogel \u00ae at the ratio of 1:25, higher IgG titers could be elicited with no detectable viral load upon challenge.Generation of recombinant yeast-expressed RBD of SARS-CoVThe yeast-expressed SARS-CoV RBD193-N1, wt-RBD219 and RBD219-N1 were expressed and purified as previously described [20, 21] .", [["alum", "CHEMICAL", 4, 8], ["RBD219-N1", "CHEMICAL", 235, 244], ["Alhydrogel", "CHEMICAL", 250, 260], ["alum", "CHEMICAL", 4, 8], ["RBD219-N1", "CHEMICAL", 235, 244], ["Alhydrogel", "CHEMICAL", 250, 260], ["alum", "SIMPLE_CHEMICAL", 4, 8], ["Alhydrogel", "SIMPLE_CHEMICAL", 165, 175], ["RBD219-N1", "SIMPLE_CHEMICAL", 235, 244], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 250, 262], ["IgG", "GENE_OR_GENE_PRODUCT", 292, 295], ["recombinant yeast", "ORGANISM", 380, 397], ["RBD", "GENE_OR_GENE_PRODUCT", 408, 411], ["SARS-CoVThe yeast", "ORGANISM", 415, 432], ["SARS-CoV", "ORGANISM", 443, 451], ["wt-RBD219", "GENE_OR_GENE_PRODUCT", 463, 472], ["RBD219-N1", "GENE_OR_GENE_PRODUCT", 477, 486], ["RBD", "PROTEIN", 20, 23], ["RBD", "PROTEIN", 112, 115], ["full-length S protein", "PROTEIN", 119, 140], ["IgG", "PROTEIN", 292, 295], ["RBD", "PROTEIN", 408, 411], ["N1", "DNA", 459, 461], ["RBD219", "DNA", 466, 472], ["RBD219", "DNA", 477, 483], ["N1", "DNA", 484, 486], ["yeast", "SPECIES", 392, 397], ["yeast", "SPECIES", 427, 432], ["yeast", "SPECIES", 392, 397], ["SARS-CoVThe yeast", "SPECIES", 415, 432], ["SARS-CoV", "SPECIES", 443, 451], ["The alum formulated RBD", "TREATMENT", 0, 23], ["immune enhancement", "PROBLEM", 34, 52], ["other adjuvants formulations", "TREATMENT", 67, 95], ["an Alhydrogel \u00ae dose-ranging study", "TEST", 162, 196], ["RBD219", "TEST", 235, 241], ["Alhydrogel", "TEST", 250, 260], ["higher IgG titers", "PROBLEM", 285, 302], ["detectable viral load", "PROBLEM", 329, 350], ["recombinant yeast", "PROBLEM", 380, 397], ["SARS", "PROBLEM", 415, 419], ["CoVThe yeast", "TEST", 420, 432], ["CoV RBD193", "TEST", 448, 458], ["wt", "TEST", 463, 465], ["RBD219", "TEST", 466, 472], ["RBD219", "TEST", 477, 483], ["viral load", "OBSERVATION", 340, 350], ["recombinant yeast", "OBSERVATION", 380, 397]]], ["Briefly, 1 mL of P. pastoris X33 seed stock expressing RBD193-N1, wt RBD219, and RBD219-N1 was inoculated into 500 ml BMG (buffered minimal glycerol) medium and the culture was incubated overnight at 30\u00b0C with constant shaking at 250 rpm until an OD600 of ~10.", [["RBD219-N1", "CHEMICAL", 81, 90], ["glycerol", "CHEMICAL", 140, 148], ["glycerol", "CHEMICAL", 140, 148], ["P. pastoris X33", "ORGANISM", 17, 32], ["RBD193-N1", "CELL", 55, 64], ["RBD219", "GENE_OR_GENE_PRODUCT", 69, 75], ["RBD219-N1", "CELL", 81, 90], ["glycerol", "SIMPLE_CHEMICAL", 140, 148], ["RBD193", "PROTEIN", 55, 61], ["P. pastoris", "SPECIES", 17, 28], ["P. pastoris", "SPECIES", 17, 28], ["P. pastoris", "TREATMENT", 17, 28], ["RBD193", "TEST", 55, 61], ["wt RBD219", "TEST", 66, 75], ["RBD219", "TEST", 81, 87], ["buffered minimal glycerol) medium", "TREATMENT", 123, 156], ["the culture", "TEST", 161, 172], ["constant shaking", "PROBLEM", 210, 226]]], ["Approximately 250 ml of overnight culture were inoculated into 5 L sterile Basal Salt Media or Low Salt medium [20] .", [["overnight culture", "TEST", 24, 41], ["5 L sterile Basal Salt Media", "TREATMENT", 63, 91], ["Low Salt medium", "TREATMENT", 95, 110]]], ["Fermentation was maintained at 30\u00b0C, pH 5.0 and 30% of dissolved oxygen concentration until the exhaustion of glycerol, and the pH and the temperature were then ramped to 6.5 and 25\u00b0C, respectively, over an hour followed by continuous feeding of methanol at 11 ml/L/hr for ~70 hours.", [["oxygen", "CHEMICAL", 65, 71], ["glycerol", "CHEMICAL", 110, 118], ["methanol", "CHEMICAL", 246, 254], ["oxygen", "CHEMICAL", 65, 71], ["glycerol", "CHEMICAL", 110, 118], ["methanol", "CHEMICAL", 246, 254], ["oxygen", "SIMPLE_CHEMICAL", 65, 71], ["glycerol", "SIMPLE_CHEMICAL", 110, 118], ["methanol", "SIMPLE_CHEMICAL", 246, 254], ["Fermentation", "TEST", 0, 12], ["pH", "TEST", 37, 39], ["dissolved oxygen concentration", "TREATMENT", 55, 85], ["glycerol", "TREATMENT", 110, 118], ["the pH", "TEST", 124, 130], ["the temperature", "TEST", 135, 150], ["continuous feeding of methanol", "TREATMENT", 224, 254]]], ["The fermentation supernatant (FS) was harvested for further purification.", [["supernatant", "ANATOMY", 17, 28], ["further purification", "TREATMENT", 52, 72]]], ["To purify RBD193-N1, wt-RBD219, and RBD219-N1, ammonium sulfate was added to the FS until the molarity reached 2 M. The FS containing 2 M ammonium sulfate was purified by hydrophobic interaction chromatography using Butyl Sepharose HP resin followed by size exclusion chromatography using Superdex 75 resin [20, 21] .ReagentsAlhydrogel \u00ae (aluminum oxy hydroxide) was purchased from Brenntag (Ballerup, Denmark), AddaVax (MF59-like adjuvant; squalene oil-in water emulsion) was purchased from Invivogen (San Diego, CA, USA).", [["ammonium sulfate", "CHEMICAL", 47, 63], ["ammonium sulfate", "CHEMICAL", 138, 154], ["Alhydrogel \u00ae", "CHEMICAL", 325, 337], ["aluminum oxy hydroxide", "CHEMICAL", 339, 361], ["Brenntag", "CHEMICAL", 382, 390], ["AddaVax", "CHEMICAL", 412, 419], ["MF59", "CHEMICAL", 421, 425], ["squalene", "CHEMICAL", 441, 449], ["RBD193-N1", "CHEMICAL", 10, 19], ["RBD219-N1", "CHEMICAL", 36, 45], ["ammonium sulfate", "CHEMICAL", 47, 63], ["ammonium sulfate", "CHEMICAL", 138, 154], ["Alhydrogel", "CHEMICAL", 325, 335], ["aluminum oxy hydroxide", "CHEMICAL", 339, 361], ["squalene", "CHEMICAL", 441, 449], ["RBD193-N1", "SIMPLE_CHEMICAL", 10, 19], ["wt-RBD219", "SIMPLE_CHEMICAL", 21, 30], ["RBD219-N1", "SIMPLE_CHEMICAL", 36, 45], ["ammonium sulfate", "SIMPLE_CHEMICAL", 47, 63], ["2 M ammonium sulfate", "SIMPLE_CHEMICAL", 134, 154], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 325, 337], ["aluminum oxy hydroxide", "SIMPLE_CHEMICAL", 339, 361], ["Brenntag", "SIMPLE_CHEMICAL", 382, 390], ["AddaVax", "SIMPLE_CHEMICAL", 412, 419], ["MF59", "SIMPLE_CHEMICAL", 421, 425], ["squalene oil", "SIMPLE_CHEMICAL", 441, 453], ["RBD193", "TEST", 10, 16], ["wt", "TEST", 21, 23], ["RBD219", "TEST", 24, 30], ["RBD219", "TEST", 36, 42], ["ammonium sulfate", "TREATMENT", 47, 63], ["the FS", "TEST", 77, 83], ["The FS", "TEST", 116, 122], ["ammonium sulfate", "TREATMENT", 138, 154], ["Butyl Sepharose HP resin", "TREATMENT", 216, 240], ["ReagentsAlhydrogel \u00ae (aluminum oxy hydroxide)", "TREATMENT", 317, 362], ["AddaVax (MF59", "TREATMENT", 412, 425], ["adjuvant", "TREATMENT", 431, 439], ["squalene oil", "TREATMENT", 441, 453]]], ["The SARS S protein vaccine, produced .", [["The SARS S protein vaccine", "TREATMENT", 0, 26]]], ["CC-BY-NC-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.15.098079 doi: bioRxiv preprint in the baculovirus/insect cell expression platform and pre-formulated with aluminum, was obtained from BEI Resources, NIAID, NIH (Manassas, VA, USA).Binding StudyOne ml of TBS containing 18 to 180 \u00b5g RBD219-N1 and 400 \u00b5g Alhydrogel \u00ae were prepared to study the binding of RBD219-N1 to Alhydrogel \u00ae at different ratios (from 1:2 to 1:22).", [["cell", "ANATOMY", 201, 205], ["aluminum", "CHEMICAL", 250, 258], ["RBD219-N1", "CHEMICAL", 447, 456], ["Alhydrogel", "CHEMICAL", 460, 470], ["aluminum", "CHEMICAL", 250, 258], ["RBD219-N1", "CHEMICAL", 375, 384], ["Alhydrogel", "CHEMICAL", 396, 406], ["RBD219-N1", "CHEMICAL", 447, 456], ["Alhydrogel", "CHEMICAL", 460, 470], ["baculovirus", "ORGANISM", 182, 193], ["insect cell", "CELL", 194, 205], ["aluminum", "SIMPLE_CHEMICAL", 250, 258], ["RBD219-N1", "SIMPLE_CHEMICAL", 375, 384], ["RBD219-N1", "SIMPLE_CHEMICAL", 447, 456], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 460, 472], ["baculovirus", "SPECIES", 182, 193], ["bioRxiv", "TREATMENT", 158, 165], ["the baculovirus", "TREATMENT", 178, 193], ["aluminum", "TREATMENT", 250, 258], ["TBS", "TEST", 347, 350], ["RBD219", "TEST", 375, 381], ["RBD219", "TEST", 447, 453], ["Alhydrogel", "TEST", 460, 470]]], ["The prepared RBD219-N1/ Alhydrogel \u00ae slurry was mixed for one hour to ensure the binding of RBD219-N1 to Alhydrogel \u00ae reached an equilibrium state.", [["RBD219-N1", "CHEMICAL", 13, 22], ["Alhydrogel", "CHEMICAL", 24, 34], ["RBD219-N1", "CHEMICAL", 92, 101], ["Alhydrogel", "CHEMICAL", 105, 115], ["RBD219-N1", "CHEMICAL", 13, 22], ["RBD219-N1", "CHEMICAL", 92, 101], ["Alhydrogel", "CHEMICAL", 105, 115], ["RBD219-N1", "SIMPLE_CHEMICAL", 13, 22], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 24, 36], ["RBD219-N1", "SIMPLE_CHEMICAL", 92, 101], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 105, 117], ["The prepared RBD219", "TEST", 0, 19], ["N1/ Alhydrogel \u00ae slurry", "TREATMENT", 20, 43], ["RBD219", "TEST", 92, 98], ["Alhydrogel", "TEST", 105, 115]]], ["The slurry was then centrifuged at 13,000 x g for 5 minutes, and the supernatant was collected while the Alhydrogel \u00ae pellet was resuspended with an equal volume of removed supernatant.", [["supernatant", "ANATOMY", 69, 80], ["supernatant", "ANATOMY", 173, 184], ["The slurry", "TREATMENT", 0, 10], ["the supernatant", "TREATMENT", 65, 80], ["the Alhydrogel \u00ae pellet", "TREATMENT", 101, 124]]], ["The RBD219-N1 protein content in the supernatant fraction and the pellet fraction were then measured using a micro BCA assay (ThermoFisher, Waltham, MS, USA).", [["supernatant", "ANATOMY", 37, 48], ["RBD219-N1", "GENE_OR_GENE_PRODUCT", 4, 13], ["RBD219", "PROTEIN", 4, 10], ["N1 protein", "PROTEIN", 11, 21], ["The RBD219", "TEST", 0, 10], ["protein content", "TEST", 14, 29], ["the supernatant fraction", "TEST", 33, 57], ["the pellet fraction", "TEST", 62, 81], ["a micro BCA assay", "TEST", 107, 124], ["N1 protein content", "OBSERVATION", 11, 29], ["supernatant fraction", "OBSERVATION", 37, 57], ["pellet fraction", "OBSERVATION", 66, 81]]], ["Similarly, the presence of RBD219-N1 in the pellet and supernatant fractions was also evaluated using SDS-PAGE.", [["pellet", "ANATOMY", 44, 50], ["supernatant fractions", "ANATOMY", 55, 76], ["RBD219-N1", "CHEMICAL", 27, 36], ["RBD219-N1", "CHEMICAL", 27, 36], ["RBD219-N1", "GENE_OR_GENE_PRODUCT", 27, 36], ["RBD219", "TEST", 27, 33], ["supernatant fractions", "OBSERVATION_MODIFIER", 55, 76]]], ["Briefly, after the slurry was centrifuged and separated into pellet and supernatant fractions, the Alhydrogel \u00ae pellet was further resuspended with desorption buffer (100 mM sodium citrate, 92 mM dibasic sodium phosphate at pH 8.9) and mixed for 1 hour.", [["pellet", "ANATOMY", 61, 67], ["supernatant fractions", "ANATOMY", 72, 93], ["Alhydrogel", "CHEMICAL", 99, 109], ["sodium citrate", "CHEMICAL", 174, 188], ["sodium phosphate", "CHEMICAL", 204, 220], ["sodium citrate", "CHEMICAL", 174, 188], ["sodium phosphate", "CHEMICAL", 204, 220], ["Alhydrogel", "SIMPLE_CHEMICAL", 99, 109], ["sodium citrate", "SIMPLE_CHEMICAL", 174, 188], ["dibasic sodium phosphate", "SIMPLE_CHEMICAL", 196, 220], ["the Alhydrogel \u00ae pellet", "TREATMENT", 95, 118], ["desorption buffer", "TREATMENT", 148, 165], ["100 mM sodium citrate", "TREATMENT", 167, 188], ["mM dibasic sodium phosphate", "TEST", 193, 220], ["pH", "TEST", 224, 226]]], ["The desorbed RBD was then separated from Alhydrogel \u00ae by centrifugation at 13,000 x g for 5 minutes.", [["Alhydrogel \u00ae", "CHEMICAL", 41, 53], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 41, 53], ["RBD", "PROTEIN", 13, 16], ["The desorbed RBD", "PROBLEM", 0, 16], ["RBD", "OBSERVATION", 13, 16]]], ["Ten microliters of desorbed RBD from the pellet fraction and free RBD in the supernatant fraction were loaded on 4-20% Tris glycine gels and stained by Coomassie blue.AnimalsSix-to eight-week-old, female Balb/c mice were purchased from Charles River (Wilmington, MA, USA), and housed in an subcutaneously (s.c.) or intramuscularly (i.m.) followed by two boosters at 21-day intervals.", [["supernatant", "ANATOMY", 77, 88], ["subcutaneously", "ANATOMY", 290, 304], ["Tris glycine", "CHEMICAL", 119, 131], ["Coomassie blue", "CHEMICAL", 152, 166], ["Tris glycine", "CHEMICAL", 119, 131], ["Coomassie blue", "CHEMICAL", 152, 166], ["Tris glycine gels", "SIMPLE_CHEMICAL", 119, 136], ["Coomassie blue", "SIMPLE_CHEMICAL", 152, 166], ["Balb/c mice", "ORGANISM", 204, 215], ["RBD", "PROTEIN", 28, 31], ["RBD", "PROTEIN", 66, 69], ["mice", "SPECIES", 211, 215], ["Coomassie blue", "SPECIES", 152, 166], ["mice", "SPECIES", 211, 215], ["desorbed RBD", "PROBLEM", 19, 31], ["the pellet fraction", "TEST", 37, 56], ["free RBD", "PROBLEM", 61, 69], ["the supernatant fraction", "TEST", 73, 97], ["20% Tris glycine gels", "TREATMENT", 115, 136], ["pellet fraction", "OBSERVATION", 41, 56], ["free RBD", "OBSERVATION", 61, 69], ["Coomassie blue", "OBSERVATION", 152, 166]]], ["The detailed study designs are described as the following:AnimalsAntigens screening.", [["The detailed study", "TEST", 0, 18], ["AnimalsAntigens screening", "TEST", 58, 83]]], ["Mice (15 per group) were immunized s.c. with 100 \u00b5L yeast-expressed recombinant RBD proteins (RBD193-N1, wt-RBD219, and RBD219-N1) formulated with 10 mg/mL Alhydrogel \u00ae at days 0 (20 \u00b5g RBD), 21 (10 \u00b5g RBD), and 42 (10 \u00b5g RBD).", [["Alhydrogel", "CHEMICAL", 156, 166], ["Alhydrogel", "CHEMICAL", 156, 166], ["Mice", "ORGANISM", 0, 4], ["RBD", "GENE_OR_GENE_PRODUCT", 80, 83], ["RBD193-N1", "CELL", 94, 103], ["wt-RBD219", "CELL", 105, 114], ["RBD219-N1", "CELL", 120, 129], ["recombinant RBD proteins", "PROTEIN", 68, 92], ["RBD193", "PROTEIN", 94, 100], ["N1", "PROTEIN", 101, 103], ["Mice", "SPECIES", 0, 4], ["yeast", "SPECIES", 52, 57], ["yeast", "SPECIES", 52, 57], ["RBD proteins", "TEST", 80, 92], ["RBD193", "TEST", 94, 100], ["wt", "TEST", 105, 107], ["RBD219", "TEST", 108, 114], ["RBD219", "TEST", 120, 126]]], ["TBS/Alhydrogel \u00ae buffer and 9 \u00b5g of alum pre-formulated SARS S protein were used as the negative and positive controls, respectively.", [["alum", "CHEMICAL", 36, 40], ["TBS", "SIMPLE_CHEMICAL", 0, 3], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 4, 16], ["alum pre-formulated SARS S protein", "PROTEIN", 36, 70], ["TBS", "TEST", 0, 3], ["Alhydrogel \u00ae buffer", "TREATMENT", 4, 23], ["alum pre-formulated SARS S protein", "TREATMENT", 36, 70]]], ["Sera from 5 mice were collected at day 50 to evaluate the pre-challenge neutralizing antibody titers.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["mice", "ORGANISM", 12, 16], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["Sera", "TEST", 0, 4], ["the pre-challenge neutralizing antibody titers", "TEST", 54, 100]]], ["All mice were then challenged intranasally (i.n.) with 10x LD50 SARS-CoV MA15 virus (~5.6 logs TCID50) at day 52.AnimalsThree mice in each group were further sacrificed at days 55 and 56 to determine the viral loads.", [["intranasally", "ANATOMY", 30, 42], ["mice", "ORGANISM", 4, 8], ["SARS-CoV MA15 virus", "ORGANISM", 64, 83], ["mice", "ORGANISM", 126, 130], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 4, 8], ["SARS-CoV MA15 virus", "SPECIES", 64, 83], ["mice", "SPECIES", 126, 130], ["10x LD50 SARS", "TEST", 55, 68], ["the viral loads", "PROBLEM", 200, 215], ["viral loads", "OBSERVATION", 204, 215]]], ["The remaining 9 mice in each group were used to monitor clinical disease (weight loss) and mortality daily for up to three weeks.AnimalsAdjuvant screening.", [["weight loss", "DISEASE", 74, 85], ["mice", "ORGANISM", 16, 20], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["clinical disease (weight loss)", "PROBLEM", 56, 86], ["AnimalsAdjuvant screening", "TEST", 129, 154]]], ["Mice (4 per group) were immunized intramuscularly (i.m.) with 100 \u00b5L RBD219-N1 formulated with two adjuvants at days 0 (20 \u00b5g RBD), 21 (10 \u00b5g RBD), and 42 (10 \u00b5g RBD).", [["RBD219-N1", "CHEMICAL", 69, 78], ["Mice", "ORGANISM", 0, 4], ["RBD219-N1", "SIMPLE_CHEMICAL", 69, 78], ["Mice", "SPECIES", 0, 4], ["two adjuvants", "TREATMENT", 95, 108]]], ["A total of three groups were tested, including RBD219-N1 with 500 \u00b5g Alhydrogel \u00ae (sometimes referred to in the manuscript as \"alum\") in group 1, RBD219-N1 in 50% (v/v) MF59like adjuvant in group 2.", [["Alhydrogel", "CHEMICAL", 69, 79], ["RBD219-N1", "CHEMICAL", 146, 155], ["MF59like", "CHEMICAL", 169, 177], ["RBD219-N1", "CHEMICAL", 47, 56], ["Alhydrogel", "CHEMICAL", 69, 79], ["RBD219-N1", "SIMPLE_CHEMICAL", 47, 56], ["RBD219-N1", "SIMPLE_CHEMICAL", 146, 155], ["v) MF59like", "SIMPLE_CHEMICAL", 166, 177], ["RBD219", "TEST", 47, 53], ["RBD219", "TEST", 146, 152], ["adjuvant in group", "TREATMENT", 178, 195]]], ["Mice immunized with RBD alone in group 3 were used as a negative control.", [["Mice", "ORGANISM", 0, 4], ["RBD", "PROTEIN", 20, 23], ["Mice", "SPECIES", 0, 4]]], ["At day 52, sera were collected to evaluate IgG and neutralizing antibody titers.", [["sera", "ANATOMY", 11, 15], ["sera", "ORGANISM_SUBSTANCE", 11, 15], ["IgG", "GENE_OR_GENE_PRODUCT", 43, 46], ["IgG", "PROTEIN", 43, 46], ["sera", "TEST", 11, 15], ["IgG", "TEST", 43, 46], ["neutralizing antibody titers", "TEST", 51, 79]]], ["At day 63, mice were i.n. challenged with SARS-CoV (2x LD50 (~10 5 TCID50) SARS-CoV (MA-15), and finally, at day 66 and day 69, or day 3 and day 6 post-challenge, lungs from 2 mice were collected for histopathology and viral titration.AnimalsAlhydrogel \u00ae dose range screening.", [["lungs", "ANATOMY", 163, 168], ["Alhydrogel \u00ae", "CHEMICAL", 242, 254], ["mice", "ORGANISM", 11, 15], ["SARS-CoV", "ORGANISM", 42, 50], ["SARS-CoV", "ORGANISM", 75, 83], ["lungs", "ORGAN", 163, 168], ["mice", "ORGANISM", 176, 180], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 176, 180], ["mice", "SPECIES", 11, 15], ["SARS-CoV", "SPECIES", 42, 50], ["mice", "SPECIES", 176, 180], ["SARS", "PROBLEM", 42, 46], ["SARS", "TEST", 75, 79], ["CoV (MA", "TEST", 80, 87], ["histopathology", "TEST", 200, 214], ["viral titration", "TREATMENT", 219, 234], ["AnimalsAlhydrogel", "TREATMENT", 235, 252], ["lungs", "ANATOMY", 163, 168], ["viral titration", "OBSERVATION", 219, 234]]], ["Mice (6 per group) were i.m. immunized with Alhydrogel \u00ae formulated RBD219-N1 at days 0 (10 or 20 \u00b5g RBD), 21 (10 \u00b5g RBD), and 42 (10 \u00b5g RBD).", [["Alhydrogel \u00ae", "CHEMICAL", 44, 56], ["RBD219-N1", "CHEMICAL", 68, 77], ["Mice", "ORGANISM", 0, 4], ["RBD219-N1", "SIMPLE_CHEMICAL", 68, 77], ["Mice", "SPECIES", 0, 4], ["Alhydrogel", "TREATMENT", 44, 54]]], ["In group 1, a formulation of 0.2 mg/mL RBD in 5 mg/mL Alhydrogel \u00ae (2.5 mg/mL aluminum) with the dose of 20 \u00b5g/10 \u00b5g/10 \u00b5g of RBD for prime/1st boost/2nd boost was used for immunization, respectively.", [["Alhydrogel \u00ae", "CHEMICAL", 54, 66], ["aluminum", "CHEMICAL", 78, 86], ["aluminum", "CHEMICAL", 78, 86], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 54, 66], ["aluminum", "SIMPLE_CHEMICAL", 78, 86], ["RBD", "PROTEIN", 126, 129], ["Alhydrogel", "TREATMENT", 54, 64], ["RBD", "PROBLEM", 126, 129], ["prime/1st boost/2nd boost", "TREATMENT", 134, 159], ["immunization", "TREATMENT", 173, 185]]], ["In group 2, the formulation 0.2 mg/mL RBD in 1.6 mg/mL Alhydrogel \u00ae (consisted of 0.8 mg/mL aluminum) was tested, more specifically, a dosing regimen of 20 \u00b5g/10 \u00b5g/10 \u00b5g RBD for prime/1st boost/2nd boost was used while in group 3, 10 \u00b5g RBD were for all three immunizations.", [["RBD", "DISEASE", 38, 41], ["Alhydrogel \u00ae", "CHEMICAL", 55, 67], ["aluminum", "CHEMICAL", 92, 100], ["RBD", "DISEASE", 238, 241], ["aluminum", "CHEMICAL", 92, 100], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 55, 67], ["aluminum", "SIMPLE_CHEMICAL", 92, 100], ["the formulation", "TREATMENT", 12, 27], ["Alhydrogel", "TREATMENT", 55, 65], ["a dosing regimen", "TREATMENT", 133, 149], ["prime/1st boost/2nd boost", "TREATMENT", 179, 204], ["all three immunizations", "TREATMENT", 251, 274]]], ["Alhydrogel \u00ae alone and pre-formulated SARS-S protein (3 \u00b5g) were used in groups 4 and 5, respectively, as negative and positive controls.", [["Alhydrogel \u00ae", "CHEMICAL", 0, 12], ["Alhydrogel", "SIMPLE_CHEMICAL", 0, 10], ["SARS-S protein", "GENE_OR_GENE_PRODUCT", 38, 52], ["S protein", "PROTEIN", 43, 52], ["Alhydrogel", "TREATMENT", 0, 10]]], ["At day 52, sera were collected to evaluate IgG and neutralizing antibody titers.", [["sera", "ANATOMY", 11, 15], ["sera", "ORGANISM_SUBSTANCE", 11, 15], ["IgG", "GENE_OR_GENE_PRODUCT", 43, 46], ["IgG", "PROTEIN", 43, 46], ["sera", "TEST", 11, 15], ["IgG", "TEST", 43, 46], ["neutralizing antibody titers", "TEST", 51, 79]]], ["At day 63, mice were i.n. challenged with SARS-CoV (2x LD50 (~10 5 TCID50) SARS-CoV (MA-15)), and finally, on day 66 (day 3 post-challenge) and day 70 (day 6 post-challenge), lungs from 3 mice were collected for histopathology and viral titration.Animals.", [["lungs", "ANATOMY", 175, 180], ["mice", "ORGANISM", 11, 15], ["SARS-CoV", "ORGANISM", 42, 50], ["lungs", "ORGAN", 175, 180], ["mice", "ORGANISM", 188, 192], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 188, 192], ["mice", "SPECIES", 11, 15], ["SARS-CoV", "SPECIES", 42, 50], ["mice", "SPECIES", 188, 192], ["SARS", "PROBLEM", 42, 46], ["SARS", "TEST", 75, 79], ["CoV (MA", "TEST", 80, 87], ["histopathology", "TEST", 212, 226], ["viral titration", "TREATMENT", 231, 246], ["lungs", "ANATOMY", 175, 180], ["viral titration", "OBSERVATION", 231, 246]]], ["CC-BY-NC-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.15.098079 doi: bioRxiv preprint ELISA RBD-specific IgG titers of polyclonal sera from the immunized mice were measured by ELISA, as previously described [14, 15, 20] .", [["sera", "ANATOMY", 219, 223], ["sera", "ORGANISM_SUBSTANCE", 219, 223], ["mice", "ORGANISM", 243, 247], ["RBD", "PROTEIN", 181, 184], ["mice", "SPECIES", 243, 247], ["mice", "SPECIES", 243, 247], ["bioRxiv preprint ELISA RBD", "TEST", 158, 184], ["specific IgG titers", "TEST", 185, 204], ["polyclonal sera", "TEST", 208, 223]]], ["Briefly, 96-well ELISA plates were pre-coated with yeast-expressed RBD protein (1 \u00b5g/ml) overnight at 4 \u00b0C. After blocking and then incubating with serially diluted mouse sera, bound IgG antibody was detected using HRP-conjugated antimouse IgG (1:2000) , followed by the same protocol as described [14, 15, 20] .Titration of SARS CoV-specific neutralizing antibodiesMice were anesthetized with isoflurane and then bled from the retro-orbital sinus plexus.", [["sera", "ANATOMY", 171, 175], ["retro-orbital sinus plexus", "ANATOMY", 428, 454], ["isoflurane", "CHEMICAL", 394, 404], ["isoflurane", "CHEMICAL", 394, 404], ["RBD", "GENE_OR_GENE_PRODUCT", 67, 70], ["mouse", "ORGANISM", 165, 170], ["sera", "ORGANISM_SUBSTANCE", 171, 175], ["IgG", "GENE_OR_GENE_PRODUCT", 183, 186], ["HRP", "SIMPLE_CHEMICAL", 215, 218], ["SARS CoV", "ORGANISM", 325, 333], ["Mice", "ORGANISM", 366, 370], ["isoflurane", "SIMPLE_CHEMICAL", 394, 404], ["retro-orbital sinus plexus", "MULTI-TISSUE_STRUCTURE", 428, 454], ["RBD protein", "PROTEIN", 67, 78], ["IgG antibody", "PROTEIN", 183, 195], ["HRP", "PROTEIN", 215, 218], ["antimouse IgG", "PROTEIN", 230, 243], ["SARS CoV-specific neutralizing antibodies", "PROTEIN", 325, 366], ["yeast", "SPECIES", 51, 56], ["mouse", "SPECIES", 165, 170], ["Mice", "SPECIES", 366, 370], ["yeast", "SPECIES", 51, 56], ["mouse", "SPECIES", 165, 170], ["SARS CoV", "SPECIES", 325, 333], ["ELISA plates", "TEST", 17, 29], ["yeast", "TEST", 51, 56], ["RBD protein", "TEST", 67, 78], ["serially diluted mouse sera", "TEST", 148, 175], ["bound IgG antibody", "TEST", 177, 195], ["HRP", "TEST", 215, 218], ["SARS CoV", "TEST", 325, 333], ["specific neutralizing antibodiesMice", "TREATMENT", 334, 370], ["isoflurane", "TREATMENT", 394, 404], ["retro-orbital sinus plexus", "ANATOMY", 428, 454]]], ["After heat inactivation at 56 \u00b0C for 30 min, sera were stored at 4 \u00b0C. The assay for virus-specific neutralizing antibodies was performed on serial 2-fold diluted samples of each serum as described previously [8, 22] .Collection of lungs, histology, immunohistochemistry, and virus titrationAfter SARS-CoV challenge, mice were euthanized on different days depending on the study and their lungs were removed.Collection of lungs, histology, immunohistochemistry, and virus titrationLung lobes were placed in 10% neutral buffered formalin for histological examination using either hematoxylin and eosin (for cellular infiltrates) or immunohistochemistry (IHC), specific for eosinophils, as described previously [8, 22] .", [["sera", "ANATOMY", 45, 49], ["samples", "ANATOMY", 163, 170], ["serum", "ANATOMY", 179, 184], ["lungs", "ANATOMY", 232, 237], ["lungs", "ANATOMY", 389, 394], ["lungs", "ANATOMY", 422, 427], ["titrationLung lobes", "ANATOMY", 472, 491], ["cellular infiltrates", "ANATOMY", 606, 626], ["eosinophils", "ANATOMY", 672, 683], ["formalin", "CHEMICAL", 528, 536], ["hematoxylin", "CHEMICAL", 579, 590], ["eosin", "CHEMICAL", 595, 600], ["sera", "ORGANISM_SUBSTANCE", 45, 49], ["serum", "ORGANISM_SUBSTANCE", 179, 184], ["lungs", "ORGAN", 232, 237], ["CoV", "ORGANISM", 302, 305], ["mice", "ORGANISM", 317, 321], ["lungs", "ORGAN", 389, 394], ["lungs", "ORGAN", 422, 427], ["formalin", "SIMPLE_CHEMICAL", 528, 536], ["hematoxylin", "SIMPLE_CHEMICAL", 579, 590], ["cellular", "CELL", 606, 614], ["eosinophils", "CELL", 672, 683], ["neutralizing antibodies", "PROTEIN", 100, 123], ["eosinophils", "CELL_TYPE", 672, 683], ["mice", "SPECIES", 317, 321], ["mice", "SPECIES", 317, 321], ["heat inactivation", "TREATMENT", 6, 23], ["The assay", "TEST", 71, 80], ["virus", "PROBLEM", 85, 90], ["specific neutralizing antibodies", "TEST", 91, 123], ["Collection of lungs", "TEST", 218, 237], ["histology", "TEST", 239, 248], ["immunohistochemistry", "TEST", 250, 270], ["CoV challenge", "TREATMENT", 302, 315], ["the study", "TEST", 369, 378], ["Collection of lungs", "TEST", 408, 427], ["histology", "TEST", 429, 438], ["immunohistochemistry", "TEST", 440, 460], ["virus titrationLung lobes", "TREATMENT", 466, 491], ["histological examination", "TEST", 541, 565], ["hematoxylin", "TREATMENT", 579, 590], ["eosin", "TREATMENT", 595, 600], ["cellular infiltrates", "PROBLEM", 606, 626], ["immunohistochemistry (IHC", "TEST", 631, 656], ["eosinophils", "PROBLEM", 672, 683], ["lungs", "ANATOMY", 232, 237], ["lungs", "ANATOMY", 389, 394], ["lungs", "ANATOMY", 422, 427], ["infiltrates", "OBSERVATION", 615, 626]]], ["For virus quantitation, the remaining tissue specimen was processed as previously described [8, 22] .", [["tissue specimen", "ANATOMY", 38, 53], ["tissue specimen", "CANCER", 38, 53], ["virus quantitation", "TEST", 4, 22], ["the remaining tissue specimen", "TEST", 24, 53]]], ["Evaluations for histopathology were done by an experimental human pathologist masked as to the vaccine/dosage of each specimen source; assessment of the extent of pathologic damage and the eosinophilic component of the inflammatory infiltrates was then provided.Statistical analysisNeutralizing antibody titers, weight loss, lung virus titers, IgG titers, histopathologic score and eosinophilic infiltration scores were averaged for each group of mice.Vaccine integrity evaluation through binding and point-of-injection studiesAs a vaccine, recombinant protein antigens alone often do not induce a sufficient immune response, necessitating their evaluation as proteins formulated with adjuvants.", [["specimen", "ANATOMY", 118, 126], ["lung", "ANATOMY", 325, 329], ["eosinophilic", "ANATOMY", 382, 394], ["weight loss", "DISEASE", 312, 323], ["human", "ORGANISM", 60, 65], ["lung", "ORGAN", 325, 329], ["mice", "ORGANISM", 447, 451], ["IgG", "PROTEIN", 344, 347], ["recombinant protein antigens", "PROTEIN", 541, 569], ["human", "SPECIES", 60, 65], ["mice", "SPECIES", 447, 451], ["human", "SPECIES", 60, 65], ["mice", "SPECIES", 447, 451], ["Evaluations", "TEST", 0, 11], ["histopathology", "TEST", 16, 30], ["the vaccine", "TREATMENT", 91, 102], ["assessment", "TEST", 135, 145], ["pathologic damage", "PROBLEM", 163, 180], ["the eosinophilic component", "PROBLEM", 185, 211], ["the inflammatory infiltrates", "PROBLEM", 215, 243], ["Statistical analysis", "TEST", 262, 282], ["Neutralizing antibody titers", "TEST", 282, 310], ["weight loss", "PROBLEM", 312, 323], ["lung virus titers", "TEST", 325, 342], ["IgG titers", "TEST", 344, 354], ["histopathologic score", "TEST", 356, 377], ["eosinophilic infiltration scores", "PROBLEM", 382, 414], ["Vaccine integrity evaluation", "TEST", 452, 480], ["injection studies", "TEST", 510, 527], ["a vaccine", "TREATMENT", 530, 539], ["recombinant protein antigens", "TEST", 541, 569], ["their evaluation", "TEST", 640, 656], ["adjuvants", "TREATMENT", 685, 694], ["pathologic", "OBSERVATION_MODIFIER", 163, 173], ["damage", "OBSERVATION", 174, 180], ["eosinophilic", "OBSERVATION_MODIFIER", 189, 201], ["inflammatory", "OBSERVATION_MODIFIER", 219, 231], ["infiltrates", "OBSERVATION", 232, 243], ["lung", "ANATOMY", 325, 329], ["virus", "OBSERVATION", 330, 335], ["eosinophilic infiltration", "OBSERVATION", 382, 407]]], ["When Alhydrogel \u00ae is used as an adjuvant, the antigen is typically fully .", [["Alhydrogel \u00ae", "CHEMICAL", 5, 17], ["Alhydrogel", "CHEMICAL", 5, 15], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 5, 17], ["Alhydrogel", "TREATMENT", 5, 15], ["an adjuvant", "TREATMENT", 29, 40]]], ["CC-BY-NC-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.15.098079 doi: bioRxiv preprint adsorbed to alum to maximize potency.", [["alum", "CHEMICAL", 187, 191], ["alum", "SIMPLE_CHEMICAL", 187, 191], ["bioRxiv", "TREATMENT", 158, 165]]], ["The binding efficiency of RBD219-N1 to Alhydrogel \u00ae was performed to evaluate the minimum RBD219-N1 to Alhydrogel \u00ae ratio required to ensure complete protein binding.", [["RBD219-N1", "CHEMICAL", 26, 35], ["RBD219-N1", "CHEMICAL", 26, 35], ["Alhydrogel", "CHEMICAL", 39, 49], ["RBD219-N1", "CHEMICAL", 90, 99], ["Alhydrogel", "CHEMICAL", 103, 113], ["RBD219-N1", "SIMPLE_CHEMICAL", 26, 35], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 39, 51], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 103, 115], ["RBD219", "PROTEIN", 26, 32], ["RBD219", "TEST", 26, 32], ["Alhydrogel \u00ae", "TEST", 39, 51], ["the minimum RBD219", "TEST", 78, 96], ["Alhydrogel \u00ae ratio", "TREATMENT", 103, 121], ["complete protein binding", "PROBLEM", 141, 165]]], ["By measuring the protein content in the supernatant and the pellet fraction after adsorption and centrifugation, the percentage of RBD bound onto Alhydrogel \u00ae at different RBD219-N1 to Alhydrogel \u00ae ratio was determined ( Figure 1A ).", [["supernatant", "ANATOMY", 40, 51], ["Alhydrogel \u00ae", "CHEMICAL", 146, 158], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 146, 158], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 185, 197], ["RBD", "PROTEIN", 131, 134], ["the protein content", "TEST", 13, 32], ["centrifugation", "TREATMENT", 97, 111], ["RBD bound", "PROBLEM", 131, 140], ["Alhydrogel", "TEST", 146, 156], ["RBD219", "TEST", 172, 178], ["Alhydrogel \u00ae ratio", "TEST", 185, 203], ["protein content", "OBSERVATION", 17, 32]]], ["An Alhydrogel \u00ae to RBD ratio greater than 7.4 resulted in complete adsorption.", [["Alhydrogel", "CHEMICAL", 3, 13], ["Alhydrogel", "SIMPLE_CHEMICAL", 3, 13], ["RBD", "PROTEIN", 19, 22], ["An Alhydrogel \u00ae to RBD ratio", "TEST", 0, 28]]], ["SDS-PAGE analysis of a formulation of 0.2 mg/mL RBD with 1.6 mg/mL Alhydrogel \u00ae (1:8 ratio) further confirmed that no protein remained in the supernatant fraction after adsorption ( Figure 1B) .Antigen screeningIn this pilot study, we compared safety, immunogenicity, and efficacy of the various yeast-expressed RBD-and S vaccines [8] using a lethal mouse model of SARS--CoV infection.", [["supernatant", "ANATOMY", 142, 153], ["Alhydrogel", "CHEMICAL", 67, 77], ["SARS--CoV infection", "DISEASE", 365, 384], ["Alhydrogel", "CHEMICAL", 67, 77], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 67, 79], ["RBD", "GENE_OR_GENE_PRODUCT", 312, 315], ["mouse", "ORGANISM", 350, 355], ["SARS--CoV", "ORGANISM", 365, 374], ["RBD", "PROTEIN", 312, 315], ["yeast", "SPECIES", 296, 301], ["mouse", "SPECIES", 350, 355], ["yeast", "SPECIES", 296, 301], ["mouse", "SPECIES", 350, 355], ["SARS--CoV", "SPECIES", 365, 374], ["SDS", "TEST", 0, 3], ["a formulation", "TREATMENT", 21, 34], ["protein", "PROBLEM", 118, 125], ["Antigen screening", "TEST", 194, 211], ["this pilot study", "TEST", 214, 230], ["the various yeast", "PROBLEM", 284, 301], ["expressed RBD", "PROBLEM", 302, 315], ["S vaccines", "TREATMENT", 320, 330], ["a lethal mouse model", "TREATMENT", 341, 361], ["SARS", "PROBLEM", 365, 369], ["CoV infection", "PROBLEM", 371, 384], ["infection", "OBSERVATION", 375, 384]]], ["Figure 2a shows that mice immunized with RBD-219N1 had the highest titer of neutralizing antibodies compared to mice immunized with alum-adjuvanted RBD193-N1, wt-RBD219 and the S protein vaccines.", [["RBD-219N1", "CHEMICAL", 41, 50], ["mice", "ORGANISM", 21, 25], ["RBD-219N1", "ORGANISM", 41, 50], ["mice", "ORGANISM", 112, 116], ["wt", "ORGANISM", 159, 161], ["-RBD219", "SIMPLE_CHEMICAL", 161, 168], ["RBD", "PROTEIN", 41, 44], ["neutralizing antibodies", "PROTEIN", 76, 99], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 112, 116], ["RBD", "TEST", 41, 44], ["neutralizing antibodies", "PROBLEM", 76, 99], ["alum-adjuvanted RBD193", "TEST", 132, 154], ["wt", "TEST", 159, 161], ["RBD219", "TEST", 162, 168], ["the S protein vaccines", "TREATMENT", 173, 195]]], ["Importantly, endpoint evaluation for mortality has shown that a 100% survival rate was found for mice immunized with alum-adjuvanted RBD219-N1, while mice immunized with alum-adjuvanted wt-RBD219 and RBD193-N1 vaccines showed 88% survival and those immunized with alum-adjuvanted S protein showed only 67% survival.", [["RBD219-N1", "CHEMICAL", 133, 142], ["alum", "CHEMICAL", 264, 268], ["alum", "CHEMICAL", 264, 268], ["mice", "ORGANISM", 97, 101], ["RBD219-N1", "SIMPLE_CHEMICAL", 133, 142], ["mice", "ORGANISM", 150, 154], ["wt-RBD219", "ORGANISM", 186, 195], ["RBD193-N1", "ORGANISM", 200, 209], ["alum", "SIMPLE_CHEMICAL", 264, 268], ["adjuvanted S protein", "PROTEIN", 269, 289], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 150, 154], ["endpoint evaluation", "TEST", 13, 32], ["a 100% survival rate", "TREATMENT", 62, 82], ["alum-adjuvanted RBD219", "TREATMENT", 117, 139], ["alum-adjuvanted wt", "TEST", 170, 188], ["RBD219", "TEST", 189, 195], ["RBD193", "TEST", 200, 206], ["N1 vaccines", "TREATMENT", 207, 218], ["alum", "TEST", 264, 268], ["adjuvanted S protein", "TEST", 269, 289]]], ["All mice in the TBS control group died within 6 days post-challenge ( Figure 2B ).", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["Furthermore, mice immunized with RBD219-N1, similar to wt-RBD219 and RBD193-N1, consistently showed less than 10% weight loss throughout the study period, while mice immunized with other alum-formulated vaccines including the S protein showed a maximum of 15-20% weight loss ( Figure 2C ).", [["weight loss", "DISEASE", 114, 125], ["alum", "CHEMICAL", 187, 191], ["weight loss", "DISEASE", 263, 274], ["alum", "CHEMICAL", 187, 191], ["mice", "ORGANISM", 13, 17], ["RBD219-N1", "ORGANISM", 33, 42], ["wt-RBD219", "ORGANISM", 55, 64], ["RBD193-N1", "CELL", 69, 78], ["mice", "ORGANISM", 161, 165], ["alum", "SIMPLE_CHEMICAL", 187, 191], ["S protein", "PROTEIN", 226, 235], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 161, 165], ["RBD219", "TEST", 33, 39], ["wt", "TEST", 55, 57], ["RBD219", "TEST", 58, 64], ["RBD193", "TEST", 69, 75], ["weight loss", "PROBLEM", 114, 125], ["the study", "TEST", 137, 146], ["other alum-formulated vaccines", "TREATMENT", 181, 211], ["the S protein", "TEST", 222, 235], ["weight loss", "PROBLEM", 263, 274], ["less", "OBSERVATION_MODIFIER", 100, 104]]], ["This was accompanied by more than a 3-log reduction of infectious viral loads within the lungs when compared to mice vaccinated with TBS/Alhydrogel \u00ae (Figures 2D and 2E) .", [["lungs", "ANATOMY", 89, 94], ["lungs", "ORGAN", 89, 94], ["mice", "ORGANISM", 112, 116], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 137, 149], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 112, 116], ["infectious viral loads within the lungs", "PROBLEM", 55, 94], ["TBS", "TEST", 133, 136], ["Alhydrogel", "TREATMENT", 137, 147], ["infectious", "OBSERVATION", 55, 65], ["viral loads", "OBSERVATION", 66, 77], ["lungs", "ANATOMY", 89, 94]]], ["None of the mice given TBS/Alhydrogel \u00ae produced detectable neutralizing antibodies, whereas their geometric means of lung virus titers were 10 9.9 and 10 8.9 TCID50/g on days 1 and 2 post-challenge, respectively.Antigen screeningWith these results, RBD219-N1 was chosen for further development.Adjuvant screeningIt is known that alum (generally a Th2 adjuvant) and MF59 (a Th1/Th2 balanced adjuvant in the form of oil-in-water emulsion) are two of the most common adjuvants used in licensed vaccines with very well-established safety records [23, 24] .", [["lung", "ANATOMY", 118, 122], ["Alhydrogel \u00ae", "CHEMICAL", 27, 39], ["alum", "CHEMICAL", 330, 334], ["MF59", "CHEMICAL", 366, 370], ["alum", "CHEMICAL", 330, 334], ["MF59", "CHEMICAL", 366, 370], ["mice", "ORGANISM", 12, 16], ["TBS", "SIMPLE_CHEMICAL", 23, 26], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 27, 39], ["lung", "ORGAN", 118, 122], ["virus", "ORGANISM", 123, 128], ["RBD219-N1", "CELL", 250, 259], ["alum", "SIMPLE_CHEMICAL", 330, 334], ["MF59", "SIMPLE_CHEMICAL", 366, 370], ["neutralizing antibodies", "PROTEIN", 60, 83], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["TBS", "TEST", 23, 26], ["Alhydrogel", "TEST", 27, 37], ["detectable neutralizing antibodies", "PROBLEM", 49, 83], ["lung virus titers", "TEST", 118, 135], ["Antigen screeningWith", "TEST", 213, 234], ["RBD219", "TEST", 250, 256], ["Adjuvant screening", "TEST", 295, 313], ["a Th2 adjuvant", "TREATMENT", 346, 360], ["MF59", "TREATMENT", 366, 370], ["a Th1/Th2 balanced adjuvant", "TREATMENT", 372, 399], ["oil-in-water emulsion", "TREATMENT", 415, 436], ["licensed vaccines", "TREATMENT", 483, 500], ["neutralizing antibodies", "OBSERVATION", 60, 83], ["lung", "ANATOMY", 118, 122], ["virus", "OBSERVATION", 123, 128], ["alum", "OBSERVATION", 330, 334]]], ["In this study, we compared Alhydrogel \u00ae and AddaVax (MF59-like adjuvant) for their ability to improve the efficacy of RBD219-N1 in mice.", [["Alhydrogel", "CHEMICAL", 27, 37], ["AddaVax", "CHEMICAL", 44, 51], ["MF59", "CHEMICAL", 53, 57], ["RBD219-N1", "CHEMICAL", 118, 127], ["Alhydrogel", "CHEMICAL", 27, 37], ["AddaVax", "CHEMICAL", 44, 51], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 27, 39], ["AddaVax", "SIMPLE_CHEMICAL", 44, 51], ["MF59", "SIMPLE_CHEMICAL", 53, 57], ["RBD219-N1", "SIMPLE_CHEMICAL", 118, 127], ["mice", "ORGANISM", 131, 135], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 131, 135], ["this study", "TEST", 3, 13], ["Alhydrogel \u00ae", "TREATMENT", 27, 39], ["AddaVax (MF59", "TREATMENT", 44, 57], ["adjuvant", "TREATMENT", 63, 71], ["RBD219", "TEST", 118, 124]]], ["Figure 3 and Supplementary neutralizing antibody responses and did not protect against SARS-CoV infection, as evaluated by the isolation of the infectious virus and quantitative PCR (qPCR) for viral RNA.", [["SARS-CoV infection", "DISEASE", 87, 105], ["SARS-CoV", "ORGANISM", 87, 95], ["viral RNA", "RNA", 193, 202], ["SARS-CoV", "SPECIES", 87, 95], ["Supplementary neutralizing antibody responses", "TEST", 13, 58], ["SARS", "PROBLEM", 87, 91], ["CoV infection", "PROBLEM", 92, 105], ["the infectious virus", "PROBLEM", 140, 160], ["quantitative PCR", "TEST", 165, 181], ["viral RNA", "PROBLEM", 193, 202], ["infection", "OBSERVATION", 96, 105], ["infectious", "OBSERVATION", 144, 154], ["viral RNA", "OBSERVATION", 193, 202]]], ["Unlike MF59-like adjuvant formulated RBD219-N1 and RBD219-N1 alone, we also noted that RBD219-N1 formulated with Alhydrogel \u00ae did not induce a cellular infiltration within the lungs (Figure 4 and Supplementary Table 1 ).", [["cellular", "ANATOMY", 143, 151], ["lungs", "ANATOMY", 176, 181], ["MF59", "CHEMICAL", 7, 11], ["RBD219-N1", "CHEMICAL", 37, 46], ["RBD219-N1", "CHEMICAL", 51, 60], ["RBD219-N1", "CHEMICAL", 87, 96], ["Alhydrogel \u00ae", "CHEMICAL", 113, 125], ["RBD219-N1", "CHEMICAL", 51, 60], ["RBD219-N1", "CHEMICAL", 87, 96], ["Alhydrogel \u00ae", "CHEMICAL", 113, 125], ["MF59", "SIMPLE_CHEMICAL", 7, 11], ["RBD219-N1", "SIMPLE_CHEMICAL", 37, 46], ["RBD219-N1", "SIMPLE_CHEMICAL", 51, 60], ["RBD219-N1", "SIMPLE_CHEMICAL", 87, 96], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 113, 125], ["cellular", "CELL", 143, 151], ["lungs", "ORGAN", 176, 181], ["MF59", "TEST", 7, 11], ["RBD219", "TEST", 37, 43], ["RBD219", "TEST", 51, 57], ["RBD219", "TEST", 87, 93], ["Alhydrogel", "TREATMENT", 113, 123], ["a cellular infiltration", "PROBLEM", 141, 164], ["cellular", "OBSERVATION_MODIFIER", 143, 151], ["infiltration", "OBSERVATION", 152, 164], ["lungs", "ANATOMY", 176, 181]]], ["Taken together, these results suggest that RBD219-N1/Alhydrogel \u00ae was potentially both effective and safe, and therefore alum was chosen as the optimal adjuvant and further studied for the dose-ranging study.Alhydrogel \u00ae dose-ranging studyAlthough RBD219-N1 formulated on Alhydrogel \u00ae at a ratio of 1:25 was effective in immunized animals against lethal SARS-CoV challenge without inducing apparent pulmonary immunopathology, it was of further interest to compare different aluminum ratios, including the efficacy of RBD219-N1 formulated on Alhydrogel \u00ae at both 1:25 and 1:8 ratios in mice.", [["pulmonary", "ANATOMY", 399, 408], ["RBD219-N1", "CHEMICAL", 43, 52], ["Alhydrogel \u00ae", "CHEMICAL", 53, 65], ["Alhydrogel \u00ae", "CHEMICAL", 208, 220], ["RBD219-N1", "CHEMICAL", 248, 257], ["Alhydrogel \u00ae", "CHEMICAL", 272, 284], ["SARS", "DISEASE", 354, 358], ["pulmonary immunopathology", "DISEASE", 399, 424], ["aluminum", "CHEMICAL", 474, 482], ["RBD219-N1", "CHEMICAL", 517, 526], ["Alhydrogel \u00ae", "CHEMICAL", 541, 553], ["RBD219-N1", "CHEMICAL", 43, 52], ["Alhydrogel \u00ae", "CHEMICAL", 53, 65], ["alum", "CHEMICAL", 121, 125], ["Alhydrogel", "CHEMICAL", 208, 218], ["aluminum", "CHEMICAL", 474, 482], ["RBD219-N1", "CHEMICAL", 517, 526], ["RBD219-N1", "SIMPLE_CHEMICAL", 43, 52], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 53, 65], ["alum", "SIMPLE_CHEMICAL", 121, 125], ["Alhydrogel", "SIMPLE_CHEMICAL", 208, 218], ["RBD219-N1", "SIMPLE_CHEMICAL", 248, 257], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 272, 284], ["SARS-CoV", "ORGANISM", 354, 362], ["pulmonary", "ORGAN", 399, 408], ["aluminum", "SIMPLE_CHEMICAL", 474, 482], ["RBD219-N1", "SIMPLE_CHEMICAL", 517, 526], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 541, 553], ["mice", "ORGANISM", 585, 589], ["mice", "SPECIES", 585, 589], ["SARS-CoV", "SPECIES", 354, 362], ["mice", "SPECIES", 585, 589], ["RBD219", "TEST", 43, 49], ["Alhydrogel", "TREATMENT", 53, 63], ["alum", "TREATMENT", 121, 125], ["the dose-ranging study", "TEST", 185, 207], ["Alhydrogel", "TREATMENT", 208, 218], ["RBD219", "TEST", 248, 254], ["Alhydrogel", "TREATMENT", 272, 282], ["lethal SARS", "PROBLEM", 347, 358], ["CoV challenge", "TREATMENT", 359, 372], ["pulmonary immunopathology", "PROBLEM", 399, 424], ["different aluminum ratios", "TEST", 464, 489], ["RBD219", "TEST", 517, 523], ["Alhydrogel", "TREATMENT", 541, 551], ["pulmonary", "ANATOMY", 399, 408], ["immunopathology", "OBSERVATION", 409, 424]]], ["Sera were collected 10 days after the last vaccination to test RBD219-N1-specific IgG antibody responses by ELISA and neutralizing antibodies against live SARS-CoV infections.", [["Sera", "ANATOMY", 0, 4], ["SARS-CoV infections", "DISEASE", 155, 174], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["RBD219-N1", "SIMPLE_CHEMICAL", 63, 72], ["IgG", "ORGANISM", 82, 85], ["SARS-CoV", "ORGANISM", 155, 163], ["RBD219", "PROTEIN", 63, 69], ["IgG antibody", "PROTEIN", 82, 94], ["neutralizing antibodies", "PROTEIN", 118, 141], ["SARS-CoV", "SPECIES", 155, 163], ["the last vaccination", "TREATMENT", 34, 54], ["test", "TEST", 58, 62], ["RBD219", "TEST", 63, 69], ["specific IgG antibody responses", "TEST", 73, 104], ["ELISA", "TEST", 108, 113], ["neutralizing antibodies", "TEST", 118, 141], ["live SARS", "PROBLEM", 150, 159], ["CoV infections", "PROBLEM", 160, 174], ["infections", "OBSERVATION", 164, 174]]], ["Results showed that mice immunized with RBD219-N1/Alhydrogel \u00ae at a 1:25 ratio produced significantly higher neutralizing antibody titers and RBD219-N1-specific IgG titers than those vaccinated at a 1:8 ratio ( Figure 5A-B) .", [["RBD219-N1", "CHEMICAL", 40, 49], ["mice", "ORGANISM", 20, 24], ["RBD219-N1", "SIMPLE_CHEMICAL", 40, 49], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 50, 62], ["RBD219-N1", "GENE_OR_GENE_PRODUCT", 142, 151], ["IgG", "GENE_OR_GENE_PRODUCT", 161, 164], ["RBD219", "PROTEIN", 142, 148], ["IgG", "PROTEIN", 161, 164], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["RBD219", "TEST", 40, 46], ["Alhydrogel", "TEST", 50, 60], ["significantly higher neutralizing antibody titers", "PROBLEM", 88, 137], ["RBD219", "TEST", 142, 148], ["specific IgG titers", "TEST", 152, 171]]], ["Consistent with the antibody responses, mice immunized with an RBD219-N1/Alhydrogel \u00ae ratio of 1:25 were completely protected against lethal challenge with SARS-CoV, as indicated by the undetectable infectious virus within the lungs and also a lack of morbidity and mortality ( Figure 6 ).", [["lungs", "ANATOMY", 227, 232], ["SARS", "DISEASE", 156, 160], ["mice", "ORGANISM", 40, 44], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 73, 85], ["SARS-CoV", "ORGANISM", 156, 164], ["lungs", "ORGAN", 227, 232], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["SARS-CoV", "SPECIES", 156, 164], ["the antibody responses", "TEST", 16, 38], ["an RBD219", "TEST", 60, 69], ["SARS", "PROBLEM", 156, 160], ["the undetectable infectious virus", "PROBLEM", 182, 215], ["undetectable", "OBSERVATION_MODIFIER", 186, 198], ["infectious", "OBSERVATION", 199, 209], ["lungs", "ANATOMY", 227, 232]]], ["In contrast, infectious virus was recovered from the lungs of mice immunized with a 1:8 ratio of RBD219-N1/Alhydrogel \u00ae (Groups 2 and 3) by day 5 post-challenge and one mouse from each group died.", [["lungs", "ANATOMY", 53, 58], ["lungs", "ORGAN", 53, 58], ["mice", "ORGANISM", 62, 66], ["RBD219-N1", "SIMPLE_CHEMICAL", 97, 106], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 107, 119], ["mouse", "ORGANISM", 169, 174], ["mice", "SPECIES", 62, 66], ["mouse", "SPECIES", 169, 174], ["mice", "SPECIES", 62, 66], ["mouse", "SPECIES", 169, 174], ["infectious virus", "PROBLEM", 13, 29], ["RBD219", "TEST", 97, 103], ["infectious", "OBSERVATION", 13, 23], ["lungs", "ANATOMY", 53, 58]]], ["As expected, mice immunized with Alhydrogel \u00ae alone (Group 4) were not protected against a lethal viral challenge and had detectable virus in the lungs resulting in the death of 2 mice on day 4 post-challenge, while SARS-CoV S protein formulated on Alhydrogel \u00ae (Group 5) was also immunogenic and protective against SARS-CoV infection.Alhydrogel \u00ae dose-ranging studyHistopathologic examination of lung tissues using IHC (specific for eosinophils) revealed minimal eosinophilic infiltration for mice in group 1 (1:25 ratio) while somewhat increased infiltration was observed in groups 2 and 3 (1:8 ratio) and the worst eosinophils infiltration was found in the mice immunized with S protein among all groups (Supplementary Table 2 and Figure 7 ).", [["lungs", "ANATOMY", 146, 151], ["lung tissues", "ANATOMY", 397, 409], ["eosinophils", "ANATOMY", 434, 445], ["eosinophils", "ANATOMY", 618, 629], ["Alhydrogel \u00ae", "CHEMICAL", 33, 45], ["death", "DISEASE", 169, 174], ["Alhydrogel \u00ae", "CHEMICAL", 249, 261], ["SARS-CoV infection", "DISEASE", 316, 334], ["Alhydrogel", "CHEMICAL", 335, 345], ["mice", "ORGANISM", 13, 17], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 33, 45], ["lungs", "ORGAN", 146, 151], ["mice", "ORGANISM", 180, 184], ["SARS-CoV", "ORGANISM", 216, 224], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 249, 261], ["SARS-CoV", "ORGANISM", 316, 324], ["Alhydrogel", "SIMPLE_CHEMICAL", 335, 345], ["lung tissues", "TISSUE", 397, 409], ["eosinophils", "CELL", 434, 445], ["mice", "ORGANISM", 494, 498], ["eosinophils", "CELL", 618, 629], ["mice", "ORGANISM", 660, 664], ["SARS-CoV S protein", "PROTEIN", 216, 234], ["eosinophils", "CELL_TYPE", 434, 445], ["eosinophils", "CELL_TYPE", 618, 629], ["S protein", "PROTEIN", 680, 689], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 180, 184], ["mice", "SPECIES", 494, 498], ["mice", "SPECIES", 660, 664], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 180, 184], ["SARS-CoV", "SPECIES", 216, 224], ["SARS-CoV", "SPECIES", 316, 324], ["mice", "SPECIES", 494, 498], ["mice", "SPECIES", 660, 664], ["Alhydrogel", "TREATMENT", 33, 43], ["a lethal viral challenge", "TREATMENT", 89, 113], ["detectable virus in the lungs", "PROBLEM", 122, 151], ["SARS", "PROBLEM", 216, 220], ["CoV S protein", "TEST", 221, 234], ["Alhydrogel \u00ae (Group 5", "TREATMENT", 249, 270], ["SARS", "PROBLEM", 316, 320], ["CoV infection", "PROBLEM", 321, 334], ["Alhydrogel", "TREATMENT", 335, 345], ["dose-ranging study", "TEST", 348, 366], ["Histopathologic examination", "TEST", 366, 393], ["lung tissues", "TEST", 397, 409], ["IHC", "TEST", 416, 419], ["eosinophils", "TEST", 434, 445], ["minimal eosinophilic infiltration", "PROBLEM", 456, 489], ["somewhat increased infiltration", "PROBLEM", 529, 560], ["the worst eosinophils infiltration", "PROBLEM", 608, 642], ["S protein", "TREATMENT", 680, 689], ["virus", "OBSERVATION", 133, 138], ["lungs", "ANATOMY", 146, 151], ["CoV", "OBSERVATION_MODIFIER", 321, 324], ["infection", "OBSERVATION", 325, 334], ["lung tissues", "ANATOMY", 397, 409], ["minimal", "OBSERVATION_MODIFIER", 456, 463], ["eosinophilic infiltration", "OBSERVATION", 464, 489], ["increased", "OBSERVATION_MODIFIER", 538, 547], ["infiltration", "OBSERVATION", 548, 560], ["worst", "OBSERVATION_MODIFIER", 612, 617], ["eosinophils infiltration", "OBSERVATION", 618, 642]]], ["The results confirm the protective efficacy of RBD219-N1/Alhydrogel \u00ae , and its superiority to the S-protein in terms of protection and reduction or prevention in eosinophilic infiltration, as well as the favorable effects of Alhydrogel \u00ae for eliciting high titer neutralizing antibody and maximal reductions in immune enhancement comparing to other groups.DISCUSSIONThe RBD of the S1 protein of SARS-CoV, which is responsible for the attachment of the receptor ACE2 and initiates the process for cell binding and entry, has been proven as a promising vaccine candidate [25] .", [["eosinophilic", "ANATOMY", 163, 175], ["cell", "ANATOMY", 497, 501], ["RBD219-N1", "CHEMICAL", 47, 56], ["S-protein", "CHEMICAL", 99, 108], ["Alhydrogel \u00ae", "CHEMICAL", 226, 238], ["SARS", "DISEASE", 396, 400], ["RBD219-N1", "CHEMICAL", 47, 56], ["Alhydrogel", "CHEMICAL", 57, 67], ["RBD219-N1", "SIMPLE_CHEMICAL", 47, 56], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 57, 69], ["S-protein", "SIMPLE_CHEMICAL", 99, 108], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 226, 238], ["SARS-CoV", "ORGANISM", 396, 404], ["ACE2", "GENE_OR_GENE_PRODUCT", 462, 466], ["cell", "CELL", 497, 501], ["RBD", "PROTEIN", 371, 374], ["S1 protein", "PROTEIN", 382, 392], ["ACE2", "PROTEIN", 462, 466], ["SARS-CoV", "SPECIES", 396, 404], ["RBD219", "TEST", 47, 53], ["Alhydrogel", "TREATMENT", 57, 67], ["reduction", "TREATMENT", 136, 145], ["eosinophilic infiltration", "PROBLEM", 163, 188], ["Alhydrogel \u00ae", "TREATMENT", 226, 238], ["high titer neutralizing antibody", "PROBLEM", 253, 285], ["maximal reductions in immune enhancement", "PROBLEM", 290, 330], ["SARS", "PROBLEM", 396, 400], ["CoV", "PROBLEM", 401, 404], ["the receptor ACE2", "TREATMENT", 449, 466], ["cell binding", "PROBLEM", 497, 509], ["eosinophilic infiltration", "OBSERVATION", 163, 188], ["reductions", "OBSERVATION_MODIFIER", 298, 308], ["immune enhancement", "OBSERVATION", 312, 330]]], ["It has been expressed as a recombinant protein with a hexahistidine tag, a GST protein or Fc fragment in several different expression platforms including E. coli, insect cells, and mammalian cells to simplify the purification process and these constructs were shown to trigger neutralizing antibodies and immunity [12, [14] [15] [16] [17] .", [["cells", "ANATOMY", 170, 175], ["cells", "ANATOMY", 191, 196], ["GST", "GENE_OR_GENE_PRODUCT", 75, 78], ["E. coli", "ORGANISM", 154, 161], ["insect cells", "CELL", 163, 175], ["mammalian cells", "CELL", 181, 196], ["[14] [15] [16] [17]", "SIMPLE_CHEMICAL", 319, 338], ["recombinant protein", "PROTEIN", 27, 46], ["hexahistidine tag", "PROTEIN", 54, 71], ["GST protein", "PROTEIN", 75, 86], ["Fc fragment", "PROTEIN", 90, 101], ["insect cells", "CELL_TYPE", 163, 175], ["mammalian cells", "CELL_TYPE", 181, 196], ["neutralizing antibodies", "PROTEIN", 277, 300], ["E. coli", "SPECIES", 154, 161], ["E. coli", "SPECIES", 154, 161], ["a hexahistidine tag", "TREATMENT", 52, 71], ["a GST protein", "PROBLEM", 73, 86], ["Fc fragment", "PROBLEM", 90, 101], ["E. coli", "PROBLEM", 154, 161], ["insect cells", "PROBLEM", 163, 175], ["mammalian cells", "PROBLEM", 181, 196], ["the purification process", "PROBLEM", 209, 233], ["neutralizing antibodies", "TEST", 277, 300], ["Fc fragment", "OBSERVATION", 90, 101], ["E. coli", "OBSERVATION", 154, 161], ["mammalian cells", "OBSERVATION", 181, 196]]], ["However, an additional tag on a recombinant protein-based vaccine should be avoided because it can potentially trigger an undesired immune response.", [["recombinant protein", "PROTEIN", 32, 51], ["an additional tag", "PROBLEM", 9, 26], ["a recombinant protein-based vaccine", "TREATMENT", 30, 65], ["an undesired immune response", "PROBLEM", 119, 147]]], ["In our previous studies [20, 21] , we have expressed and purified several tag-free recombinant RBD constructs in yeast using a scalable process and discovered that the yeastexpressed RBD219-N1 induced a stronger RBD-specific antibody response and a high level of neutralizing antibodies in immunized mice when formulated with Alhydrogel \u00ae , and thus, a very promising vaccine candidate.", [["RBD219-N1", "CHEMICAL", 183, 192], ["Alhydrogel \u00ae", "CHEMICAL", 326, 338], ["RBD219-N1", "CHEMICAL", 183, 192], ["RBD", "GENE_OR_GENE_PRODUCT", 95, 98], ["RBD219-N1", "GENE_OR_GENE_PRODUCT", 183, 192], ["mice", "ORGANISM", 300, 304], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 326, 338], ["tag-free recombinant RBD constructs", "DNA", 74, 109], ["RBD219", "PROTEIN", 183, 189], ["RBD", "PROTEIN", 212, 215], ["neutralizing antibodies", "PROTEIN", 263, 286], ["yeast", "SPECIES", 113, 118], ["mice", "SPECIES", 300, 304], ["yeast", "SPECIES", 113, 118], ["mice", "SPECIES", 300, 304], ["several tag-free recombinant RBD constructs", "PROBLEM", 66, 109], ["the yeastexpressed RBD219", "TEST", 164, 189], ["a stronger RBD", "PROBLEM", 201, 215], ["specific antibody response", "PROBLEM", 216, 242], ["neutralizing antibodies", "TREATMENT", 263, 286]]], ["In this study, we conducted for the first time an efficacy study in which we screened several different yeast-expressed RBD proteins and compared them to the S protein as a positive control.", [["RBD", "GENE_OR_GENE_PRODUCT", 120, 123], ["RBD proteins", "PROTEIN", 120, 132], ["S protein", "PROTEIN", 158, 167], ["yeast", "SPECIES", 104, 109], ["yeast", "SPECIES", 104, 109], ["this study", "TEST", 3, 13], ["an efficacy study", "TEST", 47, 64], ["several different yeast", "PROBLEM", 86, 109], ["expressed RBD proteins", "PROBLEM", 110, 132], ["a positive control", "TREATMENT", 171, 189]]], ["RBD219-N1 formulated with Alhydrogel \u00ae triggered higher neutralizing titers than the other Alhydrogel \u00ae -formulated RBD constructs or the S protein; the RBD219-N1 formulated with Alhydrogel \u00ae immunized mice were fully protected with 100% survival rate.", [["RBD219-N1", "CHEMICAL", 0, 9], ["Alhydrogel \u00ae", "CHEMICAL", 26, 38], ["Alhydrogel", "CHEMICAL", 91, 101], ["RBD219-N1", "CHEMICAL", 153, 162], ["Alhydrogel \u00ae", "CHEMICAL", 179, 191], ["RBD219-N1", "SIMPLE_CHEMICAL", 0, 9], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 26, 38], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 91, 103], ["RBD219-N1", "SIMPLE_CHEMICAL", 153, 162], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 179, 191], ["mice", "ORGANISM", 202, 206], ["Alhydrogel \u00ae -formulated RBD constructs", "DNA", 91, 130], ["S protein", "PROTEIN", 138, 147], ["mice", "SPECIES", 202, 206], ["mice", "SPECIES", 202, 206], ["RBD219", "TEST", 0, 6], ["Alhydrogel", "TREATMENT", 26, 36], ["higher neutralizing titers", "PROBLEM", 49, 75], ["RBD constructs", "PROBLEM", 116, 130], ["the S protein", "TEST", 134, 147], ["the RBD219", "TEST", 149, 159], ["Alhydrogel", "TREATMENT", 179, 189]]], ["The RBD219-N1 construct was further selected for adjuvant screening and adjuvant dose-ranging studies.DISCUSSIONBefore testing different adjuvants, we investigated the immunization routes (s.c. and i.m) for RBD219-N1 adsorbed to Figures.", [["RBD219", "CHEMICAL", 207, 213], ["RBD219-N1", "CHEMICAL", 207, 216], ["RBD219-N1 construct", "DNA", 4, 23], ["The RBD219", "TEST", 0, 10], ["adjuvant screening", "TEST", 49, 67], ["adjuvant dose", "TREATMENT", 72, 85], ["ranging studies", "TEST", 86, 101], ["different adjuvants", "TREATMENT", 127, 146], ["the immunization routes", "TREATMENT", 164, 187], ["RBD219", "TEST", 207, 213]]], ["It was found that both immunization routes were able to induce high titers of specific IgG and neutralizing antibodies against infections of SARS pseudovirus in Figure.1C ).", [["infections", "DISEASE", 127, 137], ["SARS pseudovirus", "DISEASE", 141, 157], ["IgG", "GENE_OR_GENE_PRODUCT", 87, 90], ["SARS pseudovirus", "ORGANISM", 141, 157], ["IgG", "PROTEIN", 87, 90], ["neutralizing antibodies", "PROTEIN", 95, 118], ["SARS pseudovirus", "SPECIES", 141, 157], ["both immunization routes", "TREATMENT", 18, 42], ["specific IgG", "TEST", 78, 90], ["neutralizing antibodies", "TEST", 95, 118], ["infections", "PROBLEM", 127, 137], ["SARS pseudovirus", "PROBLEM", 141, 157]]], ["Although the antibody responses induced through the s.c. route were significantly higher than those through the i.m. route, the i.m. route was selected for subsequent adjuvant optimization because i.m. injection of the vaccines containing adjuvants has less chance to induce adverse local effects than s.c. injection [26] and the majority of the clinically used vaccines are administered via the i.m.DISCUSSIONroute [27] .DISCUSSIONThe superiority of the RBD219-N1 vaccine antigen to the S protein was reflected both in terms of eliciting neutralizing antibodies and protective immunity, and that the alum-adjuvanted RBD219-N1 resulted in little to no cellular or eosinophilic .", [["cellular", "ANATOMY", 652, 660], ["RBD219-N1", "CHEMICAL", 617, 626], ["RBD219-N1", "CHEMICAL", 617, 626], ["s.c.", "SIMPLE_CHEMICAL", 302, 306], ["RBD219-N1", "GENE_OR_GENE_PRODUCT", 455, 464], ["cellular", "CELL", 652, 660], ["RBD219-N1 vaccine antigen", "PROTEIN", 455, 480], ["S protein", "PROTEIN", 488, 497], ["neutralizing antibodies", "PROTEIN", 539, 562], ["the antibody responses", "TEST", 9, 31], ["the s.c. route", "TREATMENT", 48, 62], ["the i.m. route", "TREATMENT", 124, 138], ["subsequent adjuvant optimization", "TREATMENT", 156, 188], ["the vaccines", "TREATMENT", 215, 227], ["adjuvants", "TREATMENT", 239, 248], ["vaccines", "TREATMENT", 362, 370], ["the RBD219", "TEST", 451, 461], ["the S protein", "TEST", 484, 497], ["neutralizing antibodies", "TEST", 539, 562], ["the alum-adjuvanted RBD219", "TEST", 597, 623], ["eosinophilic", "PROBLEM", 664, 676], ["neutralizing antibodies", "OBSERVATION", 539, 562], ["eosinophilic", "OBSERVATION", 664, 676]]], ["CC-BY-NC-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.15.098079 doi: bioRxiv preprint immunopathology compared to either the S-protein or an M59-like adjuvant-formulated RBD219-N1 vaccine.", [["immunopathology", "DISEASE", 175, 190], ["RBD219-N1", "CHEMICAL", 259, 268], ["RBD219-N1", "SIMPLE_CHEMICAL", 259, 268], ["bioRxiv preprint immunopathology", "PROBLEM", 158, 190], ["the S-protein", "TEST", 210, 223], ["an M59", "TEST", 227, 233], ["adjuvant", "TREATMENT", 239, 247], ["N1 vaccine", "TREATMENT", 266, 276]]], ["With regards to the former observation, it was previously shown that removal of immune-enhancing epitopes located outside the S-protein RBD domain may result in an immunogen, which is less likely to induce immunopathology [11, 28] .", [["immunopathology", "DISEASE", 206, 221], ["epitopes", "PROTEIN", 97, 105], ["S-protein RBD domain", "PROTEIN", 126, 146], ["removal", "TREATMENT", 69, 76], ["immune-enhancing epitopes", "TREATMENT", 80, 105], ["the S-protein RBD domain", "PROBLEM", 122, 146], ["an immunogen", "TEST", 161, 173], ["immunopathology", "PROBLEM", 206, 221], ["less likely", "UNCERTAINTY", 184, 195]]], ["This finding led to the initial selection of the RBD as a vaccine antigen [29] .", [["RBD", "PROTEIN", 49, 52], ["a vaccine antigen", "TEST", 56, 73]]], ["With regards to adjuvant selection, alum prevented or reduced immune enhancement, a finding that confirms a previous observation for doubly inactivated virus, viral-like particle vaccines and S protein [8] .", [["alum", "CHEMICAL", 36, 40], ["alum", "CHEMICAL", 36, 40], ["alum", "SIMPLE_CHEMICAL", 36, 40], ["S protein", "PROTEIN", 192, 201], ["adjuvant selection", "TREATMENT", 16, 34], ["alum", "TREATMENT", 36, 40], ["reduced immune enhancement", "PROBLEM", 54, 80], ["a previous observation", "TEST", 106, 128], ["doubly inactivated virus", "PROBLEM", 133, 157], ["viral-like particle vaccines", "TREATMENT", 159, 187]]], ["For example, Tseng et al. reported that mice immunized with alum-formulated virus-like-particle and inactivated virus vaccines showed less immunopathology than the non-adjuvanted vaccines.", [["alum", "CHEMICAL", 60, 64], ["immunopathology", "DISEASE", 139, 154], ["alum", "CHEMICAL", 60, 64], ["mice", "ORGANISM", 40, 44], ["alum", "SIMPLE_CHEMICAL", 60, 64], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["alum", "TREATMENT", 60, 64], ["formulated virus", "PROBLEM", 65, 81], ["inactivated virus vaccines", "TREATMENT", 100, 126], ["the non-adjuvanted vaccines", "TREATMENT", 160, 187]]], ["Such findings provided the basis for suggesting that eosinophilic immunopathology may occur through mechanisms other than Th2 immunity [30, 31] .DISCUSSIONTo understand the mechanisms of potential immunopathology linked to SARS vaccines, it's been shown that high levels of eosinophilic immunopathology were observed with modified vaccinia virus Ankara-based vaccine platform vaccines, [2] [3] [4] [5] [6] [7] and this vaccine platform was found to induce both Th1 (IFN-gamma, IL-2) and Th2 (IL-4, IL-5) cytokines and down-regulation of anti-inflammatory cytokines (IL-10, TGF-beta) upon infection, causing severe infiltration of neutrophils, eosinophils, and lymphocytes into the lung.", [["eosinophilic", "ANATOMY", 53, 65], ["neutrophils", "ANATOMY", 630, 641], ["eosinophils", "ANATOMY", 643, 654], ["lymphocytes", "ANATOMY", 660, 671], ["lung", "ANATOMY", 681, 685], ["eosinophilic immunopathology", "DISEASE", 53, 81], ["immunopathology", "DISEASE", 197, 212], ["SARS", "DISEASE", 223, 227], ["eosinophilic immunopathology", "DISEASE", 274, 302], ["[2] [3] [4] [5] [6] [7]", "CHEMICAL", 386, 409], ["infection", "DISEASE", 588, 597], ["vaccinia virus Ankara", "ORGANISM", 331, 352], ["[2] [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 386, 409], ["Th1", "GENE_OR_GENE_PRODUCT", 461, 464], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 466, 475], ["IL-2", "GENE_OR_GENE_PRODUCT", 477, 481], ["Th2", "GENE_OR_GENE_PRODUCT", 487, 490], ["IL-4", "GENE_OR_GENE_PRODUCT", 492, 496], ["IL-5", "GENE_OR_GENE_PRODUCT", 498, 502], ["IL-10", "GENE_OR_GENE_PRODUCT", 566, 571], ["TGF-beta", "GENE_OR_GENE_PRODUCT", 573, 581], ["neutrophils", "CELL", 630, 641], ["eosinophils", "CELL", 643, 654], ["lymphocytes", "CELL", 660, 671], ["lung", "ORGAN", 681, 685], ["IFN", "PROTEIN", 466, 469], ["Th2 (IL-4, IL-5", "PROTEIN", 487, 502], ["cytokines", "PROTEIN", 504, 513], ["anti-inflammatory cytokines", "PROTEIN", 537, 564], ["IL-10", "PROTEIN", 566, 571], ["TGF-beta", "PROTEIN", 573, 581], ["neutrophils", "CELL_TYPE", 630, 641], ["eosinophils", "CELL_TYPE", 643, 654], ["lymphocytes", "CELL_TYPE", 660, 671], ["vaccinia virus", "SPECIES", 331, 345], ["eosinophilic immunopathology", "PROBLEM", 53, 81], ["potential immunopathology", "PROBLEM", 187, 212], ["SARS vaccines", "TREATMENT", 223, 236], ["eosinophilic immunopathology", "PROBLEM", 274, 302], ["modified vaccinia virus Ankara-based vaccine platform vaccines", "TREATMENT", 322, 384], ["this vaccine platform", "TEST", 414, 435], ["Th1", "TEST", 461, 464], ["IFN", "TEST", 466, 469], ["gamma", "TEST", 470, 475], ["IL", "TEST", 477, 479], ["Th2", "TEST", 487, 490], ["IL", "TEST", 492, 494], ["IL", "TEST", 498, 500], ["cytokines", "TEST", 504, 513], ["anti-inflammatory cytokines", "TEST", 537, 564], ["IL", "TEST", 566, 568], ["TGF", "TEST", 573, 576], ["infection", "PROBLEM", 588, 597], ["severe infiltration of neutrophils", "PROBLEM", 607, 641], ["eosinophils", "TEST", 643, 654], ["lymphocytes into the lung", "PROBLEM", 660, 685], ["eosinophilic", "OBSERVATION", 53, 65], ["eosinophilic immunopathology", "OBSERVATION", 274, 302], ["anti-inflammatory cytokines", "OBSERVATION", 537, 564], ["infection", "OBSERVATION", 588, 597], ["severe", "OBSERVATION_MODIFIER", 607, 613], ["infiltration", "OBSERVATION", 614, 626], ["neutrophils", "ANATOMY", 630, 641], ["lung", "ANATOMY", 681, 685]]], ["These pieces of evidence suggest that Th2 is not the sole factor but rather a mixed Th1 and Th2 response is responsible for the immunopathology.", [["Th2", "GENE_OR_GENE_PRODUCT", 38, 41], ["Th2", "GENE_OR_GENE_PRODUCT", 92, 95], ["the sole factor", "PROBLEM", 49, 64], ["the immunopathology", "PROBLEM", 124, 143], ["evidence suggest", "UNCERTAINTY", 16, 32], ["Th2", "OBSERVATION", 38, 41], ["responsible for", "UNCERTAINTY", 108, 123], ["immunopathology", "OBSERVATION", 128, 143]]], ["Additionally, it was found that IL-6 was shown to have a prominent role in SARS-CoV-induced immune enhancement [7] in experimental animals, as well as in lung pathology in SARS patients [32] .DISCUSSIONThe prominent role of IL-6 in host Th17 immune responses suggest that this pathway might also comprise a component of coronavirus vaccine immune enhancement [9] .", [["lung", "ANATOMY", 154, 158], ["SARS", "DISEASE", 172, 176], ["IL-6", "GENE_OR_GENE_PRODUCT", 32, 36], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 75, 83], ["lung", "ORGAN", 154, 158], ["patients", "ORGANISM", 177, 185], ["IL-6", "GENE_OR_GENE_PRODUCT", 224, 228], ["host Th17", "CELL", 232, 241], ["coronavirus", "ORGANISM", 320, 331], ["IL-6", "PROTEIN", 32, 36], ["IL-6", "PROTEIN", 224, 228], ["patients", "SPECIES", 177, 185], ["SARS-CoV", "SPECIES", 75, 83], ["coronavirus", "SPECIES", 320, 331], ["a prominent role in SARS", "PROBLEM", 55, 79], ["CoV", "TEST", 80, 83], ["immune enhancement", "PROBLEM", 92, 110], ["IL", "TREATMENT", 224, 226], ["this pathway", "PROBLEM", 272, 284], ["coronavirus vaccine immune enhancement", "PROBLEM", 320, 358], ["prominent", "OBSERVATION_MODIFIER", 57, 66], ["immune enhancement", "OBSERVATION", 92, 110], ["lung", "ANATOMY", 154, 158], ["pathology", "OBSERVATION", 159, 168], ["coronavirus", "OBSERVATION", 320, 331]]], ["The finding that Th17 lymphocytes activate eosinophils [30] , and that eosinophils comprise a key element of Th17 responses is consistent with these findings [30] .", [["Th17 lymphocytes", "ANATOMY", 17, 33], ["eosinophils", "ANATOMY", 43, 54], ["eosinophils", "ANATOMY", 71, 82], ["Th17 lymphocytes", "CELL", 17, 33], ["eosinophils", "CELL", 43, 54], ["eosinophils", "CELL", 71, 82], ["Th17", "CELL", 109, 113], ["Th17 lymphocytes", "CELL_TYPE", 17, 33], ["eosinophils", "CELL_TYPE", 43, 54], ["eosinophils", "CELL_TYPE", 71, 82], ["eosinophils", "TEST", 43, 54], ["eosinophils", "TEST", 71, 82], ["Th17 lymphocytes", "OBSERVATION", 17, 33], ["consistent with", "UNCERTAINTY", 127, 142]]], ["Of interest, monoclonal antibodies directed at interfering with IL-6 binding with its receptor are now being investigated as possible immunotherapies for patients with COVID19 [33] .DISCUSSIONFinally, in the Alhydrogel \u00ae dose-ranging study, we observed that a higher concentration of Alhydrogel \u00ae was required to trigger a fully protective immune response with attenuated eosinophils infiltration, while S protein induced a higher degree of eosinophilic cellular infiltration, which is consistent with the previous finding [8] .", [["eosinophils", "ANATOMY", 372, 383], ["cellular", "ANATOMY", 454, 462], ["Alhydrogel", "CHEMICAL", 284, 294], ["Alhydrogel \u00ae", "CHEMICAL", 284, 296], ["IL-6", "GENE_OR_GENE_PRODUCT", 64, 68], ["patients", "ORGANISM", 154, 162], ["Alhydrogel", "SIMPLE_CHEMICAL", 284, 294], ["eosinophils", "CELL", 372, 383], ["S protein", "GENE_OR_GENE_PRODUCT", 404, 413], ["eosinophilic cellular", "CELL", 441, 462], ["monoclonal antibodies", "PROTEIN", 13, 34], ["IL-6", "PROTEIN", 64, 68], ["eosinophils", "CELL_TYPE", 372, 383], ["S protein", "PROTEIN", 404, 413], ["patients", "SPECIES", 154, 162], ["monoclonal antibodies", "TREATMENT", 13, 34], ["immunotherapies", "TREATMENT", 134, 149], ["Alhydrogel \u00ae", "TREATMENT", 284, 296], ["attenuated eosinophils infiltration", "PROBLEM", 361, 396], ["S protein", "TEST", 404, 413], ["eosinophilic cellular infiltration", "PROBLEM", 441, 475], ["eosinophils infiltration", "OBSERVATION", 372, 396], ["higher degree", "OBSERVATION_MODIFIER", 424, 437], ["eosinophilic cellular infiltration", "OBSERVATION", 441, 475], ["consistent with", "UNCERTAINTY", 486, 501]]], ["Table 1A further summarized the comparison of eosinophilic immunopathology induced by different SARS-CoV vaccines, including the S protein, virus-like particle (VLP) expressing spike protein and the inactivated whole virus vaccines.", [["eosinophilic immunopathology", "DISEASE", 46, 74], ["SARS-CoV", "ORGANISM", 96, 104], ["virus-like particle", "GENE_OR_GENE_PRODUCT", 140, 159], ["VLP", "ORGANISM", 161, 164], ["whole virus", "ORGANISM", 211, 222], ["S protein", "PROTEIN", 129, 138], ["virus-like particle (VLP) expressing spike protein", "PROTEIN", 140, 190], ["SARS-CoV", "SPECIES", 96, 104], ["eosinophilic immunopathology", "PROBLEM", 46, 74], ["different SARS", "PROBLEM", 86, 100], ["CoV vaccines", "TREATMENT", 101, 113], ["the S protein", "TREATMENT", 125, 138], ["virus", "PROBLEM", 140, 145], ["spike protein", "PROBLEM", 177, 190], ["the inactivated whole virus vaccines", "TREATMENT", 195, 231], ["eosinophilic immunopathology", "OBSERVATION", 46, 74]]], ["The results indicated that the vaccine using VLP expressing S protein triggered worse eosinophilic infiltration than the inactivated whole virus vaccines, and S protein showed the least .", [["eosinophilic", "ANATOMY", 86, 98], ["VLP", "ORGANISM", 45, 48], ["S protein", "GENE_OR_GENE_PRODUCT", 60, 69], ["eosinophilic", "PATHOLOGICAL_FORMATION", 86, 98], ["S protein", "GENE_OR_GENE_PRODUCT", 159, 168], ["S protein", "PROTEIN", 60, 69], ["S protein", "PROTEIN", 159, 168], ["the vaccine", "TREATMENT", 27, 38], ["VLP", "TREATMENT", 45, 48], ["eosinophilic infiltration", "PROBLEM", 86, 111], ["the inactivated whole virus vaccines", "TREATMENT", 117, 153], ["S protein", "TEST", 159, 168], ["eosinophilic infiltration", "OBSERVATION", 86, 111]]], ["CC-BY-NC-ND 4.0 International license was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.15.098079 doi: bioRxiv preprint eosinophil infiltration among them either with or without formulated with alum.", [["eosinophil", "ANATOMY", 175, 185], ["alum", "CHEMICAL", 249, 253], ["eosinophil", "CELL", 175, 185], ["alum", "SIMPLE_CHEMICAL", 249, 253], ["bioRxiv preprint eosinophil infiltration", "TREATMENT", 158, 198], ["eosinophil infiltration", "OBSERVATION", 175, 198]]], ["Our studies find that the RBD can elicit far less immunopathology than even the S protein.", [["RBD", "DISEASE", 26, 29], ["RBD", "GENE_OR_GENE_PRODUCT", 26, 29], ["RBD", "PROTEIN", 26, 29], ["S protein", "PROTEIN", 80, 89], ["Our studies", "TEST", 0, 11], ["the RBD", "PROBLEM", 22, 29]]], ["Similar to what was seen for the whole virus vaccine against SARS, lung eosinophil infiltration was observed in mice immunized with MERS gamma irradiation-inactivated whole virus vaccine after challenge with MERS-CoV (Table 1B) [34] .", [["lung eosinophil", "ANATOMY", 67, 82], ["SARS", "DISEASE", 61, 65], ["MERS gamma", "CHEMICAL", 132, 142], ["lung eosinophil", "CELL", 67, 82], ["mice", "ORGANISM", 112, 116], ["MERS gamma", "GENE_OR_GENE_PRODUCT", 132, 142], ["whole virus", "ORGANISM", 167, 178], ["MERS-CoV", "ORGANISM", 208, 216], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 112, 116], ["MERS-CoV", "SPECIES", 208, 216], ["the whole virus vaccine", "TREATMENT", 29, 52], ["SARS", "PROBLEM", 61, 65], ["lung eosinophil infiltration", "PROBLEM", 67, 95], ["MERS gamma irradiation", "TREATMENT", 132, 154], ["whole virus vaccine", "TREATMENT", 167, 186], ["lung", "ANATOMY", 67, 71], ["eosinophil infiltration", "OBSERVATION", 72, 95]]], ["These findings further suggested that Alhydrogel \u00ae formulated RBD219-N1 was a safer SARS-CoV vaccine than the ones listed in Table 1A .DISCUSSIONCollectively, all the preclinical data suggested that SARS-CoV RBD219-N1 formulated with alum is a potentially safe and efficacious vaccine against SARS-CoV infection.", [["Alhydrogel \u00ae", "CHEMICAL", 38, 50], ["RBD219-N1", "CHEMICAL", 62, 71], ["SARS-CoV RBD219-N1", "CHEMICAL", 199, 217], ["alum", "CHEMICAL", 234, 238], ["SARS-CoV infection", "DISEASE", 293, 311], ["Alhydrogel", "CHEMICAL", 38, 48], ["RBD219-N1", "CHEMICAL", 62, 71], ["alum", "CHEMICAL", 234, 238], ["Alhydrogel \u00ae", "SIMPLE_CHEMICAL", 38, 50], ["RBD219-N1", "SIMPLE_CHEMICAL", 62, 71], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 84, 92], ["SARS-CoV", "ORGANISM", 199, 207], ["alum", "SIMPLE_CHEMICAL", 234, 238], ["SARS-CoV", "ORGANISM", 293, 301], ["SARS-CoV", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 199, 207], ["SARS-CoV", "SPECIES", 293, 301], ["Alhydrogel", "TEST", 38, 48], ["a safer SARS-CoV vaccine", "TREATMENT", 76, 100], ["SARS", "PROBLEM", 199, 203], ["CoV RBD219", "TEST", 204, 214], ["alum", "TREATMENT", 234, 238], ["safe and efficacious vaccine", "TREATMENT", 256, 284], ["SARS", "PROBLEM", 293, 297], ["CoV infection", "PROBLEM", 298, 311], ["infection", "OBSERVATION", 302, 311]]], ["We have developed the scalable process and partnered with WRAIR and manufactured RBD219-N1 protein under current good manufacturing practices (cGMP) in 2016.", [["cGMP", "CHEMICAL", 143, 147], ["cGMP", "SIMPLE_CHEMICAL", 143, 147], ["RBD219", "PROTEIN", 81, 87], ["N1 protein", "PROTEIN", 88, 98], ["the scalable process", "PROBLEM", 18, 38], ["scalable", "OBSERVATION_MODIFIER", 22, 30], ["process", "OBSERVATION", 31, 38]]], ["The bulk drug substance has been frozen (-70\u00b0C to -80\u00b0C) in a temperature-regulated storage location and under stability testing since its manufacturing date (July 2016) and remains stable.", [["stable", "OBSERVATION_MODIFIER", 182, 188]]], ["This vaccine candidate is ready for formulation and can be rapidly transitioned to clinical testing.", [["This vaccine", "TREATMENT", 0, 12], ["formulation", "TREATMENT", 36, 47], ["clinical testing", "TEST", 83, 99]]], ["The preclinical data reported here suggest that SARS-CoV RBD219-N1 formulated with alum is a safer and more efficacious vaccine against SARS-CoV infection compared to many other candidate vaccines.ACKNOWLEDGMENTThis study was supported by a grant from the National Institutes of Health (R01AI098775).DISCLOSURESSome of the authors have developed subunit vaccines against MERS coronavirus infection.", [["SARS-CoV RBD219-N1", "CHEMICAL", 48, 66], ["alum", "CHEMICAL", 83, 87], ["SARS-CoV infection", "DISEASE", 136, 154], ["MERS coronavirus infection", "DISEASE", 371, 397], ["alum", "CHEMICAL", 83, 87], ["SARS-CoV", "ORGANISM", 48, 56], ["alum", "SIMPLE_CHEMICAL", 83, 87], ["SARS-CoV", "ORGANISM", 136, 144], ["MERS coronavirus", "ORGANISM", 371, 387], ["coronavirus", "SPECIES", 376, 387], ["SARS-CoV", "SPECIES", 48, 56], ["SARS-CoV", "SPECIES", 136, 144], ["MERS coronavirus", "SPECIES", 371, 387], ["The preclinical data", "TEST", 0, 20], ["SARS", "PROBLEM", 48, 52], ["CoV RBD219", "TEST", 53, 63], ["alum", "TREATMENT", 83, 87], ["SARS", "PROBLEM", 136, 140], ["CoV infection", "PROBLEM", 141, 154], ["subunit vaccines", "TREATMENT", 346, 362], ["MERS coronavirus infection", "PROBLEM", 371, 397], ["infection", "OBSERVATION", 145, 154]]], ["They are involved in the process of developing a vaccine against SARS-CoV-2.", [["SARS", "DISEASE", 65, 69], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV", "SPECIES", 65, 73], ["a vaccine", "TREATMENT", 47, 56]]]]}